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Chapter 1
Introduction
1.1 Motivation
Pancreatic patients continue to have one of the worst prognosis, being the 7th deadliest
cancer worldwide (Ferley et al. 2013) and the 4th in Germany, with a 5-year overall sur-
vival rate of 8% (Cancer in Germany 2009–2010. 9th edition. 2014). Usually patients
with early-stage cancers undergo surgery, while chemo-radiotherapy is the standard
option for advanced cancers. These patients suffer mainly from recurrences in the pri-
mary tumour periphery (Kessel et al. 2013), indicating the need of dose escalation to
improve the local control while limiting side effects.
Ion-beam therapy with proton or heavy ion-beams has been pointed out as a possible
alternative for these patients (Combs et al. 2013; Tsujii et al. 2013). Its physical charac-
teristics offer the possibility for highly conformal treatments, while from a radiobiological
viewpoint heavy ions increase the relative biological effectiveness specially in the tu-
mour region (Durante and Loeffler 2010). Additionally, when the dose is delivered to
the tumour through a beam scanning technique a potential gain in dose conformity is
obtained, which is reflected in the widening of the therapeutic window (Moding, Kastan,
and Kirsch 2013).
Nevertheless, a strong drawback from this precision radiotherapy modality is the high
sensitivity of the ion range to density changes in the beam-path, which reduces the tu-
mour coverage, increases the dose inhomogeneities and may cause overdose in nor-
mal tissues. These variations can result either from anatomy changes between treat-
ment sessions (inter-fractional), patient positioning, patient’s motion during the treat-
ment delivery (intra-fractional) or beam application uncertainties (range, position and
width).
Inter-fractional changes in pancreatic patients occur due to tumour volume changes,
organ filling (intestine and stomach) and loss of adipose tissue (Dalal et al. 2012).
Intra-fractional variations are caused by respiration and peristaltic induced movement
(Goldstein et al. 2010; Kumagai et al. 2009). Besides range changes, these variations
may result in an inhomogeneous dose distribution, as consequence of the interference
between the dynamic beam delivery and the target motion in scanned beam delivery
systems. This phenomenon is called interplay effect.
The assessment of the impact of the motion on the delivered treatment dose, and the
evaluation of motion mitigation techniques to be implemented in the clinical environ-
ment, must be conducted prior to the application of ion-beams to pancreatic patients
(Bert and Durante 2011). Consequently, from the pre-implementation phase to the
actual irradiation of the patients, the application of scanned ion-beams to pancreatic
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patients was investigated at the Heidelberg Ion-Beam Therapy Center (HIT) .
This dissertation was supported by the Deutschen Forschungsgemeinschaft (DFG)
within the Klinische Forschergruppe Schwerionentherapie (KFO 214) and by the Hei-
delberg University Hospital.
1.2 Scope of this work
This dissertation focuses on the quantification of the dosimetric impact of the inter- and
intra-fractional anatomic changes observed for pancreatic patients when treated with
ion-beams delivered through a scanning system. Moreover, clinically feasible strate-
gies were developed in order to increase the treatment robustness against the resulting
range uncertainties and interplay effect.
The analysis is gradually accomplished through the definition of robust beam arrange-
ment, evaluation of safety margins to the tumour, prediction of dosimetric changes
based on pre-treatment imaging, and, finally, analysis of the influence of the breath-
ing motion and its variability on the delivered dose.
The study is also split in a pre-implementation stage, i.e. prediction of the potential un-
certainties and definition of protocols, and in the follow-up stage, in which the current
patients were evaluated and changes to the current protocols suggested.
1.2.1 Structure of the dissertation
This dissertation is organised in 7 chapters. Chapter 2 gives an overview of the phys-
ical and biological characteristics of the ion-beams, technical issues in an ion-beam
facility, the impact of organ motion on beam delivery, as well as the treatment planning
process and the main challenges of pancreatic cancer. Chapter 3 gives an insight into
the software and tools used in this work and describes their main functionalities and
limitations.
Chapter 4 covers the inter-fractional motion and strategies to increase the planning
robustness, while chapter 5 focuses on the assessment of the intra-fractional motion
component and methods to deal with it. Chapter 6 gives an outlook of an MRI-based
approach for motion monitoring, aiming to determine the importance of the motion de-
tection via MRI, and to define the procedure to its inclusion in the clinical workflow for
future patients.
Finally, a discussion of the results and conclusions is presented in chapter 7.
Chapter 2
Fundamentals and background
The combination of physical and biological advantages of ions beam irradiation over
photon therapy contributed to the worldwide increase of this therapeutic modality in the
last years. From the sixty-two worldwide facilities in operation just ten of them are pre-
pared to deliver charged particles heavier than protons, as cited by the Particle Therapy
Co-Operative Group (PTCOG).
This chapter reviews the main characteristics of charged particles beams, that made
this technique arise as a potential therapeutic for many tumour locations, describes the
workflow of an ion-beam treatment, the major drawbacks of this technique and con-
cludes with the reasoning of its application in pancreatic patients.
2.1 General rationale for ion-beam therapy
Charged particles have been pointed as the ideal irradiation technique for a tumour in
challenging locations, i.e., surrounded by risk organs, and also for radio-resistant tu-
mours. These advantages emerge from the physical aspects of how their energy is
deposited in tissues and how the radiobiology is affected due to the high density of en-
ergy depositions inside the cell.
2.1.1 Physical aspects
The growing application of charged particles in the radiotherapy field comes mainly
due to its very characteristic depth-dose profile, which exhibits low entrance dose and
a strong increase with a sharp fall-off dose at the end of its path - the Bragg peak
(Schardt, Elsässer, and Schulz-Ertner 2010). This depth profile contrasts with the con-
ventional photon beam, where the dose distribution in the patient suffers an exponential
decline in depth, as shown in the figure (2.1 a).
The Bragg peak reflects the phenomenon that high energetic particles deposit relatively
little energy when entering in the tissues but tend to deposit extremely large amounts of
energy in a very narrow peak at the end of their range. This behaviour is due to the en-
ergy loss increasing with lower velocities, as shown below. The depth and magnitude
of this Bragg peak is determined by the mass and charge, as well as the initial energy
of the particle (IAEA 2008).
In clinical situations, with tumours of thickness of centimeters, the Bragg peak must
be broadened by use of a superposition of beams with different energies, a so-called
3
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spread-out Bragg peak, SOBP, (see fig. 2.1 b).
Figure 2.1: Depth dose profile comparison for photons, protons and carbon ions. a) Depth dose profile
for X-rays and high-energy charged particles. b) For clinical targets sizes the spread-out Bragg peak
(SOBP) distributes the dose within the tumour. The physical dose profile is corrected according to the
RBE in the tumor region. The differential RBE of carbon ions leads to an increase of effectiveness
specially in the SOBP as compared to protons. For the case of heavy charged particles, as result of
nuclear interactions and fragmentation, a dose tail after the Bragg peak is formed. Image adapted from
Durante and Loeffler (2010)).
Stopping power of charged particles
As in the case of photons the absorbed dose D, in Gray [Gy], is proportional to the
mean energy deposited by the ionizing radiation in a mass element (IAEA 2007). For
charged particles this mean energy is calculated as the product of the particle fluence
and the energy loss of the particles per unit path length dE/dx, describing the slowing-
down process of the particles in the tissue interaction, named as linear stopping power,
i.e, S =  dE/dx.
For therapeutic energies ( 220MeV for protons and  430MeV /u for carbon ions),
the stopping power is mainly due to electronic interactions and the energy-loss is domi-
nated by the inelastic interaction with the target electrons. It is given by the Bethe-Bloch
formula (Linz 2011):
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This relativistic expression includes the shell correction factor, C/Zt, the density effect
correction, /2, the nuclear charge of the projectile and target, Zp and Zt, respectively,
the mass and charge of the electron, me and e, and the mean ionisation energy of the
target atom,
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Range of particles
Given the energy-loss the total path length of the particle with initial kinetic energy E
can be determined from its integration, which is referred as continuous slowing down
approximation (CSDA) (ICRU 2005). Assuming that ions travel only straight ahead
(negligible lateral scattering) the total path length is approximated to the mean range,
R(E), as in the equation (2.2).
R(E) =
Z 0
E
dE 0
dx
 1
dE 0 (2.2)
However, the successive ionisations present small statistical fluctuations in the energy
loss of the individual particles which leads to a broadening of the peak in the depth dose
distribution, a phenomenon called range straggling (Newhauser and Zhang 2015).
Multiple Coulomb scattering
An ion passing close to a nucleus will be elastically deflected due to Coulomb scattering,
losing a negligible amount of energy but experiencing changes in the trajectory, which
although small are significant due to the large number of scattering events. This phys-
ical process is characterised by the scattering power (Newhauser and Zhang 2015).
The multiple Coulomb scattering will result in a considerable blur of the lateral penum-
bra sharpness for protons beams, but it is relatively small for heavy ions. This is simply
due to the higher mass, which leads to generally smaller deflection. Hence, this small
lateral deflection of heavy ions in the medium makes this therapeutic modality optimal
for challenging locations, i.e, tumours surrounded by organs-at-risk (OARs).
Nuclear interactions and fragmentation
Charged particles undergo nuclear interactions with the target nuclei of the absorbed
material. These interactions can be either elastic (leading to Coulomb scattering) or
non-elastic. The latter are of strong significance for particle therapy as they result in
the non-conservation of the total kinetic energy of the process: light fragments are cre-
ated from the disintegration of the projectile and target nuclei, ions are extracted from
the target and a build up of neutrons, protons and other secondaries occurs (Schardt,
Elsässer, and Schulz-Ertner 2010).
For ions heavier than protons, with energies of several hundreds of MeV/u, nuclear
interactions result mainly in the production of the projectile nuclear fragments. These
lower-Z fragments retain most of the velocity and mass of the primary particle, but be-
cause of their lower charge their range is larger than that of primary projectile. As a
consequence, a dose tail after the Bragg peak is formed, as depicted in the figure (2.1
b) for a carbon ions beam. Target fragments are also produced, but with very little en-
ergy, so that they do not lead to a significant change of the particle spectrum.
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2.1.2 Biological characterisation
The potential of radiation to induce cell killing through DNA damage is quantified by
the number and density of single or double strand break lesions in the DNA molecule
(Joiner and Kogel 2009).
The number of surviving cells, when a tissue is irradiated with a certain dose is a com-
mon indicator of the therapeutic quality and is phenomenologically described by the
linear-quadratic (LQ) model, which relates the fraction of surviving cells S after an ab-
sorbed dose D as described by the equation (2.3).
S(D) = e (D+D
2) (2.3)
The radio-sensitivity of cells is characterised by the parameters  and  parameters,
which related to the way that the cell is inactivated, i.e. by a single lethal event or by
accumulation of sub-lethal events, respectively (Joiner and Kogel 2009).
Relative biological effectiveness
Charged particles interact with targets differently than X-rays, hence their efficacy is de-
fined by the Relative Biological Effectiveness (RBE), which represents the ratio of the
X-ray dose divided by the dose of ion that results in the same biological effect. There-
fore, in ion-beam therapy, the dose is referred as biological dose or RBE-weighted
dose, i.e. the product of the absorbed dose and RBE, given in Gy (RBE) (IAEA 2007).
The RBE depends on several parameters, including the cell type, the dose, the particle
type and the beam energy. This yields a different RBE for each tumour location and
treatment field that has to be modulated during the treatment planning in order to obtain
an accurate calculation of the effective dose in tissues.
For protons, a constant RBE of 1.1 is used as an approximation to convert the physical
dose to the biological effective dose (Bauer et al. 2016; Paganetti 2014), figure (2.2 a).
However, studies showed that in the very distal part of the SOBP the RBE increases.
This behaviour is known from in in-vitro studies, but it is not considered to be clinically
relevant.
For carbon ions the RBE values are generally much higher and more variable, and its
variation along the Bragg curve needs to be considered in treatment planning (see fig.
2.2 b). Also the tumour and ion species dependence has to be taken into account.
Different models are available to describe the RBE effect for each voxel of the tissues,
like the approaches developed at the Lawrence Berkeley Laboratory (LBL), National
Institute of Radiological Science (NIRS) and in the GSI Helmholtz Center for Heavy Ion
Research (GSI).
The concept developed by GSI, also adopted by HIT, is called Local Effect Model (LEM)
(Elsässer, Krämer, and Scholz 2008) and estimates the RBE for different ions and cell
types as a combination of the clinical photon dose response and the microscopic track
structure of the various ions in the spectrum of secondary particles.
Linear energy transfer and track structure
The linear energy transfer, LET, describes the deposited energy in the target medium
by the slowing-down of the primary particles and is a particularly important concept
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Figure 2.2: a)Variation in depth of the absorbed dose of a monoenergetic (dotted line) and a spread
out (slid line) proton beam and the corresponding RBE weighted dose, assuming a factor of 1.1. at
all depths.b) Depth dose profile of the absorved dose and isoeffective dose variations for a SOBP of a
carbon ion-beam. The RBE increases with depth. Source IAEA (2008).
in particle therapy (Durante and Loeffler 2010; Schardt, Elsässer, and Schulz-Ertner
2010). This happens as RBE is directly related to LET and, therefore, increases with
it for clinically relevant LET values. The LET of ion-beams is partically identical to the
stopping power and thus depends quadratically on the projectile charge. Hence, fast
moving light ions have low LET, and their biological effectiveness is close to that of
X-rays; slow heavy ions have high LET, and are more effective than X-rays for killing
cells (IAEA 2007).
For high-LET particles there is an enhancement of the biological effectiveness at the
Bragg peak region, that is due to the dense ionisation on the primary particles tracks,
which produces more DNA damage. Thus the inspection of the spatial distribution of
deposited energy for different particles is an indicator of the biological effect induced
by particles. Particles with a higher LET show a more dense track structure and hence
larger biological effects caused by ionizing radiation. This is being considered as ad-
vantageous for the treatment of radio-resistant tumours.
Moreover, high-LET particles result in different biological response of the cells. One of
these aspects is related with the oxygen enhancement ratio (OER), which measures
the tumour sensitivity to the presence or absence of oxygen by the ratio of radiation
dose required to produce a given effect with no oxygen present (hypoxia) to the dose
required to produce the same effect in the normal oxygen concentration (normaxic).
For these particles the OER is reduced, which is mainly beneficial in the treatment of
certain radio-resistant tumours possessing a large percentage of hypoxic cells (Schlaff
et al. 2014).
Another biological aspect affected by the LET is the cell cycle sensitivity to the radia-
tion. Opposed to the photon irradiation in which radiation damages cells occurs mainly
in the cell-division stage, using heavy ions the cycle sensitivity is very frail. This char-
acteristic will be essentially important for slowly growing tumours, which are usually
photon-resistant.
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2.2 Implementation in a clinical facility
An ion-beam facility comprises different components and can exhibit different imple-
mentations of beam production, transport and delivery to the tumour. Consequently,
the adopted Treatment Planning System (TPS) must be able to handle the facility fea-
tures and optimise a clinically feasible plan.
2.2.1 Ion sources, accelerator and transport lines
Either proton or heavy ion-beams are produced in ion sources and then accelerated in
order to reach the necessary depth in the patient. This corresponds approximately to
an energy of 150 MeV and 250 MeV/u for protons and carbon ions, respectively, for 16
cm depth.
An injection system injects ions either directly from the source (e.g. for protons in a
cyclotron) or from the low energy beam-line into the accelerator.
The accelerator can be either a cyclotron or a synchrotron. In a cyclotron the beam
intensities can be controlled but not the extracted energy, which can only be achieved
by means of passive degraders in the beam line. On the contrary, synchrotrons pro-
vide a pulse-to-pulse active energy variation but require an injection system and a more
complex extraction system, as well as, energy dependent high energy beam-lines.
2.2.2 Beam delivery systems
The transport of the particle beam to the tumour and its distribution over the prescribed
volume can be performed by a passive or an active delivery system, or a combination
of both (Kraft 2000; Schulz-Ertner and Tsujii 2007).
The two extreme forms, the fully passive system (Chu, Ludewigt, and Renner 1993)
and the fully active system (Haberer et al. 1993), are explained below.
2.2.2.1 Passive systems
In a passive system, as the one depicted in the figure (2.3 a), the beam is three- dimen-
sionally modulated using physical and mechanical field shaping elements.
The initially mono-energetic sharp beam is broadened by a scattering device to a flat
profile in the transverse direction. In depth, the Bragg peak is spread out by a range
modulator for the total length of the tumour volume. This SOBP is then shifted in depth
by absorber plates, named range-shifters.
For each patient and field, the lateral beam collimation is obtained by a physical colli-
mator and distally by a range compensator that considers the tissue composition. This
system has as limitation the fixed SOBP width, due to which the range adjustment at
the distal contour of the target may result in dose deposition outside the proximal region
of the target volume.
For treatments with carbon ions-beam it is also necessary to combine a rotating mod-
ulator wheel, or ridge filter, that produce a constant biological effect, which considers
the RBE variation in depth. However, this hardware-generated RBE does not consider
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the tissue-specific effects.
Figure 2.3: Diagram of two possible configurations for a beam shaping system:
a) Passive - the initial pencil beam is broadened by a scattering system. Thus, the beam is conformed
to the target volume through beam shaping devices (i.e. collimator, compensator). Figure from Schardt,
Elsässer, and Schulz-Ertner (2010)).
b) Active - scheme of the raster scanning system implemented at GSI and HIT, with representation of
the dipole magnets for the beam deflection and the synchrotron control system for the variation of the
beam energy, figure adapted from Durante and Loeffler (2010)). In contrary to the figure representation,
at HIT and GSI the irradiation is performed from the proximal target slice (Emin) to the distal one (Emax)
as consequence of the Therapy Control System (TCS) configuration.
Active systems
The implementation of an active scanning system is based on the sampling of the tu-
mour in iso-energy slices (IES) and voxels. Each voxel is irradiated with a pencil beam
where the energy of the beam is changed per slice by a range shifter or directly at the
accelerator. There are some variations of the active beam scanning, for instance the
”spot scanning” system from the Paul Scherrer Institut (PSI) (Pedroni et al. 1995), and
the ”raster scanning” technique developed by GSI (Haberer et al. 1993), and also in-
stalled at HIT. A diagram of the second one is depicted in figure (2.3 b).
In raster scanning systems each IES of the tumour is irradiated continuously point-by-
point in a defined path through the deflection of the pencil beam in the horizontal and
vertical direction using dipole magnets. While in spot scanning the beam is paused
during the transition from one scan position to the next one. In depth, the energy of the
pencil beam is adjusted resulting in irradiation of a different IES.
The advantage of active systems, compared with the passive beam delivery, is the
high dose conformation to the target without the need of physical patient-specific com-
pensators, collimators and modulator wheel. Moreover, active scanning systems al-
lowed for the improvement of the treatment accuracy with a more complete modelling
of the RBE for carbon-ion treatments (Elsässer, Krämer, and Scholz 2008; Krämer et
al. 2000).
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The Heidelberg Ion-Beam Therapy Center
The Heidelberg Ion-Beam Therapy Center, as part of the University Clinic of Heidel-
berg, is based on the pilot project initiated at GSI, where an experimental active unit
was available before the building of the HIT facility (Haberer et al. 2004).
HIT has three clinical beam-lines, as shown in the scheme of figure (2.4), where one of
them with a scanning ion gantry. The gantry allows the use of arbitrary beam directions
in the patient anatomy, by combination of couch and gantry rotation. Additionally, an
experimental beam-line is available for research purposes. All the rooms are equipped
with the fully active intensity-controlled raster-scan system.
Three electron cyclotron resonance ion sources enable the use of protons, carbon, he-
lium and oxygen beams, each at a single time (Winkelmann et al. 2014). Clinically, only
the first two are used, while the others two are used for pre-clinical studies. Thanks to a
Linear accelerator (Linac)-synchrotron, all the beam specifics can be controlled in en-
ergy, focus and intensity, resulting in a library of energies between 50 and 430MeV /u,
which corresponds to water-equivalent ranges from 2 to 30 cm, and spot sizes between
4 and 10 mm of full width at half maximum (FWHM) (Haberer et al. 2004).
The facility also comprises a combined positron emission tomography (PET) and com-
puted tomography (CT) machine, that can be used to assess the accuracy of the ion
range. After the treatment the distribution of the +-emitter in the tissues, which were
formed in nuclear fragmentation reactions during the irradiation, can be used to de-
termine the treatment accuracy by comparison with the Monte Carlo simulated activity
distribution, based on the planned dose distribution (Bauer et al. 2013).
The patient positioning is verified in-room using fluoroscope and X-ray planar imaging.
Exterior to the treatment room, for some indications, the positioning is also verified us-
ing the PET/CT machine.
2.2.3 Treatment planning systems
The treatment planning system must handle all the features and limitations facility-
specific that affect the planning process. The facility characterisation is given by the
Therapy Control System (TCS): whether the beam shaping system is passive or ac-
tive; if it is carried out actively by spot scanning or raster scan; if the energy variation
is a passive or active system and all other characteristics of each component that in-
fluences the planned dose (Jäkel 2012; Linz 2011). Beyond that, the used ion species
also need to be considered in the beam and biological models.
Due to the facility-specific TPS requirements, the following description is adapted to
the specifications of HIT, i.e, active energy variation with raster-scanned delivery, for
protons and carbon ions, from the physics and biological point.
The current treatment planning used in the clinical routine at HIT is the Syngo® RT
Planning (Siemens Oncology Care Systems, Erlangen, Germany), that was based on
the research prototype TRiP98 (TReatment PlannIng for Particles), developed at GSI
(Krämer and Scholz 2000; Krämer et al. 2000). Both systems were used in this dis-
sertation and a detailed description of their functionalities and limitations is presented
in the chapter (3.1). An explanation of the physical and biological models is described
below.
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Figure 2.4: Overview of the HIT facility, with the representation of the ion sources, synchrotron, beam
transporting lines, the three treatment rooms (two horizontal and one gantry) and an experimental area.
Figure from Winkelmann et al. (2014).
Water-equivalent path length
The TPS must be able to perform dose calculation based on the patient-imaging data
taken prior to the treatment. This is obtained from the CT information, where the
Hounsfield units (HU), related to the electron density, need to be scaled to the cor-
responding equivalent depth in water. This conversion is performed by the water-
equivalent path length (WEPL) concept and is given in a Hounsfield look-up table
(HLUT), as represented in figure (2.5) for a carbon ion-beam.
The WEPL can be determined by measuring CT HUs of tissue equivalent phantom ma-
terials, and by their integral stopping powers of the charged particle under calibration.
Afterwards, an stoichiometric calibration of CT HUs to particle stopping powers is per-
formed (Rietzel, Schardt, and Haberer 2007; Schneider et al. 2002).
The WEPL parameter is used to characterise the beam penetration range into the pa-
tient anatomy and it is employed during the dose calculation stage.
Note that inaccuracies between the range of the planned and delivered beams can
result in a potential mismatch of the target and dose to nearby critical structures. More-
over, the TPS besides the values from the CT correspondent to the patient’s body, also
the other treatment items, as immobilisation devices, such as treatment couch and all
the components in the beam path, need to be considered during the treatment plan
process (Newhauser and Zhang 2015).
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Figure 2.5: Representation of the Hounsfield look-up table for the carbon ion treatment planing. The
measured data is represented by circles connected by the straight lines. Figure from Rietzel, Schardt,
and Haberer (2007).
Model of the Bragg peak and SOBP curves
The beam model in TRiP98 describes each individual carbon pencil beam by a double
Gaussian, considering not only the multiple scattering around the primary beam but
also taking into account the nuclear scattering fragments resulting from the beam inter-
acting with the nozzle materials. Relative to the proton beam model a single Gaussian
is used. The total dose delivered by a beam Dbeam, is the summation of the total number
of pencil beams npb weighted by their specific particle number Nbp (cf. equation 2.4).
The dose generated by an individual ion-beam of energy Ebeam, centred at (x0,y0), at a
r distance from the beam centre is given by the energy loss distribution d(Ebeam,z) de-
pendent of penetration depth z and its lateral dose distribution l(r,z), therefore assumed
by a double Gaussian profile for carbon ions (Parodi, Mairani, and Sommerer 2013)
and single for protons.
Dbeam(Ebeam; x) =
npbX
d(Ebeam; z):l(r; z):Nbp (2.4)
For low-energetic heavy ion-beams (i.e. below about 150 MeV/u) the Bragg peak be-
come very sharp driving the need of many energy slices to deliver a homogeneous
dose distribution. Therefore, a passive beam shaping element, called ripple filter, is
commonly used to broaden the Bragg peak in depth (Krämer et al. 2000). Additionally,
the limitation of the monitoring to measure low particle fluences is also overcome, due
to the increase of the minimum number of particles per point in comparison to the situ-
ation without ripple filter.
Transport models of the beams
For heavy ions, as carbon ions, the ion transport in the tissue must include not only the
energy loss of the primary particle (beam attenuation), as for proton beams, but also
the energy loss straggling and secondary fragments production.
These physical processes are calculated in TRiP98 using the YIELD transport model
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(Krämer et al. 2000); wherein each slice of the target volume the ingoing and outgoing
energy spectra, can be defined and related with the ingoing/outgoing spectra from the
neighbour slices. The number of particles can change between slices due to the sec-
ondary particles generation. This information is given by the cross section of the parent
species. The depth dose distribution is obtained from the energy integration across all
the slices, which also includes the dose tail after the Bragg-peak. An alternative to this
model is the description of fragmentation using a Monte Carlo algorithm, like FLUKA
(Battistoni et al. 2016).
Concluding, the physical dose in tissue produced by each single beam is a function
of its width, distance from the beam centre, the number of particles, and energy loss
distribution (energy and depth dependent).
Biological dose
The biological model implemented at TRiP98 and Syngo® RT considers, for carbon
ions, the RBE variation with the depth, dose and the fragment spectra of the entire
beams. For heavy ions, this is not only implemented as a scaling factor but as an entire
optimisation problem, where the biological interaction process is described by the LEM
(Krämer and Scholz 2000).
The LEM combines the information of the cells response to the X-ray, the ion-track
structure and the size of the cell nucleus, correlating the local ionisation densities to
the biological effectiveness in each point of the treatment field. As a consequence the
RBE distribution is not homogeneous as can be shown in figure (2.6) for a pancreatic
patient in the TPS Syngo® RT.
For protons, a RBE of 1.1 is assigned for all beam energies and depths (ICRU 2007),
as discussed in the section (2.1.2).
Figure 2.6: Transveral view of the distribution of the physical and biological dose with the respective
RBE distribution for a pancreatic patient planned for carbon ions.
Plan optimisation
For facilities with active field shaping and energy variation, the TPS must be able to
perform the treatment plan optimisation through the different combination of the beam
intensities, positions and energies. In order to handle this complex library of parame-
ters, the optimiser offers the inverse planning functionality. From the definition of the
target prescription dose, constraints to the OARs and beam incidence directions, the
optimiser determines the set of plan parameters that match the planner requests.
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The plan optimisation to the desired dose distribution can be performed through Single-
Field Uniform Dose (SFUD) or Intensity Modulated Particle Therapy (IMPT). When the
plan is optimised using IMPT, it uses the full potential from the scanning delivery, hence
all the treatment fields are optimised simultaneously resulting in beams that may be
inhomogeneous in dose individually, while when summed up create a homogeneous
dose. Consequently, more optimal dose distributions in terms of organ at risk sparing
are achievable through the use of higher dose gradients. Lomax (2008c) stated that
these plans are highly sensitive to set-up and range uncertainties. In contrast, with
SFUD each field delivers a uniform dose distribution, through the different weighting of
each spot but with lower dose gradients. However, strategies to improve IMPT robust-
ness are possible and may result in better plans compared to the SFUD (Chen et al.
2012; Liu et al. 2012b).
Altogether, for a beam scanning facility, the output of the TPS is given in terms of the
number of raster points (RPs) and their position in a defined order (scan path), for each
iso-energetic slice of the target volume. Furthermore, a TPS in ion-beam RT should
be likewise able to account for uncertainties, e.g. range, positioning and HU-WEPL
conversion inaccuracies. This topic is addressed in the next section.
2.3 Uncertainties in ion-beam therapy
Several sources of uncertainties are present in the clinical application of ion-beams (Li
2012) which need to be quantified, the dosimetric impact evaluated, and incorporated
in the treatment plan in order to increase the treatment robustness. Some of these un-
certainties originate from:
• Range uncertainty;
• Patient set-up error;
• Patient anatomical and physiological changes;
• Intra-fraction organ motion;
• Relative biological effectiveness (RBE) approximations.
These sources of uncertainties can have random and/or systematic error components.
While random errors may blur the dose distribution, systematic errors may cause a shift
of the cumulative dose distribution relative to the target and target dose inhomogeneities
(Van Herk 2004). A systematic uncertainty arises for example, if the CT underlying
treatment planning is not correct, as a result the range uncertainty will be carried along
all treatment fractions.
Note that for many of these uncertainties, if from a random source as a set-up error and
intra-fractional motion, a fractionated delivery has the potential to mitigate their signifi-
cance (Lomax 2008b; Wölfelschneider et al. 2015).
2.3.1 Range uncertainty
As stated in the previous section (2.2.3), the beam range is determined from the WEPL
(Rietzel, Schardt, and Haberer 2007; Schneider et al. 2002). The conversion process
from the CT numbers of the patient’s anatomy along the beam path to tissue-to-water
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relative stopping power ratio exhibits uncertainties, which translate into beam range
uncertainties. Examples are the uncertainties from the determination process of the
conversion curves, imaging artifacts (e.g. beam hardening effects) and weak depen-
dence of CT numbers on tissue compositions (Li 2012).
Clinically, proximal and distal margins of up to 3.5% of uncertainty have been added
to the calculated beam range to accommodate for such uncertainties, especially for
scattered broad beam techniques (Yang et al. 2012). Nevertheless, this procedure can
compromise the dose to critical organs distally located to the target. Hence, when pos-
sible, beam angles for which the OAR are distal to the target are avoided.
For scanning techniques, the method to account for range uncertainties is more com-
plex (Albertini, Hug, and Lomax 2011) since it also needs to include themisplacement of
individual beam spots and uncertainties in IMPT optimisation algorithms. One of the ap-
proaches under investigation is IMPT optimisation algorithm based on worst-case dose
distributions that include range uncertainty as well as set-up errors (Liu et al. 2012b).
Therefore, this method is recalled in the next point.
2.3.2 Patient set-up error
The potential patient misalignment is, in photon radiotherapy included in the treatment
planning by the use of margins to the tumour (Van Herk 2004). In charged particles
the use of target margins has been shown to have limited effect to overcome these
uncertainties. Moreover, these variations, even in the range of milimetres, can strongly
degrade the dose distribution specially for plans highly modulated, such as IMPT plans
(Lomax 2008a,b).
The improvement of the plan robustness in ion-beams can be achieved by incorporat-
ing the uncertainty information into the optimisation process (Fredriksson 2012; Unkel-
bach et al. 2009). This computation considers the systematic and random errors and
can either be performed probabilistic or non-probabilistic, whatever uncertainties are
assumed to have a normal distribution and optimised the expected value of a weighted
sum of quadratic dose deviations (Unkelbach et al. 2009), or minimising the worst case
penalty (Fredriksson 2012; Lomax 2008b). In this worst-case dose distribution, ev-
ery target voxel takes the lowest dose that can occur for any error scenario and every
healthy tissue voxel takes the highest dose.Therefore, this approach tends to over-
estimate the effect of the possible uncertainties and result in dose distributions less
conformal to the target volume.
2.3.3 Inter-fractional anatomical and physiological changes
Besides the set-up uncertainty, the patient also experiences anatomic variations along
the treatment course. These inter-fractional changes are usually due to weight loss,
tumour shrinkage and organ filling variations (e.g. stomach, bladder, intestine).
The finite range of ion-beams makes this technique highly sensitive to tissue density
changes (Bert and Durante 2011). Hence, these anatomic changes may strongly af-
fect the beam path length during the beam delivery, reducing the quality of the planned
dose distribution as a consequence of the pencil beams over- or under-shooting.
The inclusion of this additional inter-fractional uncertainty factor in the beam range
could be performed with some mitigation strategies, as adapted Planning Target Vol-
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ume (PTV) margins that consider range changes without compromising the dose to the
normal tissues (Park et al. 2012) and selection of robust beam angle configurations
(Cabal Arango 2012). The robustness of these plans needs to be quantified using an
adapted metric, like error-bars for dose distributions and dose-volume histograms, for
which site-specific robustness planning protocols still need to be established (McGowan
et al. 2015). A possible option is to evaluate the plan against a database to help in the
selection of the optimal plan.
The increase of the plan robustness usually results in a decrease in plan conformal-
ity, therefore finding the balance between dose conformation to the target and plan
robustness is one of the main tasks to establish a site-specific robustness thresholds
(Albertini, Hug, and Lomax 2011; McGowan et al. 2015).
In summary, several strategies are in research to improve the treatment plan robust-
ness. However, limited integration of robust planning in a commercial TPS is available.
Actually, the only solution is provided by RaySearch Laboratories AB (2015) through
the calculation of the minimax optimisation, in which the optimisation functions are con-
sidered under the worst case scenario (Fredriksson, Forsgren, and Hårdemark 2011).
This tool does not take into account, however, any effects resulting from fractionation
and this tend to overestimate the effects of the these uncertainties. Therefore, clinical
plans usually don’t include directly in the TPS the robustness assessment, as part of
the evaluation process, and no metric is yet available to their evaluation.
2.3.4 Intra-fractional organ motion
From the intra-fractional side, the leading factors for daily changes in the dose distribu-
tion are the breathing, cardiac beat and peristaltic movements.
Besides the influence on the radiological path length, the intra-fractional motion is also
responsible for the dose degradation. This effect occurs firstly due to the inter-field
motion (Lomax 2008b) and can be stronger if the treatment is delivered using scanning
techniques, where the temporal interference between the scanning beam movement
and the organ motion produces inhomogeneous dose distributions, the so-called intra-
field interplay effects (Bert and Durante 2011; Bert, Grözinger, and Rietzel 2008). The
diagram of figure (2.7) represents the formation of this intra-field interplay phenomenon.
The sensitivity of the dose distribution to themotion has been heavily investigated, since
the results from Phillips et al. (1992) in which a small target motion (below 3 mm) con-
ducted to dose changes of up to 20% relative to the expected.
Due to these effects, scanned beams have been mainly employed to static, or quasi-
static tumours. Otherwise, this impact must be attenuated through motion reduction or
adapted beam delivery and planning strategies (Bert et al. 2014; Engelsman, Bert, and
Paganetti 2011). Therefore, an indispensable task is the accurate motion monitoring
with an adequate latency time.
A review of the used methods in ion-beam therapy are given below.
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Figure 2.7: Diagram of a target that moves between maximum inhale (blue state) and maximum exhale
(green state), according with the breathing displayed in the bottom curve. As a consequence, each raster
point is delivered to a different target coordinate. Additionally, the beam moves along a pre-defined scan
path within a slice, resulting at the end of the treatment in a dose degradation. Figure adapted from Bert,
Grözinger, and Rietzel (2008)).
2.3.4.1 Motion monitoring
Several commercial systems are available for motion monitoring in radiation therapy.
Its operation can be radiation-based, allowing the direct visualisation of the tumour mo-
tion, or based on a surrogate signal (e.g. breathing), which should be correlated with
the tumour motion.
Concerning the systems for real time monitoring of the breathing, the most commonly
available are the following:
• Real-time position Management (RPM) System, Varian Medical Systems. It is
based on an infrared tracking camera and a reflective marker block.
• Spirometry-respiratory volume measurement, for example, the solution Active
Breathing Coordinator, Elekta. It is a computer-controlled device that pauses the
patient’s breathing during the irradiation (assisted breath-hold).
• AlignRT, Vision RT. It maps the patient surface based on the triangulation signal
from optical cameras.
• Calypso system, Varian Medical Systems. The system uses field generating coils
implanted inside or close to the tumor whose positions are detected by an elec-
tromagnetic detector array.
• AZ-733V Respiratory Gating System, Anzai Medical Co.,Ltd. It uses a pressure
sensor to detect the external respiratory motion.
The AZ-733V Respiratory Gating System, from here on called Anzai, was the system
used in the dissertation, for the time resolved computed tomography (4DCT) acquisi-
tion and breathing monitoring of the patient during the treatment delivery. This system
is constituted by a belt, which is fastened around the patient waist, a sensor port and
a load cell (device of piezoelectric material). The sensor port is responsible for the
amplification of the signal and it emits an analog signal to the wave deck hardware.
Here, the signal is preprocessed, digitalised and sent as an input to the Anzai applica-
tion software, running on an external computer. The software displays the motion and
allows the setting of the control parameter of the wave deck. The tracer signal can be
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manually corrected along the acquisition in magnification and position.
The working principle of the system is the translation of the pressure applied to the sen-
sor, by the fastened belt across the chest, to inhale/exhale of the breathing cycle. The
system assumes that the breathing cycle represents the tumour motion. The degree of
correlation between these two data dictates the accuracy in the detection of baseline
shifts, phase and amplitude changes of the tumour. Investigations on the correlation
between the Anzai belt and other monitoring systems, as well the internal motion have
been performed by several authors (Brevet 2011; Torres 2011). Brevet (2011) showed
problems of reproducibility due to the system sensitivity to the location where the sen-
sor is placed. However, was found for a thorax phantom a good correlation between
the Anzai signal and the fluoroscopic data.
2.3.4.2 Motion mitigation strategies
Motion compensation methods can be organised into two main groups: (a) techniques
in which the motion is eliminated/reduced, or (b) patient irradiation under free-breathing
but accounting with the motion effects during the treatment planning or delivery.
Note that typically several of these strategies are combined.
a) Motion reduction techniques
The simplest method to reduce the impact of motion in the delivered dose is the direct
elimination or mitigation of the patient’s motion. Frequently applied breathing control
techniques are for instance anaesthesia, breath-hold and abdominal compression.
Breath-hold in inspiration or expiration of the patient is the easiest to implement in the
clinical routine. However, this method requires patient coaching, patient cooperation
and small consecutive irradiation times. On the other hand, active breathing systems
use a spirometer to automatically suspend the patients breathing in a defined respira-
tory cycle window.
The abdominal compression consists on a plate with a fixing structure to the couch,
which mechanically applies pressure on the upper abdominal and limits the diaphragm
excursion. This method has as limitation the discomfort to the patient, or even pain in
some cases, only limits the breathing to a smaller amplitude, does not extinguish it, and
is likely to foment irregular breathing curves and internal organ motion.
b) Methods under free-breathing
These kind of strategies can be applied to the treatment planning or on the delivery
stage. If they are applied during the treatment the latency time needs to be evaluated
and can strongly affect the quality of the irradiation.
Themain advantage of thesemethods is the comfort to the patient and the treatment de-
livery under the normal patient’s anatomy and physiology (no compression or spirome-
ter). However, it requires adaptation of the treatment planning and/or delivery workflow.
b1) ITV-based treatment planning
The use of internal target volume (ITV) during the planning stage is a widely employed
strategy in photon therapy. It is able to increase the robustness of the plan by con-
sidering the tumour location and size in each breathing phase, however, for dynamic
techniques interplay may occur. By contrast, due to the range sensitivity introduced in
particle therapy, this method is usually not enough to account for all the range changes
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that might affect the plan quality and might strongly increase the dose in the normal
tissues (Rietzel and Bert 2010).
An adapted approach to ion therapy is the use of WEPL-ITVs (Graeff, Durante, and Bert
2012), where the range changes resulted from the motion are quantified, based on the
4DCT data, and included in the plan optimisation process. This technique improves
the target irradiation along the treatment but doesn’t exclude interplay effects that will
reduce the dose homogeneity.
b2) Beam rescanning
Rescanning techniques try to mitigate the dose degradation and interplay effect, be-
tween the beam scanning and the tumour motion, considering that the statistical av-
erage of local over- and under-dose has a homogeneous distribution. This method
performs a multiple ”repainting” of the optimised plan, which considers the full motion
extension with a proportional reduction of the number of particles per scan position.
There are two different approaches to deliver the treatment plan: iso-energy slice re-
painting or volumetric repainting (Graeff 2014; Schätti et al. 2013).
An issue associated with this technique is the lateral scanning and energy changing
speed, which might compromise the effect of rescanning when the delivery and motion
periods are in coherence (Bernatowicz, Lomax, and Knopf 2013). Moreover, rescan-
ning may mitigate the interplay effects but not the target motion itself, therefore, range
variations should be incorporated in the treatment planning (Rietzel and Bert 2010).
b3) Beam gating
Beam gating consists of tumour irradiation only during a specific window of breathing
phases, resulting in a smaller ITV.
The application of this technique to ion-beam therapy, and specifically to active beam
scanning, is feasible, although a residual interplay effect within the gating window can
still result in dose degradation (Rietzel and Bert 2010). This effect can be reduced with
some strategies, as beam gating with rescanning (Furukawa et al. 2007; Graeff et al.
2014) or decreasing the iso-range slice distance and increasing the pencil beams width,
which is correlated to the amount of residual motion within the gating window (Bert et al.
2009).
Drawbacks of this technique are the strong sensibility to the beam gating modality, i.e.
when phase-gating is used, baseline shifts and amplitude changes might be ignored,
while in amplitude-gating mode baseline shifts might result in the selection of an inac-
curate gating window. Additionally, it leads to an increases of the treatment time and
the residual motion within the gating window can still influence the irradiation accuracy.
Also, the fact that beam gating introduces correlation between the beam application and
the patient motion might result in larger dose degradation, compared to the no-gating
case, if the residual motion is not sufficiently small.
b4) Beam tracking
Contrary to the previously enumerated methods, beam tracking, besides restoring the
dose homogeneity, keeps the irradiation volume smaller, as ideally the safety margins
can be reduced.
Beam tracking consists in steering the beam in order to ”follow” the tumour movement.
Hence, this method requires that in real time the delivered plan is adapted based on
the feedback from the current tumour position. This is expressed in scanned delivery
by the adjustment of the lateral position and energy of each pencil beam (Bert et al.
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2007; Saito et al. 2009; Water et al. 2009).
The latency time of the system plays here an important role, since it needs to be signif-
icantly lower than the scanning time between two consecutive scan positions, and the
patient’s motion due to breathing.
Another concern when performing tracking refers to the increase of the doses to the
normal tissues, proximal to the tumour, as a result of the overlap of the beam entrance
channels. Moreover, treatment planning and quality assurance protocols need to be
adapted to include the uncertainties that might arise from this technique.
b5) 4D optimisation
Different optimisation methods have been developed to reduce the motion impact in
scanning systems. The simplest way is to optimise the planned raster field (RST) to
include the range changes from the 4DCT data (Graeff, Durante, and Bert 2012).
If besides this information, it is also included the correlation between the dose delivery
timing and the motion surrogate, a 4D-RST could be optimised. This 4D-RST will define
which beam spot is delivered in each 4DCT motion phase with the aim to obtain an uni-
form dose per motion phase (Graeff et al. 2014). In this case, it is necessary to ensure
the synchronisation between the delivery and the patient motion during the treatment,
which constitutes a weakness since changes in the the TCS need to be performed. A
full discussion of the different methods can be found in Graeff (2014).
Also in this case, treatment planning and quality assurance protocols should include
the verification of uncertainties associated with this technique.
2.4 Ion-therapy workflow for moving targets
Tumours under inter- and intra-fractional motion require an adaption of the treatment
in order to mitigate its impact and increase the treatment robustness. An example of
the workflow at HIT is shown in figure (2.8) and the description of each of the steps is
furthermore explained.
2.4.0.1 4DCT acquisition
The inclusion of the motion information in the radiotherapy workflow is usually per-
formed through the use of a 4DCT, in which the image of the moving object is retro-
spectively reconstructed according to the recorded breathing phase or amplitude of the
monitored motion pattern (Farncombe and Iniewski 2013).
The 4DCT information is not only used to delineate the tumour and normal tissues in
each of the motion phases, but also to quantify the movement of the tissues. Neverthe-
less, the patient’s motion registered from the 4DCT is only a model formed by a set of
images, based on a breathing signal that is assumed perfectly periodic and correlated
to the internal organ motion, which does not ensure the reproducibility on the treatment
day.
The image acquisition is usually performed over free breathing, therefore, the collection
of images corresponds to different physical locations of the couch. During the recon-
struction stage, the images are sorted over each breathing phase based on an external
trace signal (e.g. Anzai sensor), which is synchronised in time with the CT acquisition.
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Figure 2.8: Diagram of the treatment stages at HIT for tumour locations subject to inter- and intra-
fractional motion, where the distinguishing component is the acquisition of a 4DCT, themotionmonitoring,
and the pre-treatment CT. An example of patients that follow this protocol are the pancreatic patients.
The data sorting can be amplitude- or phase-based. When the Anzai pressure belt is
used as monitoring system a relative phase-based sorting is performed.
2.4.0.2 Target and organs-at-risk definition
The target and OARs definition in ion-beam therapy uses the same concepts of the
photon therapy, given in the ICRU report 50 and 62 (ICRU 1993, 1999), as displayed
in figure (2.9).
The physician uses the information from a native CT, optionally also a registered CT
with contrast, a Magnetic Resonance Imaging (MRI) or PET, to delineate the Gross
Tumour Volume (GTV).
A margin is added to the GTV to account for microscopic disease, defining the des-
ignated Clinical Target Volume (CTV). Although the CTV is the volume intended to be
irradiated, in order to consider random and systematic uncertainties, the volume taken
for the treatment planning is the Planning Target Volume (PTV). The PTV should be
large enough to allow the full coverage of the CTV during the entire treatment course,
but as small as possible to spare the healthy tissues. Hence, the PTV is defined as the
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CTV plus a set-up margin that can be asymmetric, depending on the included uncer-
tainties.
In case of moving targets, these uncertainties need to consider all the motion-related is-
sues by adding an intermediate step in the PTV definition, as suggested in the ICRU62
(ICRU 1999), through the inclusion of an internal margin (IM) to the CTV, which will de-
fine the Internal Target Volume (ITV). This ITV concept is usually generated based on
the 4DCT motion information, either through the union of the CTVs in each breathing
phase to represent the full set of possible positions of the tumour (Rietzel, Pan, and
Chen 2005) or using the maximum intensity projection as criteria for the target volume
contouring (Underberg et al. 2005).
However, for particle therapy, these geometric margin concepts are frequently not suffi-
cient (Bert, Grözinger, and Rietzel 2008; Mori et al. 2008; Rietzel and Bert 2010), since
the range variations and interplay effect are not included in their definitions. Hence, it
should be replaced by a concept that comprises the information from the radiobiological
path length and intra-fractional range changes.
Furthermore, the OARs should consider the internal motion being redefined as Plan-
ning Organs at Risk Volume (PRV).
Figure 2.9: Transversal view of a CT of a patient showing the ICRU target concepts (GTV, CTV, ITV, PTV)
and OARs. For the spinal cord and bowel is also shown the PRV (in black) used during the treatment
planning to account for uncertainties.
The dosimetric recommendations for the PTV follow the photon-guidelines (ICRU
1999), i.e, the PTV total volume should receive between -5% and +7% of the prescribed
dose. Hence, it is usual to quantify the PTV coverage by the volume receiving 95% of
the prescribed dose (V95), which should be superior to 95%, and the overdose volume
as the PTV that receives more than 107% of the prescribed dose (V107), which should
be as small as possible. However, considering that the volume intended to irradiate
is the CTV, and the PTV is just a strategy to reach this aim, V95 and V107 are usually
referred to the CTV.
The target dose homogeneity (HCTV ) can be quantified by the difference between the
dose covering 5% and 95% of the CTV volume, D5 and D95, respectively (eq. 2.6). This
parameter quantifies the steepness of the Dose-Volume Histogram (DVH) and ideally
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should be as small as possible.
Relative to the target dose conformity, the conformity number (CN) was used (eq. 2.6)
(Van’t Riet et al. 1997), where V95%CTV is the volume of CTV (VCTV ) receiving at least
95% of the prescribed dose and V95% is the overall volume that receives 95% of the
prescribed dose. The CN will vary between 0 and 1, with 1 for a totally conformal dose
to the target volume.
HCTV = D5  D95 (2.5)
CN =
V 295%CTV
VCTV :V95%
(2.6)
Regarding constraints for the OARs, the most used guideline is the work of Emami
et al. 1991, in which the constraints are given for a dose of 1.8 - 2.0 Gy per day, at 5 days
to week schedule. Some effort has been done by several groups to update the normal
tissues threshold dose, but still no consensus is available, mainly when speaking about
the complications under ion-beam irradiation (Schlaff et al. 2014). Therefore, the com-
mon practice is still based on the experience with photon-irradiation and adapted to the
clinical results from the previously irradiated patients.
2.4.0.3 Treatment planning for moving targets
A time-resolved (4D) TPS for moving targets in ion-beam therapy is of fundamental im-
portance to account for the dose degradation as a result from the target motion and the
beam dynamic (Bert et al. 2014). However, no commercial solution is currently avail-
able and a research-TPS is limited to some facilities.
The system available at HIT for research purposes is a 4D version of the TPS TRiP98
developed at GSI, designated as TRiP4D (Bert and Rietzel 2007; Eley et al. 2014;
Richter et al. 2014a). TRiP4D has functions that allow time resolved dose calculation
and dedicated 4D optimisation functions.
Relative to the 4D dose calculation, TRiP4D considers the specifications of the beam
scanning system at HIT and is able to simulate the temporal interference between the
beam and the target motion, given by an external surrogate signal. The information of
the patient is taken from the 4DCT, while the beam delivery sequence (BDS) (i.e, num-
ber particles per spot, intensity level and beam pauses) is obtained from the accelerator
control system (ACS).
The effect of the different breathing phases (states) in the tumour and patient geom-
etry results in changes in the dose distribution when compared with the static case.
This can be simulated through the use of transformation maps between states, namely
the three-dimensional (3D) vector fields obtained from the deformable image registra-
tion (DIR) between each breathing phase and the reference one, usually end-exhale
(0%Ex). So, as result of the use of these transformation maps the dose in each raster
point (RP), distributed to the respective breathing phase CT, is summed up in the ref-
erence state, wherein the total dose is computed. All in all, the final dose is the sum of
the contribution from each raster point in the respective breathing state.
The information about the singular time-resolved RP position is given by the temporal
correlation between the BDS and the breathing pattern, figure (2.10).
A more detailed insight of the functionalities and limitation of this TPS, in the context of
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this dissertation, is discussed in chapter 3.1.
Figure 2.10: Diagram of the time-resolved dose forward calculation based on the correlation between
the patient’s breathing state and the respective irradiated raster points. The beam delivery sequence is
sorted per breathing state (correspond to the different colours in the figure) and the dose is calculated in
the respective 4DCT state. Hence, the total dose distribution is the summation of the dose delivered in
the different CTs. The states 20%In, 25%In, 50%In,75%In,100%In correspond to the inspiration process
(full-inspiration to end-inspiration), while 100%Ex, 70%Ex, 40%Ex, 0%Ex is the expiration process from
full-expiration to end-expiration state. These sorting correspond to the used in this thesis.
Several investigations have been performed in order to assess how the scanning
parameters can be adjusted during treatment planning in order to reduce the motion im-
pact. Particularly the studies from (Bert and Durante 2011; Richter 2012; Richter et al.
2014b) in which the optimisation of the scanned parameters showed to be effective in
the plan robustness, as the beam overlap through the change of the grid spacing, beam
FWHM, beam energy layer spacing and ripple filter. However, not all the parameters
are easily adjustable, since these depend on the ACS and TCS specifications. More-
over, aspects as the homogeneity of the number of particles in neighbouring raster
points might have a superior potential to improve the intra-fractional robustness.
Another aspect of a 4D-TPS to be considered, besides the time-resolved dose calcu-
lation, is the potential to perform a 4D dose optimisation (Graeff et al. 2013). These
methods are also implemented in TRiP4D, but were out of the scope of this thesis.
Additionally, approaches like rescanning, beam gating and tracking also need to be in-
cluded in a 4D-TPS, either in the optimisation process or with aim to perform 4D dose
simulation.
2.4.0.4 Patient-specific quality assurance
To verify the reproducibility of the delivery system and motion monitoring method, a
patient-specific quality assurance (QA) under motion condition is strongly suggested
pre-treatment. Several approaches are under investigation (Batista 2015; Steidl et al.
2012), having in common the use of moving phantoms with dosimeters suitable for
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ion-beam dosimetry (Bert and Durante 2011). Moreover, due to the non-uniform dose
distribution, resulted from temporal interference between the scanned beam and phan-
tom motion, a set-up with multiple ionisation chambers is recommended.
At HIT the dynamic set-up is based on the one for static dose verifications. For static
cases the patient-specific QA is performed by transferring the treatment plan to a ho-
mogeneous phantom geometry and through comparison between the TPS calculated
and measured dose. The phantom consists in a motorised water phantom with an array
of 24 ionisation chambers (ICs). In its dynamic version, an in-house developed mini-
water phantom is mounted on the commercial QUASAR™ Respiratory Motion Platform,
which moves with a loaded respiratory motion profile of a patient (Batista 2015).
2.4.0.5 Patient immobilisation and positioning
The patient immobilisation must be able to reproduce the patient geometry from the
moment of the planning CT acquisition, which will be used for the treatment planning
purposes. Usually, in order to accomplish a reproducible positioning, stereotactic body
frames, vacuum pillows or thermal plastic restraints are used.
As for the patient repositioning, a pre-treatment soft tissue imaging is suggested, par-
ticularly for abdominal patients. This helps to verify the daily extension of the geometric
uncertainties resulting from the tissue deformations. Consequently, some of the rec-
ommended modalities are cone-beam CT or in-room CT.
As previously stated, the workflow at HIT (fig. 2.8) comprises daily orthogonal 2D X-
ray acquisitions for bony match and an additional pre-treatment CT, for specific clinical
indications (e.g. weekly for pancreatic patients).
2.4.0.6 Treatment delivery
For moving organs, as stated in the section (2.3.4.2), strategies to mitigate the motion
effect during the treatment delivery need to be applied.
At HIT the Anzai system is used to monitor the respiratory motion during the treatment
delivery as well as to control the gating treatment (when it is applied). The Anzai ouput
is connected to a data acquisition system, EtherCat system, that correlates the breath-
ing signal of the patient and the delivery temporal sequence of the accelerator. This
information can later be used in the reconstruction of the delivered dose.
2.4.0.7 In-vivo range verification
After the treatment, the irradiated tissues emit + as a result from the produced sec-
ondary fragments during the beam delivery (e.g. 11C, 10C, 15O). The distribution of
these +-emitters in the tissue can be visualised using PET-imaging.
Particularly important in the case of moving targets is the consideration of the activity
washout during the analysis of the PET-images, which is possible through the acquisi-
tion of 4D PET imaging (Kurz 2014; Parodi et al. 2009).
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2.5 Pancreatic cancer
The challenge of treating pancreatic cancer arises from the anatomic location, biology
of the malignant cells and the internal motion of the organ itself and surrounding tissues.
2.5.0.1 Anatomy
Pancreas is an abdominal organ primarily responsible for the insulin and digestive en-
zymes production. Morphologically, the organ is divided into four sectors: head, neck,
body and tail.
Its deep location in the abdomen, and in close proximity to many important structures
such as the small intestine (the duodenum) and the stomach, are the major sources
of difficulties in external radiotherapy. An example of the anatomy observed in a CT
image is shown in figure 2.11.
Figure 2.11: a) Transversal view of a computed tomography image of a pancreatic patient with the main
surrounding organs delineated. b) 3D reconstruction of the patient anatomy.
2.5.0.2 Cancer types and therapeutic modalities
The classification of the cancer type is in accordance with its origin: endocrine or ex-
ocrine. Only five percent are tumours of the endocrine pancreas, the majority being
exocrine tumours, which develop from cells that line in the system of ducts that de-
liver enzymes to the small intestine and are referred as pancreatic adenocarcionamas
(Hansen and Roach 2007). Moreover, two-thirds of the cancers are present in the pan-
creas head.
For practical purposes, tumours are generally classified as resectable (Stage I, II), un-
resectable (Stage III), and metastatic (Stage IV). According to the tumour grade, size
and symptoms the applied treatment is selected, e.g. surgery, adjuvant or concurrent
chemo-radiotherapy, usually using gemcitabine or 5-FU (Li et al. 2004). Surgical re-
section is the main therapeutic, however, overall survival after surgery alone remains
with a five-year survival rate of about 20% (Buchler, Kleeff, and Friess 2007).
Conventional photon therapy is usually performed using a three or four field design,
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which uses high energy photon fields (e.g. 18MV) particularly for lateral or oblique
fields for a prescribed dose of 45 Gy at 1.8 Gy /fx with a boost until 59.4 Gy, see figure
(2.5.0.2). The main barrier to this therapeutic modality is the critical normal tissues tol-
erance, as liver, kidneys, small bowel, and spinal cord.
For locally advanced tumours, a recent analysis showed that most tumour recurrences
occur within a 2 cm radius of the primary tumor (Kessel et al. 2013), indicating the need
for dose escalation to improve the local control while keeping reduced side-effects.
Thus, alternatives to conventional radiotherapy, which tolerate dose-escalation, have
been sought. Such modalities are intraoperative radiotherapy (IORT), stereotactic body
radiotherapy (SBRT), brachytherapy and ion-beam therapy.
The high precision of ion-beams, while delivering high doses to the tumour and sparing
Figure 2.12: Axial view of a pancreatic patient and its dose distributions under different radiotherapy
techniques. left) Tridimensional conformal photon radiotherapy; central) Intensity-Modulated Radiation
Therapy (IMRT); right) Proton plan using a passive scattering beam system. Figure from Ling et al.
(2015).
the OARs, incite its application in pancreatic patients.
Studies have been conducted to investigate the clinical application of protons (Ding
et al. 2014; Nichols et al. 2014). Simultaneously, the use of carbon ions have been
studied at NIRS and HIT (Combs et al. 2013; Shinoto et al. 2013; Tsujii et al. 2013).
While protons offer the possibility of a highly conformed treatments, carbon ion-beams
exhibit additionally a RBE enhancement of 1.16 - 2.46 for pancreatic tumour cells and
a low OER, which due to the large fraction of hypoxic cells in pancreatic tumours make
them a promising treatment option (Yamada et al. 2010).
The obtained results from NIRS are extremely promising, where the dose escalation
and concurrent gemcitabine-chemotherapy with carbon ion-beams radiotherapy have
shown an increase in the tumour local control and in the overall survival (Shinoto et al.
2016; Tsujii et al. 2013). For patients receiving a higher dose (≥ 45.6 Gy (RBE)) the
freedom from local progression rate was 83% at 2 years while the respective overall
survival rate was 48%. Concerning side effects, low toxicity was detected, with only
15% of the patients exhibiting acute gastroduodenal ulcers of grade 1 or 2.
However, the finite range of ion-beams presents strong sensitivity to density variations,
i.e. changes in the patient’s anatomy, which might be a concern for these patients. This
topic is covered in the following section.
2.5.0.3 Organ motion
The high sensitivity of the ion range to density changes in the beam path induces dose
under- and over-shoots, leading to the tumour dose degradation. These variations can
either result from inter-fractional anatomy changes, patient positioning or intra-fractional
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motion.
In pancreatic patients, the inter-fractional changes are mainly due to tumor shrinkage,
organ filling (bowel and stomach) and loss of adipose tissue. Horst et al. (2013) mea-
sured variations in the tumour location along the treatment course superior to 10 mm
for a large percentage of patients, while Liu et al. (2012a) detected a significative inter-
fractional organ deformations for abdominal organs (as pancreatic head, duodenum,
and stomach) with an average maximum overlap ratio between the volumes based on
planning and daily CTs of 80.2% for the pancreatic head.
Relative to intra-fractional changes, Mori, Shinoto, and Yamada (2014) and Mori et
al. (2010) quantified the tumour motion for two sets of patients as (9.10.4) mm and
(6.73.7) mm, respectively. These variations corresponded to changes in the maximal
dose received by the kidney of 3%, with a conventional passive carbon ion-beam. Also
Kumagai et al. (2009), pointed for the impact of the intra-fractional bowel gas move-
ment, resulting in a mean dose degradation to the target of 3.5%. Despite this under-
and over-dosage as a result from density changes, when the treatment is delivered with
a scanning system, the interplay effect will additionally play an important role.
Chapter 3
Characterization of software and tools
This chapter explores the characteristics and technical issues of the software and tools
available at HIT which were subsequently used in this dissertation.
The description of the main functionalities and limitations of these systems will help to
understand and guide in the comprehension of the adopted protocols and obtained re-
sults in the following chapters (4) and (5).
3.1 Treatment planning systems
Two TPS were used in this study. Syngo® RT Planning is the clinical system currently
in use at HIT, while TRiP98 is a research-TPS, developed as a prototype of Syngo® RT
,and therefore includes additional research features to the commercial system. One of
the features is a 4D version able to perform time-resolved dose calculations, so-called
TRiP4D.
Syngo® RT Planning and TRiP98 share the same base data. This base data corre-
sponds to the description of the HIT scanner, accelerator energies, beam focus and
intensities, RBE tables and HLUT data.
3.1.1 TRiP98
Definition and aim
TRiP98 is a command-line oriented TPS written in C programming language. It was
developed during the GSI pilot project to fulfill the need of a planning system for heavy
ions. It is particularly adapted for carbon (12C), however, other particles are available
as protons and oxygen (16O).
Its main function is the calculation and optimisation of 3D dose distribution, both consid-
ering the physical and biological effects. Moreover, handling and processing of specific
TPS data is possible.
Functionalities
A sketch of the general structure of TRiP98 is shown in figure (3.1).
Either for the purposes of dose calculation or optimisation the definition of the following
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is primarily required:
• Projectile type (carbon, proton, oxygen,..)
• CT cube; describes the three-dimensional anatomy of the patient based on a CT
data, given in terms of Hounsfield numbers, later on converted to particle ranges.
This cube must be given in a binary format with extension .ctx and accompanied
by a header file .hed that contains information about format, dimension, voxel size
and byte order.
• Volumes Of Interest (VOIs); describes the contours of the target and the critical
structures in the patient’s CT. Each VOI contains the information of the tissue type
and its shape defined per CT slice. The data is given in a file with the extension
.vdx also accompanied by a header .hed file.
Figure 3.1: Diagram of the general structure of TRiP98. Drawn in grey is the recently included OER
implementation. TRiP98’s inputs are dependent on: particle charge (Z), actual energy (E) and initial
beam energy (Eb), PET-3D map of oxygen concentration (pO2) and the dose averaged linear energy
transfer (LET). Figure adapted from Krämer et al. (2014)).
Moreover, the facility-specific characteristics need to be incorporated. A list of examples
is given below:
• Scanner capabilities, i.e. definition of the properties and limitations of the raster
scanner system, as e.g.:
– scanner path optimisation,
– water equivalent offset between beam outlet and patient’s volume,
– minimum and maximum scanner step size in both dimensions,
– lower and upper particle number limits to be allowed,
– scanner coordinate limits,
• Table of accelerator energies - contains the energy steps and respective focus
and intensity steps;
• Energy loss tables (dE/dx) - energy loss for various projectiles at various energies;
• Total reaction cross sections - includes the total cross sections for nuclear reac-
tions of various projectiles at various energies;
• Fragment spectra - spectra are organised by the primary beam energy, wherein
the spectral distributions at a particular depth is by the energy distribution de-
scribed;
• Depth dose distributions - set of tables organised by primary beam energy;
• RBE data tables - used for the biologically equivalent dose calculation, it contains
the cell specific RBE data as a function of particle species and energy;
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• OER data tables;
• HLUT - describes the relation between HU and the WEPL.
Note that TRiP98 uses the coordinate system establish to the GSI scanner, as ex-
plained by Jäkel et al. (1997), therefore defined in terms of patient, room, couch or
raster-scanner perspectives. This result in the need to convert IEC and DICOM coor-
dinates to the TRiP system (e.g. isocentre, gantry and couch angles).
a) Dose optimisation
Dose optimisation is performed by means of inverse planning with respect to GSI’s
magnetic raster scan system in order to determine the plan parameters. Necessarily it
requires the definition of the target volume and (physical or effective) prescription dose.
First, the given target volume is divided into slices of equal irradiation energy, i.e IES.
Thus, for each position in every slice, the number of particles required to obtain the
prescribed dose distribution across the target volume is determined.
Other important features that need to be defined to control the optimisation process
are:
• Isocentre coordinates, otherwise the centre of the target VOI is selected;
• Beam focus (FWHM), and lateral and depth spacing between subsequent peak
positions;
• Contour extension - function to improve the dose conformation through the exten-
sion of the considered raster positions during optmisation, relative to the target
volume;
• Dose extension - function to handle the maximum distance from which dose con-
tributions are accepted from a specific voxel.
• Couch and gantry angles (in GSI coordinate system).
TRiP can perform either single field optimisation (SFO) or multi field optimisation (MFO).
For that, the algorithms bortfeld, gradient, cjggrad, and fletcher-reeves are available.
The algorithms give similar results, the only difference is the convergence time, with
the fletcher-reeves being the faster one.
When biological optimisation is required, the RBE model for the target and residual
tissues is accounted for, therefore the tissue type of each VOIs must be specified. The
available biological algorithms are, the classical implementation of the LEM and the
low-dose approximation of LEM at therapeutic dose levels (Scholz and Kraft 1996).
After a successful optimisation, the output is obtained as:
• Treatment plan - given by the raster scanner data .rst. This file contains the plan
parameters needed to perform an irradiation with the defined scanner system,
respectively projectile type, ripple filter (if applicable), gantry and couch angle
and the complete description of the set of raster slices. Therefore, each IES is
characterised by its energy, actual beam focus and step size, extension factors
for contour and dose, the water-equivalent depth dose distribution for this energy,
and the set of RPs per slice. Each RP contains the scanner (x, y) position and
respective particle number, i.e. beam intensity.
• Dose cube - binary data cube (extension .dos with a respective .hed file) that
contains the 3D dose distribution, either physical or biological;
• RBE and survival distribution (optional);
• DVH - the histogram of the dose distribution for the selected VOIs, exported in
.gd format.
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b) Dose calculation
The beammodel included in TRiP98 accounts with the depth dose profiles but also with
the nuclear fragment spectra, in the case of heavy ion-beams calculation. This uses
the physical concepts defined in chapter (2) and was explained in section (2.2.3).
The algorithms available in TRiP98 are:
• Classic - dose calculation on the CT grid is performed by locating four neighbour-
ing raster points for each voxel and interpolating the modified intensities.
• All points- account for all the neighbouring raster beam spots whichmay contribute
to a given voxel. Hence, the Gaussian shape of each beam spot is explicitly
calculated, i.e. pencil beam method.
• Multiple scatter - based on the All points method but considering the broadening
of each beam spot as a function of depth.
Advantages & drawbacks
The main limitations of TRiP98 are:
• lack of a graphical user interface leading to a need for an auxiliary visualisation
software (as Slicer RT, explained in section 3.3.1);
• input and output formats are not the standard DICOM format, however, external
tools are available for the conversion of the main files;
• optimisation of the couch and gantry angles is not provided;
• optimisation is limited to the definition of the maximum dose constraint to each
OARs, with a respective VOI-specific weighting factor. Hence, no dose-volume
constraints are available.
However, the strengths of the TRiP98 as the scripting functionalities and the possibil-
ity to develop integrated new functions/modules are factors to propel its use. Some of
these functions are discussed in the next sections as they were used in this dissertation.
3.1.2 TRiP4D
One of the versions that raised from TRiP98 was the TRiP4D, which is able to generate
time-resolved treatment plans for moving tumours. Hence the estimation of the inter-
play effect and method to mitigate it (as rescanning, 4D optimisation,...) are available.
Aim
The idea of a 4D TPS is to allow the assessment of the tumour motion and the ac-
tive delivery in the plan quality. TRiP4D was developed with the aim to be compatible
with the clinical treatment planning workflow at HIT. Therefore, the 4DCT protocol and
motion monitoring data available at HIT, i.e. motion acquired with the Anzai system
(relative-phase based) were considered. Also, the BDS format at HIT was taken into
acount and is readable by TRiP4D (Richter 2012).
TRiP4D includes all the established 3D treatment planning functionality, as well as the
physical and biological beam model. Hence, 4D physical and biological dose distribu-
tions can be determined.
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4D calculation process
The description of the 4D calculation process was presented in the section (2.4.0.3).
Furthermore, figure (3.2) summarises the process by the workflow B.
The performance of a 4D calculation requires the following set of inputs:
• 4DCT data - given as a set of ordered discrete CTs. In order to calculate the total
dose distribution, one of the phases needs to be defined as reference phase;
• patient transformation map (.trf file) - obtained through deformable registration
between each breathing state and the reference phase. It is given to the TPS as
the vector field of the deformable registration between states;
• treatment plan, i.e. the raster scanner data, .rst file;
• patient surrogate signal, acquired during treatment or other breathing curve rep-
resentative of the internal/external surrogate signal, designed as .mpos file. Ad-
ditionally, the following parameters need to be defined:
– number of motion states and list of considered states,
– state handling algorithm: amplitude-based (motion range), phase-based (0 -
360°), relative-amplitude-based (0 - 200%), time-based (0 - 100%) or hilbert-
based (0 - 100%),
– state direction - coordinated direction (x, y or z) in which the state division
should be performed. For a system as Anzai, the corresponding direction is
x, i.e. anterior-posterior in patient system;
• accelerator temporal information for each raster point, where the spill file is given
in the .lmdout format.
Figure 3.2: Workflow of the 4D optimisation (A) and dose calculation (B) processes implemented in the
TPS TRiP4D according to Richter et al. (2013) and adapted from it. Input data is depicted in green boxes.
Red boxes correspond to the modules discussed more in detail in this chapter. Optional modules are
drawn in grey boxes. The modules (S), (#), (§) and ($) are described by Bert et al. (2007), Gemmel et al.
(2011), Graeff, Durante, and Bert (2012) and Lüchtenborg et al. (2011), respectively.
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Additionally, in order to perform a reconstruction of a delivered dose the target mo-
tion and the beam position must be temporally correlated (see figure 3.2). Therefore,
the beam delivery is divided into discrete phases in which sub-treatment plans are gen-
erated and dose calculated (Bert et al. 2007).
Additional functionalities
Besides the simple 4D dose calculation, TRiP4D also incorporates the following func-
tions, some of them also shown in figure (3.2) by the workflow A:
• Beam tracking (Bert et al. 2007; Lüchtenborg et al. 2011) - the beam position
is adjusted to the tumour motion in real-time based on pre-calculated correction
vectors and compensating for potential dose changes in tumour areas;
• 4D segmentation (Richter et al. 2013) - integration of deformation maps to the
transformation (i.e. propagation) of contours from a reference CT to another;
• 4D optimisation (Graeff et al. 2013) - different approaches are available, either
based on the calculation of ITVs that includes range changes (Graeff, Durante,
and Bert 2012), using rescanning or tracking parameters optimisation (Eley et al.
2014);
• Gating optimisation (Graeff et al. 2014): an example is the multigating technique,
where specific beam spots are assigned to a defined motion phase during the
treatment planning.
In preparation of the next chapter, the concept of 4D segmentation and 4D ITV optimi-
sation are discussed in more detailed here.
a) 4D segmentation and propagation
The VOIs are usually defined by the physician just for the planning CT, which results in
the lack of adapted contours to the 4DCT states. Therefore, an automated transforma-
tion of the manually delineated contours from the planning-CT to the reference 4DCT
state and from this state to each of the 4DCT states, is a welcoming feature. Richter
et al. (2013) implemented it through a 4D contour data model, a contour propagation
algorithm, and a contour manipulation functionality.
Each VOI in TRiP98 is given as polygons on axial CT slices, which can be converted
into the voxel space by defining which voxel belongs to a specific VOI. Concerning the
4D case, this was performed through the concept of Volumetric Boolean Mask (VBM).
Here the 4D-VOIs are represented as boolean masks held in a CT-like dataset structure
in which a single binary digit (bit) is set to ”1” if the voxel is inside of the VOI, and ”0”
otherwise. The definition of the voxels inside or outside the contour is performed by
the point-in-polygon ray-casting algorithm. In conclusion, for different motion states the
respective VOIs will be represented by different bits. The diagram of the conversion
process, i.e. polygon contour to VBM, is shown in figure (3.3).
Later the 4D-VOIs can either be an object of basic manipulations (e.g. geometrical
unions or intersections) by simple bit mask operations or propagate based on de-
formable registration.
For the contours propagation, TRiP4D uses the VBM dataset structures to transform
from the reference state, r, to all the others states, s, as shown in figure (3.3). Every
voxel centre is displaced to its reference state position by the inverse deformation maps
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obtained during the deformable registration between the reference state (fixed cube)
and each of the others breathing stated (i.e. moving cube).
It must be taken into account that this propagation is intrinsically dependent of the
quality of the registration performed and their deformation fields. Subsequently, the
propagated contours need to be afterwards confirmed and the clinical implementation
requires a physician inspection.
Figure 3.3: (a) Conversion from a polygonal contour (red solid line) into a volumetric boolean mask
(VBM) (grey area). Inside voxels are determined based on the number of intersections of the polygon with
a ray sent to the voxel centre - ray-casting algorithm. (b) Contour propagation by inverse transformation
from a regular grid between the state 1 (light grey), 2 (dark grey) and 3 (darkest grey). (c) Patient example
in sagittal and coronal CT slices of propagated GTV contours between the reference end-exhale state
(red) and the end-inhale state (cyan). Source Richter et al. (2013).
b) 4D ITV optimisation
Target motion can be addressed in particle therapy through the use of ITVs ( i.e. union
of the CTVs in all motion states) with inclusion of the WEPL-changes along the BEV,
named as ITVWEPL. When this concept is applied field-specific as by Rietzel and Bert
(2010) the margins applied to one beam lead to an unnecessarily increase in the tar-
get size for other fields, if a common target volume is desired. On the other hand in
the approach used by Graeff, Durante, and Bert (2012) the margins are included into
the field description itself, expressly through a different conversion HU into WEPL for
each field. In brief, a modified HU-WEPL look-up table is used, in which the changes
in WEPL are adopted. As consequence, the resulting dose distribution in beam’s eye
view (BEV) was determined by the WEPL and not by the geometric length. This WEPL
conversion is performed for each raster point. Figure 3.4 shows the altered geometry-
WEPL conversion.
Considering a 4DCT, the accumulated WEPL extent is defined from the minimum to the
maximum WEPL value from all motion phases. In summary, the altered WEPL conver-
sion modifies the targeted structure in the WEPL coordinate system, independently for
each field. Hence, the target coverage is equivalent to the modified target volumes as
originally defined by Rietzel and Bert (2010).
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Figure 3.4: a1-a2) Axial CT slice at end-exhale (0%Ex) and end-inhale (100% Ex) showing the CTV
(red) and the different beam directions. b) WEPL-conversion for the angle in bold of the figure a1-a2 for
all the motion phases, with 0%Ex and 100% Ex in red. The beam is 0%Ex crosses mainly homogeneous
soft tissue while in 100% passes 100 mm of lung tissue (i.e. lower WEPL). The blue line shows the final
altered WEPL conversion for this beam position. Source Graeff, Durante, and Bert (2012)).
The 4D optimisation is then performed considering the WEPL-ITV for the reference
state and including the CTV for a subset of additional phases. In conclusion, the result
is a single irradiation raster scan file applicable to all motion phases in which the target
is continuously irradiated while sparing the OARs. The number of beam positions and
their geometric location thus remain unchanged. Instead, additional equations are in-
cluded describing the dose deposition of each beam position to each target/OAR voxel
during specific motion phases.
Advantages & drawbacks
The fact that TRiP4D is not a clinical product is maybe one of the main limitations,
however it is also the essential reason for its continuous research and constant devel-
opment of new functions.
Some of the functionalities are limited to the GSI scanner system, as multi-gating or
rescanning, since it requires changes in the TCS, not easily accomplished in a clinical
facility.
Furthermore, an extensive application of the TRiP4D functions to a larger number of
patients could result in a better understanding of their potential and limitation.
3.1.3 Syngo® RT Planning
Syngo® RT planning is the commercial solution provided by Siemens Healthcare for
treatment planning with scanned protons and carbon ion-beams. It is based on TRiP98
models, however, further developments were later performed by Siemens.
The dose is calculated for both protons and carbon ions by pencil beam algorithms as
explained in the chapter (2.2.3). The effective dose for carbon ion-beam therapy is ap-
plied by the local effect model, while for protons a fixed value 1.1 is used.
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Functionalities
The TPS is integrated with the PACS (Picture Archiving and Communication System)
network, which allows the data exchange with the treatment console and the direct plan
transference after its approval.
The system is DICOMRT based, i.e. the data is read and written in the RTCT,RTStruct,
RTPlan and RTDose formats. The system is divided into the following modules:
• Patient modelling;
– contouring of OARs and targets - Allows operation between contours, 3D
visualisation and interpolations,
– image registration features - Useful for the contouring using auxiliary imaging
modalities (as MRI, PET or even CT with contrast agent). Moreover, allow
the rigid registration (12 degrees of freedom, DOF) with follow-up CTs for
further forward dose calculation;
• Treatment planning;
– plan definition - Selection of the beam configuration (number and angles),
isocentre location and definition of the prescription dose,
– dose optimisation - Iterative optimisation through the definition of the dose
constraints, optimisation strategy (IMPT or SFUD) and technique (absolute
of effective dose). The Target and OARs constraints can be given in terms
of minimum and maximum dose, upper and lower Dose-Volume limits,
– dose calculation,
– review and compare - Evaluation of the dose distribution per beam and to-
tal, absolute or effective, and combination between dose distributions (differ-
ence, summation). Possible to visualise the beam spot distribution in BEV
with underlying Digitally Reconstructed Radiographs (DRR).
– definition of the fractionation scheme,
– plan reporting;
• Plan verification - The plan is transferred to a verification phantom (water phantom
with 24 equidistant ICs) and then the dose is recalculated within the phantom.
Later the plan is irradiated at the treatment machine and compared with the TPS
doses for each IC.
Advantages & drawbacks
The clear advantage of this system is the user-friendly features and the direct commu-
nication with the treatment delivery system. However, some relevant capabilities are
missing such as:
• beam time structure, i.e. it neglects the subsequent nature of the beam scanning
process and any target motion;
• deformable registration features;
• the inclusion of uncertainties in the dose calculation (set-up, range, internal mo-
tion, etc.);
• scripting functionalities.
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3.2 Image registration
As explained in the previous section, an indispensable step to perform a 4D dose calcu-
lation is the use of deformable registration, for the contours propagation between CTs
and also for transformation of the raster points position between states.
Besides deformable image registration, rigid registration is also required when consid-
ering CTs from different acquisition sessions, and a bony matching needs to be per-
formed to ensure the correct patient positioning.
Plastimatch was the software elected for these tasks. It is an open source software for
image computation (http://plastimatch.org/), able to perform volumetric registra-
tion of CT, MRI, and PET.
Plastimatch - functionalities
Plastimatch supports several 3D image file formats, as DICOM, Nifti, NRRDandMetaIm-
age (mha). Moreover, is able to convert between most of these formats and perform
processing of the image data.
Deformable image registration (DIR) can be performed using B-spline (Shackleford,
Kandasamy, and Sharp 2010) or Demons methods (Sharp et al. 2007a). Also algo-
rithms of the Insight Segmentation and Registration Toolkit are implemented.
TheDIR process can be controlled through different cost functions, including normalised
mutual information, normalised correlation, mean reciprocal square differences, mean
squared error (MSE) and gradient magnitude (GM) difference. Hence, multi-modality
image registration is theoretically possible.
Tools for converting and manipulating vector fields and other geometric transforms are
available, as well as the creation of synthetic vector fields.
Plastimatch also features others handy utilities which are not directly related to image
registration. In highlight, the gamma criterion, manipulation of images (directions, voxel
size, interpolations, cropping) and comparison of binary volumes (Dice similarity coef-
ficient - DSC, Hausdorff distance - HD and contour mean distance) are implemented.
Plastimatch - advantages & drawbacks
Several retrospective studies in the field of motion assessment described the applica-
tion of this software as Kumagai et al. (2009), Mori, Shinoto, and Yamada (2014), and
Mori et al. (2010), which gives a research background regarding its accuracy and ca-
pabilities.
Moreover, the fact that it is an open-source software, means that the development of
new functions is continuous and users/developers mailing-list is highly helpful.
No graphical interface is provided with the software, however, it was implemented also
as plugin in 3D Slicer platform. This system will be discussed in the next section.
Plastimatch also lacks in landmark-based rigid registration, surface matching registra-
tion and 2D-2D registration functions.
Regarding the DIR quality, since the 4D calculation is strongly dependent on it, a 3D
slicer plug-in can be used (see section 3.3.1).
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3.3 Evaluation tools
As previously stated, TRiP and Plastimatch are command-based software, without
graphical user-interface but with functions that allow batch execution. Therefore, the
adopted visualisation interface (3D Slicer) and manipulation libraries (ROOT based)
are described below.
3.3.1 3D Slicer
3D Slicer (Fedorov et al. 2012) is a software platform for analysis and visualisation of
medical images, and for research in image guided therapy.
It supports multi-modality imaging including MRI, CT, Ultrasound, nuclear medicine,
and microscopy.
Functionalities
The software is extensible, with plug-in capabilities for adding algorithms and exter-
nal applications. Therefore, different research groups developed additional modules,
some of them suit the needs of this dissertation. Those plugged modules are SlicerRT,
SlicerTRiP and Registration Quality.
a) SlicerRT
SlicerRT (Pinter et al. 2012) is a result of the joint collaboration between C. Pinter, A.
Lasso (PerkLab, Queen’s University) and K. Wang (Princess Margaret Hospital, Uni-
versity Health Network Toronto).
The main modules from this extension are: DICOM-RT import, segmentations, dose-
volume histogram, dose accumulation and comparison, contours comparison, and in-
tegration with Plastimatch functions.
b) SlicerTRiP
This module was originally developed by Kitware Inc. and Isomics Inc. and later
adapted by K. Anderle from GSI in order to upload TRiP cubes to the 3DSlicer inter-
face. Dose and CT cubes can be directly readable in TRiP98 formats. Binary masks of
structure and VBM, with multiple bin states, are also recognised.
The visualisation of the dose distribution is accomplished using a colour-wash range
defined by the prescription dose, overlying the CT image and structure set.
Additionally TRiP DVH files (in .gd format) can be loaded and the DVH is displayed.
c) Registration quality
This extension was a collaboration between GSI, HIT and University Clinic of Erlangen,
having as main contributors J. Woelfelschneider, T. Brandt, D. Richter and K. Anderle.
Its aim is to provide an intuitive and systematic method to evaluate the quality of the
image registration. The available qualitative and quantitative tools include:
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• Import of data in Plastimatch format - reference, warped image (transformed),
and vector and inverse-vector fields uploaded in .mha format. Possible to define
a VOI to constraint the evaluation;
• Image checks - comparison between the reference image and the warped im-
age can be performed by false colour or check-board pattern overlay, and by the
calculation of the absolute difference cube;
• Vector field checks - using the concepts of Jacobian Determinants (JD) and In-
verse Consistency Error (ICE).
Figure (3.5) shows an example of this evaluation.
The calculation of the determinant of the Jacobian matrix gives the information of how
the volume changed between the two registered images (i.e. expansion or contraction),
where values equal to one represent no volumetric variation (Sarkar et al. 2012). The
ICE corresponds to the euclidean norm of the inverse vector field and is used to check
the consistency of the mapping between the two images (Bender and Tomé 2009).
Figure 3.5: Coronal view of the DIR quality assessment between a 0%Ex and a 100%Ex state CT. The
False Color image corresponds to the overlay between the (reference) 0%Ex CT and the transformed
100%Ex CT (i.e warped image), in which two regions with observable differences are highlighted by the
black circle. The values of the JD and ICE can also be overlaid in the patient CT, and be used to identify
regions in which the vector field can have inconsistencies. Finally, the displayed vector field map is also
shown, in which the direction and length quantifies of the transformation between images is represented
by each arrow.
3.3.2 ROOT libraries
A serie of ROOT libraries, named MvtLibraries, were developed by Richter (2012) and
adapted to suit the needs of this thesis.
These libraries include TRiP functions and are able to handle the majority of the objects
required by TRiP, such as dose and CT cubes, structure sets, breathing signals and
treatment plans.
In particular, some of the classes and functions are:
• MvtCube: handles CT, dose and vector-field cubes. Offers processing functions,
as conversion of data type, scaling, override of values, subtraction or summation
of cubes,...
• MvtCubeStats: compute statistical evaluation of the data cubes (e.g. median
value, V95, homogeneity, conformity, etc.)
• MvtMotion: manipulates motion files (.mpos), as e.g. its extension or scaling.
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3.4 Accelerator modelling
The simulation of the accelerator response during a plan irradiation is a pre-requisite for
the ”prediction” of the 4D dose distribution under a specific patient’s breathing. Based
on the treatment plan the idea is to simulate the beam delivery sequence (BDS), i.e.
the TRiP .lmdout input file. With this aim, the tool makeLmdout was developed by GSI
(Steidl 2011), and later adapted to the HIT’s synchrotron by M. Härtig (University Clinic
of Heidelberg).
The makeLmdout version used along this thesis, here named makeLmdout-MH, corre-
sponds to the HIT’s accelerator model, where the accelerator is considered in pulsed
mode, repeating accelerator cycles (aprox. 10s) and equipped with an active intensity
feedback control (DIC). In this model, the synchrotron is injected with the maximum
number of particles in every request. Then, during the extraction process, a feedback
mechanism extracts only the particles at the requested intensity.
3.4.1 makeLmdout-MH
The simulation is based on a base data obtained from irradiated plans and considering
the acceleration times, energy dependence and random intensity fluctuations.
This tool requires as input the following information:
• treatment Plan (.rst file converted to .xml format);
• motion File (.mpos file);
• spill Info, where the accelerator spill duration and pause length is specified;
• gating window information (optional);
In summary, this tool will generate as output the file containing the random simulation of
the accelerator timing and intensity patterns, which corresponds in TRiP to the .lmdout
format.
3.4.2 Conversion CVS to TRiP formats
During the irradiation of the patient its breathing signal and the accelerator delivery
sequence can be recorded through the EtherCat system, as already stated in section
(2.4). This simultaneous acquisition will result in a coincident time stamp between the
.mpos and the .lmdout signal. The EtherCat’s output is given in a Comma-separated
values (CVS) format that needs to be converted into TRiP4D formats.
In-house developed scripts, by N. Chaudhri (Heidelberg Ion-Beam Therapy center),
called CVS2MPOS and CVS2LMDOUT, convert the .cvs file to the .mpos and .lmdout
formats, respectively.
The CVS2MPOS script requires as input the .cvs file, the definition of the sampling
rate, the processing filter to use (e.g. the implemented band-pass butterworth filter of
2nd order, from 0 to 0.25Hz), and the lower and upper breathing phase thresholds.
Finally, the CVS2LMDOUT script processes and converts the .cvs file into the .lmdout
based on the raster file information, i.e. treatment plan.
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3.5 Water-equivalent path length calculations
In ion-beam therapy the density variations in the particle path are included in the dose
calculation through the concept of WEPL. The assessment of the WEPL variations may
be used as a fast method to detect inter-fractional changes. Therefore, a software able
to calculate it in a clinical scenario was pursued.
HIT is part of the SPARTA (Software Platform for Adaptivemultimodal radio- and particle-
Therapy with Autarcic extensibility) consortium, which aims to develop software that can
improve therapy planning and optimise patient-specific treatment. Project that is sup-
ported by the German Federal Ministry for Education and Research (BMBF).
Within this project at HIT the modular framework MeVisLab (http://www.mevislab.
de/) was adopted for image processing research and development of a PET-based
beam range verification tool (Bauer et al. 2013; Unholtz et al. 2011).
The selection of MeVisLab for the aim of this thesis was due to: (i) its modular structure
that allows to integrate easily new algorithms and functionalities; (ii) the aim of using
WEPL as metric to guide plan adaptation falls into the SPARTA project; and (iii) MeVis-
Lab already provide modules many of the necessary tools for this end.
The fully automated workflow implemented in MeVisLab in the context of PET-range
verification includes:
• connection to local data base and central picture archiving systems (PACS);
• mono-modal rigid image registration;
• multi-modal visualisation of dose distributions, CT images and PET images (sim-
ulated and measured);
• range comparison analysis for arbitrary modality images. (Chen et al. 2015).
Inspired in this workflow the module for CT-CT WEPL comparison, named MVLCT V eri,
was developed by W.Chen (Heidelberg Ion-Beam Therapy Center).
MVLCT V eri
This module fuses the following features:
• simultaneous import of two CTs and reference Structure Set from the PACS net-
work;
• affine rigid registration;
• rotation of the CT in BEV’s direction, based on isocentre coordinates, gantry and
couch angle;
• definition of a VOI pertaining to one of the structure set VOIs;
• calculation of WEPL values: absolute values, summation along beam path, dif-
ferences and standard deviations;
• visualisation of the results in 2D colour-maps and histograms.
The calculation of the 3D WEPL cube is performed based on the HLUT relative to the
CT scanner written into the CT’s DICOM tag, i.e. includs the HLUT data of HIT. This is
performed individually for each of the uploaded CTs.
In order to speed up the conversion CT-WEPL, the calculation is only performed for a
defined VOI. This VOI is set from a selected structure plus a dilatation or contraction
margin in BEV.
The establishment of a workflow and the realisation of its application is explained in
detail in the next chapter.
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Altogether, the presented set of software and tools will be used in the next chapters,
in which the details of its application will be translated into the research needs of this
thesis.
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Chapter 4
Inter-fractional motion
4.1 Aim of this chapter
In this chapter the dosimetric impact of anatomical variations of the target, and sur-
rounding normal tissues, on the plan quality along the treatment course will be evalu-
ated. Moreover, different approaches to mitigate their impact will be investigated.
Firstly, the significance of the beam configuration for the plan robustness to inter-fractional
changes is presented. In a second study the influence of planning margins is assessed.
Furthermore, this chapter also proposes a prediction method to assess the impact of
daily variations on the plan quality based on pre-treatment CT imaging.
It has to be emphasised that the evaluated and proposed methods are dependent on
the available TPS and are aimed to be clinically applicable to the HIT workflow.
4.2 Materials and methods
4.2.1 Dataset description
A set of ten pancreatic patients, already treated with photon radiotherapy, was used in
an in-silico analysis of the inter-fractional plan quality for the treatment with scanned
carbon ions. This set of patients will be referred as dataset A along this work.
All the patients were imaged with CT in 5 weeks for positioning verification purposes.
All the acquisitions were in free-breathing and with the same CT acquisition protocol.
The CT images were registered to the first week CT, CT1, through rigid registration.
CT1 was used as planning CT. Registration was performed by bony anatomy matching
and was validated using anatomical landmarks and visual inspection.
All weekly-CTs included physician-approved contours of the GTV from each imaging
session. The CTV was defined as the GTV plus an isotropic margin of 5 mm.
The CTV variation in volume and centre of mass (COM) over the treatment for each pa-
tient was evaluated. The ∆COM corresponds to the length of the vector displacement
between the CT1 and the follow-up imaging sessions, CTi, from the centre of mass of
the contoured CTV. The CTV volume was measured in cubic centimeters and the rel-
ative variation to the planning VOI was determined by ∆V = (VCTV 1   VCTV i)/VCTV 1.
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4.2.2 Treatment plan optimisation and dose forward calculations
Treatment plans were optimised and calculated using TRiP98, using the beam base
data and RBE dataset from HIT.
Plans were tailored to deliver carbon ion IMPT to the ITV, aiming to get full coverage of
the CTV, with a biological dose of 15 x 3 Gy (RBE). The spinal cord, kidneys, stomach
and bowel were considered as OARs and plans were optimised to respect the tolerance
dose suggested by the literature (Bentzen et al. 2010; Emami et al. 1991). The same
/ equal to 2 was used for the various organs.
The plans were generated for a scanning raster spacing of 3 x 3 mm in lateral direction
and a iso-energy slice spacing of 3 mm water-equivalent for a pencil beam focus of 10
mm FWHM. These parameters were adopted from the work from Richter (2012), for
moving targets.
In order to improve the dose conformation to the target, raster points around the ITV
were considered in a margin of a factor of 0.9 applied to the focus FWHM for each
IES. The dose optimisation was performed considering the dose contributions for every
voxel within a maximum distance of 3 sigma of the focus size and using the algorithm
fletcher-reeves.
The physical dose calculation relied on the method all points, while the biological ef-
fects were then considered through the use of the low dose algorithm (see chapter 3.1
for details).
Relative to the follow-up imaging, the dose forward calculation was then performed for
the four rigidly registered CTs by direct application of the raster-scan sequence obtained
from the previous optimisation. The same TPS and algorithms were employed.
4.2.3 Beam geometry selection
Since the selected beam entrance channel affects the plan quality, as result of density
variation along the beam path, plan robustness can potentially be improved through the
selection of a beam geometry which is less susceptible to density fluctuations. Hence,
for each patient, six plans for different beam geometries for the first week CT were gen-
erated. A sketch of these beam directions is shown in figure (4.1).
The selection of these beam geometries considered the preceding work from Dreher
et al. (2015), in which OAR constraints and target coverage were assessed in the gen-
eration of clinically feasible plans.
Figure 4.1: Diagram of the six beam configurations (A to F) evaluated for inter-fractional plan robustness.
4.2.4 ITV definition: From geometric to range-margins
In order to incorporate inter-fractional changes through the use of margins, three ap-
proaches to define an ITV for dose optimisation were investigated. These are outlined
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in the figure (4.2) and described below:
• Geometrical, ITVG. Geometric expansion of the CTV by application of a 3 and 5
mm symmetric margin, ITVG3 and ITVG5, respectively. Results were compared
with the use of no additional margin (ITVG0).
• Uniform range-margin, ITVHU . Based on the geometric concept (ITVG), a uni-
form range-margin was introduced into the optimisation by replacing the HU val-
ues in an isotropic CTV-ITV margin of 3 or 5 mm with the patient-specific median
density of the pancreas. These VOIs were respectively defined as ITVHU3 and
IITVHU3. In addition, the areas inside the ITVHU , in which the density was less
than twice the standard deviation of the median CTV HU value, were also over-
written.
• Beam specific, ITVAsy. Based on a water-equivalent-path length ITV, ITVWEPL,
it was used to assess the needed margins to overcome the range uncertainties,
caused by anatomy variations along the treatment couse. This ITVWEPL consid-
ers the changes of the WEPL over the set of weekly-CTs. To this end, an adap-
tation of the method defined by Graeff, Durante, and Bert (2012) was employed,
using the TPS TRiP4D, but considering the set of inter-fractional CTs (cf. chapter
3.1). The ITVWEPL was generated/optimised from the set of follow-up CTs and
respective CT-specific CTV contours. In this process, the range changes were
computed for all the CTs in the defined beam directions giving origin to a modified
HU-WEPL look-up table (cf. chapter 3.1). During the plan optimisation, the algo-
rithm ensures an adequate CTV coverage along the imaging set. As product of
this optimisation, not only the dose distribution but an ITVWEPL contour per beam
direction was obtained. From this ideal ITVWEPL per patient were then defined
beam-specific ITV (ITVAsy) built from the patient’s population variations. Details
of this generalisation are given below.
Figure 4.2: Scheme of the ITV concepts used during the plan optimisation. a) Geometric margins of 3
and 5 mm applied to the CTV, named as ITVG3 and ITVG5, respectively. Also depicts the uniform range
margin of 5 mm (ITVHU5), which considers an override of the CT densities during the optimisation stage
in a margin of 5 mm around the CTV. b) From the different CTV contours (CT1 - CT5) the ITVWEPL was
calculated in order to ensure the full coverage of the CTV along the treatment course accounting with
the density variations in the beam path. The ITVWEPL for each beam direction is then generalised to a
ITVAsy, not patient-specific.
The definition of a suitable PTV was out of the scope of this thesis, as margins for set-
up, range and beam application uncertainties are subject of a separate investigation.
Likewise intra-fractional motion uncertainties were also not considered in this chapter
and will be handled in chapter (5.1).
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4.2.4.1 Data analysis
For all the geometries and ITV concepts, the target coverage was evaluated through
the assessment of the dose received by the weekly CTV (CTV1 to CTV5). The consid-
ered parameters were the CTV volume that receives more than 95% of the prescribed
dose (V 95CTV ), the volume of the CTV that receives more than 107% of the prescribed
dose (V 107CTV ), the mean and maximum dose to the CTV. Additionally, the CTV dose
homogeneity and conformity were also evaluated through the parameters HCTV and
CN, respectively, as given by the equations (2.6) and (2.5). This evaluation was per-
formed using ROOT MvtLibraries (see section 3.3.2.
The field-specific ITVWEPL was evaluated by comparison with the CTV1 and ITVG5,
in terms of volumetric changes (∆V) and ratio of the overlapping volumes, here done
by the Dice Similarity Coefficient (DSC) (Birkfellner et al. 2012). The DSC is a tridi-
mensional overlapping similarity measure, mathematically expressed by the equation
(4.1), where the number of voxels of the A (reference) and B (evaluated) volumes are
considered.
To extract the information of the margins direction and size, the variation of the centre
of mass (∆COM) and the Hausdorff distance (HD) between ITVWEPL and CTV were
evaluated (Birkfellner et al. 2012). The HD identifies the largest of all distances from the
contour under evaluation to the closest voxel on the reference contour (Birkfellner et al.
2012). To reduce the patient specificity when applying this concept to other patients,
the 95th percentile of the HD as evaluation metric was selected, HD95.
Both volumetric parameters were evaluated using the 3DSlicer software, cf. chapter
(3.3.1). A diagram of these two metrics is shown in the figure (4.3).
The COM variation was measured in CT coordinates (x,y,z) and then converted to the
HIT beam scan coordinate system using the couch and gantry angles (Jäkel et al. 1997).
Hence, the evaluated COM values were transformed to lateral, depth and cranio-caudal
directions, relatives to the beam entrance direction.
DSC(A;B) =
2jA \Bj
jAj+ jBj (4.1)
Figure 4.3: Graphic representation of the Hausdorff distance (HD) and Dice Similarity Coefficient (DSC)
for comparison of the contour B against the reference contour (A). The HD corresponds to the largest
distance between a point from the volume B and the closest voxel on the reference contour. DSC is
obtained by the ratio of the overlapping volume between contours (A \ B) and the summation of the
individual volumes.
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4.2.5 Assessment of anatomic variations through WEPL-maps
4.2.5.1 Aim
A major constraint to perform plan adaption is the complexity and time consumption
required. In ion-beam therapy, the concept of water-equivalent path length (WEPL)
describes the density of the transversed material in the particle path. During dose cal-
culation, it is the WEPL that accounts for the particle range in the beam trajectory,
through the transformation between the CT system (i.e HU) into the water-equivalent
system.
Since the WEPL is only dependent on the HU-value, its calculation is a quite fast pro-
cess that could be implemented as verification procedure based on a pre-treatment CT
(Mori et al. 2009). However, this method just includes the variations as consequence
from different densities, without performing a dose calculation, i.e, ignoring the different
beam intensities and energies in each raster point. Therefore, a correlation between
these two quantities, dose and WEPL, needs to be established in a way to define an
acceptance threshold for which the patient can be safely treated or the treatment plan
re-calculated for the new CT. Neverthless, this method doesn’t dispense a clinical eval-
uation and an investigation of the reasoning for such WEPL variations.
To sum up, the aim of this section is to suggest a method to estimate the impact of
anatomical changes on the dose distribution based on WEPL variations and correlate
them with dosimetric indicators to assess the need of re-planning. The purposed work-
flow need to be clinically feasible, i.e. end-to-end within an acceptable time (below 10
min) and an intuitive decision-making process.
4.2.5.2 Material and methods
For the same set of patients, dataset A, the dose distributions optimised for the CTVG0
and the forward dose distributions for each of the weekly CTs were accounted. In or-
der to assess the correlation between the dose distribution variation and the WEPL
changes, the WEPL-maps per individual beam direction were calculated, correspond-
ing to the beam configurations A-D of the figure (4.1).
The WEPL cubes were calculated and evaluated in the MeVisLab platform, available
and partially developed at HIT. For the intended functions of this chapter a newly devel-
oped module MVLCT V eri was employed (cf. chapter 3.5). MVLCT V eri was specifically
created for the computation of the WEPL in follow-up CT images on a regular basis with
an intuitive user interface (see figure 4.4).
In a pre-processing stage, performed in an additional MeVisLab module, all the CTs,
which include a stereotaxic frame and the imaging couch, were cleaned up from these
devices to the external contour size.
Regarding the WEPL assessment, the adopted workflow is outlined in the figure 4.5
and described below.
In a DICOM manager module, the reference CT, respective structure set, and the CT
under evaluation, were loaded into the MVLCT V eri main module. Since the dataset A
was already rigidly registered in the previous study the registration step was skipped.
Subsequently, both CTs were rotated into the BEV according to the plan informations
(isocentre, couch and gantry angles). In figure (4.4 a) the menu for the plan definition
is shown and figure (4.6) shows the rotation of a patient in BEV for an oblique posterior
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Figure 4.4: MeVisLab Interface in the MVLCT V eri module. a) Menu for the definition of the isocentre,
gantry and couch angles with the function to apply a CT rotation in BEV. b) Main menu for the definition
of the parameters used during the WEPL calculation.
Note: this image wasmodified to fit into the page width discarding functionalities related to other modules.
beam.
Secondly in the menu b), depicted in figure (4.4 b), the WEPL calculation parame-
ters were set up. Starting by the definition of the VOIWEPL in which the WEPL will be
computed; such is performed through the selection of a reference structure plus an
additional margin. Hence, in BEV the VOIWEPL is defined by this dilatated structure
while in beam direction is limited by the patient’s skin to the proximal or distal side of
the structure. A sketch of this volume, VOIWEPL, is presented in figure (4.7).
In order to be clinically relevant and correspondent to the dose calculation results, the
VOIWEPL was selected as the CTV plus a dilatation margin of 4.8 x 4.8 x 4.5 mm. In
the proximal-distal direction the patient surface was defined as starting point, i.e., con-
sidering 15% of the CT value in BEV, and the distal edge of the CTV plus the additional
expansion of (aprox.5 mm) as ending point (see fig. 4.7).
The WEPL is then calculated, for each voxel inside the VOIWEPL, from the HLUT of
the respective CT. Thus, the accumulated-WEPL (accWEPL) along the beam path of
the VOIWEPL was computed. The differences of the accWEPL between each CT and
planning CT (∆accWEPL) were evaluated through the 2D difference colour-maps and
histogram. These differences (∆accWEPL) correspond to the sum of absolute differ-
ences.
Additionally, to help in the interpretation of the results, MVLCT V eri possesses a syn-
chronised cursor to move between maps, and simultaneously, within the unidimen-
sional overlaid profiles of the CT Hounsfield Units along the defined axis.
Regarding the definition of a correlation between dose distribution and WEPL maps,
V 95CTV and HCTV were considered as metric of the dose distribution quality, while the
WEPL was evaluated by: (i) mean of the variations (ii) standard deviations; (iii) vari-
ance of the ∆accWEPL; and (iv) percentage of voxels of the ∆accWEPL with less that
3mmwater variation (PVin). The PVin parameter is the easiest method to quantify the
∆accWEPL based on its histogram, where the area of the histogram between a defined
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Figure 4.5: Diagram of the proposed workflow for the quantification of the anatomic variations and clinical
decision on the subject of re-planning. The grey boxes correspond to functions outside the MVLCT V eri
module. The dashed lines correspond to a non-direct data connection.
Figure 4.6: Example of the BEV rotation of a CT for a oblique posterior beam. The module MVLCT V eri
displays the CT in the three new axis after rotation, where a) correspond to the BEV, and b) and c) to the
other two directions (x, y) with the beam always coming from the left side.
acceptance threshold, e.g. from -3 to 3 mmwater difference, can be used as criterion for
the accWEPL evaluation.
Additionally, the gamma-index  (Low et al. 1998) was adapted for the comparison of
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Figure 4.7: Sketch of the definition of the VOI for the WEPL evaluation (yellow region) defined based on
a contour (here the CTV, in red) plus a dilatation margin. In the proximal direction starts from the 15% of
the maximal CT value for every CT voxel. Distally it is limited by the CTV plus a defined margin.
the dose distributions from the planning CT and weekly-CT, where for all the points
the dose difference between the two distributions,DpCT and DwCT , respectively, and
determined the distance between the points rpCT and rwCT . This criterion gives the
spatial information of the dose differences in the normal tissues, not possible through
the V 95CTV . The gamma-index, as given by the equation (4.2), was calculated using
the Plastimatch software and evaluated in terms of percentage of voxels with  < 1
(i.e. gamma passing-rate, gammap:rate), gamma index distribution and fail-map (i.e,
red colouring for the voxels with  > 1). The acceptance criteria of 3% dose difference
(∆d) and 3mm distance to agreement (DTA) was chosen. The
 =
r
[DpCT (~rpCT ) DwCT (~rwCT )]2
∆d2 +
j~rpCT ; ~rwCT j2
DTA2
(4.2)
The measure of the correlation accuracy was assessed using the Pearson correlation
coefficient (r) and the p-value. The Pearson correlation indicates the strength of the
linear association between two parameters, while the p-value determines the statistical
significance in a hypothesis test.
A linear regression was calculated for the data and evaluated in terms of the coefficient
of determination (R2), the distribution of the residuals and the confidence internal (Con-
fInt) [2.5%; 97.5%]. The complete statistical analysis was performed using R scripts
(Pruim 2011).
Note that, in first instance, the evaluation was performed just for the single beams
configurations with the aim to exclude issues arising from the multi-fields plan optimi-
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sation, once the WEPL is always a calculation per-field. The use of multiple beams will
be addressed in section (4.4).
4.3 Results
The impact of anatomy and range changes on the target coverage and dose homo-
geneity among beam geometries, margins concepts, patients and fractions was initially
explored. Volume and COM variations (figure 4.1) of the CTV along the treatment were
used to transcribe the dose degradation effect into clinical reasons.
Finally, the applicability of the ∆accWEPL criterion as translator of the anatomy changes
into dose distribution modifications is presented.
4.3.1 Variability of the volume and positioning of the target
The individual CTV volume and positioning, for each CT and patient, was measured
and compared with the reference volume, CTV1. The total results are presented in the
table (4.1). It was noticed the maximum volume and COM variation for patient A1, while
patient A5 shows a nearly constant CTV volume along the treatment course, and pa-
tient A10 exhibiting a steady COM. In average this set of patients showed a decrease of
the CTV volume along the treatment (-2.6%5.5%) and a ∆COM for all the CTs within
the range [0.0; 7.7] mm.
Table 4.1: Dataset A - description of the CTV mean and standard deviation variation in volume (ΔV) and
position (ΔCOM), relative to the initial volume.
Patient ∆Volume (%) ∆COM (mm)
A1 -10.56.5 3.7 2.1
A2 -8.28.2 2.30.2
A3 -1.02.5 2.21.8
A4 -4.92.7 2.50.9
A5 0.20.8 1.20.8
A6 2.30.5 2.20.4
A7 1.84.1 1.40.1
A8 2.02.1 0.50.2
A9 -6.20.8 1.80.1
A10 -1.10.7 0.30.2
Mean -2.65.5 1.8 1.3
4.3.2 Beam geometry
The beam geometry showed a substantial impact on target coverage and homogeneity
over the treatment course. The summary of the results for the V95CTV is laid out in the
table (4.2). The evaluation of the CN, DmaxCTV and median doses can be found in the
appendix (A.1.1).
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Table 4.2: Comparison of the dose distributions in terms of V95CTV , expressed by themean and standard
deviation over all patients and weekly-CTs per beam incidences and ITV-concepts. The margins ITVG0,
ITVG3 and ITVG5 correspond to the simple geoemtric expansion of the CTV by a 0, 3 or 5 mm margin,
respectively. In ITVHU3 and ITVHU5 an uniform density VOI was used during the optimisation process,
while the forward dose calculation used the original CT’s densities. The ITVAsy correspond to the testing
of the assymetric concept based on the ITVWEPL, therefore the forward dose calculation for all the CTs
and patients was only performed for the less robust beam configurations, i.e. C and D.
V95CTV Gy (RBE)
Margin
B.geom A B C D E F
ITVG0 95.62.8 96.4 2.7 88.77.0 90.85.6 98.02.0 98.91.5
ITVG3 98.11.7 98.61.6 92.66.4 94.04.2 98.91.7 99.51.2
ITVG5 99.21.2 99.41.2 95.85.2 96.73.1 99.41.3 99.61.2
ITVHU3 98.11.6 98.61.6 92.66.3 94.24.1 99.11.4 99.51.2
ITVHU5 99.21.2 99.41.2 95.85.1 96.83.0 99.41.2 99.61.2
ITVAsy n.a n.a 97.53.9 98.12.1 n.a n.a
The configuration C and D (cf. figure 4.1) showed the worst mean average coverage
as well as standard deviations along the treatment. Resulting in a constant V95CTV de-
crease, regardless of the used margin, as visible in the respective columns in table 4.2
and in the figure 4.8 a). In terms of HCTV (see fig. 4.8 b) these beam geometries tend
to be less homogeneous dose distributions along the treatment course. Moreover, it is
also visible a mean increase in the CN of (0.080.07) comparative to the other geome-
tries (0.020.04), considering all the patients, CTs and margins concepts. Figure (4.9)
shows some examples of dose distributions with different beam geometries. Additional
dose distributions are presented in the appendix (A.4) and (A.5).
The results from C and D are related with the observed range uncertainties in the ante-
rior abdomen region due to the inter-fractional variability of the patient anatomy (bowel,
stomach and weight loss). Figure (4.9) discloses these inter-fractional changes con-
tributors through the axial view of the dose distribution in one of the follow-up CTs for
four patients. In particular, patient A3 exhibits a strong under-dose when planned for
an anterior beam as result of density changes in the bowel/stomach. Another example
pointing for the lack of robustness of an anterior beam, is the patient A8 that exhibits
accentuated weight loss, this is visible in figure (4.9) from the comparison of the distri-
bution between the first and last week CT.
Relative to Patient A1, is observed that even when used an oblique posterior beam,
due to the target deformation, resulted in a V95CTV reduction of approximately 4% for
one of the CTs, although the tumor COM shift was below 3mm.
As example of a plan with a lateral right beam, patient A10 (fig. 4.9 c) shows range
changes as resulted from the bowel and liver position leading to health tissues over-
shooting.
It is noticed that although the geometry D is not robust against inter-fractional changes,
the use of this beam direction combined with a robust one, as the case of the geometry
E, will improve the dose distribution along the treatment course. This fact is a conse-
quence of the reduction of the weight of the non-robust beam compared with the single
beam irradiation.
In summary, V95CTV for non-robust geometries decreased by up to 30% and 28%, for
a 3 mm and 5 mm margin, respectively (fig.4.8). Considering all the patients, CTs and
margins for the set of the geometry C and D, this correspond to a mean variation of the
V95CTV of (-4.54.8)%, the HCTV of (4.36.5)% and the mean dose of (-0.030.04)
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Gy (RBE) /fx. In contrast, for the others beam’s configurations (A, B, E, F), the V95CTV ,
HCTV and mean dose were nearly conserved, i.e. mean variations along patients, CTs
and margins of (-0.71.2)%, (0.51.3) and (-0.010.03) Gy (RBE)/fx, respectively.
Relative to the V107CTV and maximum dose, no significant differences were found.
All these results are available in more details in the appendix (A.1.1).
Figure 4.8: Results from the CTV dose evaluation from the weekly dose distribution obtained from
different optimisations (in beam direction and ITV) comparatively to the planned dose distribution. a)
Variation of the V95CTV b)Variation of the HCTV . Each box represents 25 - 75% of the data, with the
median value represented as the solid line and the outlier as the dots.
Figure 4.9: Forward dose distribution of the optimised plan for the ITVG5 (white contour) in one of the
weekly CTs for four different patients exhibiting different inter-fractional changes. Depict is the value of
the V95CTV , in the respective CT, for the CTV (in blue). a) Patient A3 for an anterior beam as results
of changes in the bowel/stomach. b) Patient A1 with an oblique posterior beam showing tumour de-
formation. c) Patient A10 planned with a lateral right beam with bowel and liver position alterations. d)
Patient A8 for an anterior beam exhibiting an accentuated weight loss between the CT1 and CT5. e)Dose
distribution for the same CT and patient as in the figure a) but showing the retrospectively determined
ITVWEPL (black contour) in comparison to the ITVG5 and the dose distribution for the new optimisation.
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4.3.3 ITV concepts
The selection of a robust beam geometry (as A, B, E and F) together with the use of
geometric margins showed to be able to mitigate some of the effects coming from the
inter-fractional range changes, as seen in the table (4.2) and figure (4.8). The figure
(4.10) details the use of a 5 mm margin, per patient and beam configuration, where
the use of the ITVG5 was enough to keep the mean V95CTV above 99% for the named
robust geometries.
From the outliers of figure (4.8 a and b) is concluded that even for the more robust
geometries there are cases of patients, and isolated fractions with dose degradation,
however only a maximal variation of 3.4% in the V95CTV was reached (when using the
ITVG0). The analysis of these particular cases, was found to correspond to patients
with changes in the tumour volume and COM (e.g. figure (4.9 b). To overcome these
situations the use of the two oblique posterior beams (configuration F) showed to be
more stable along the treatment course.
Other analysed option to increase the plan robustness was the use of symmetric range-
uniform margins, ITVHU . The results of the forward dose distributions for all the pa-
tients, also presented in the table (4.2) and figure (4.8), led to the conclusion that
the used of 3 and 5 mm HU-uniform was not sufficient to mitigate the extreme range
changes in the anterior and lateral beam direction, without significant improvement over
the geometric concept. Hence, these conclusions drove to the investigation of asym-
metric margins.
Figure 4.10: Distribution of the V95CTV per patient and beam geometry of the dose distributions obtained
from the forward calculation of the treatment plan optimised to the ITVG5.
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4.3.3.1 Asymmetric margin analysis
The obtained ITVWEPL per beam direction, which includes the range variations along
the weekly-CTs, allowed to get the information of how asymmetrically the ITV needs to
be defined to maintain the CTV coverage. A representative example of the ITVWEPL
shape for an anterior beam is shown in figure (4.9 c).
The ITVWEPL size and shape necessary to keep the CTV coverage does not need to be
volumetrically larger than a 5 mm expansion, with the analysis of the ITVWEPL volume
showing a volume (-26.06.3)% smaller than the ITVG5, as result of tight margins in the
lateral direction to the beam and a margin increase for the non-robust beam geometries
in the depth beam direction. The complete results of the ITVWEPL for each patient and
beam’s incidence is outlined in the appendix (A.1.
The margin size and expansion direction were assessed from the COM variation and
HD95 value. The mean V95CTV over the course of the treatment when no margins are
applied, was used as metric of the inter-fractional changes per beam direction. Its cor-
relation with the DSC and the HD95 led to the selection of the HD95 as indicator of range
changes, due to a positive linear relation (r=0.78) versus the smaller correlation coef-
ficient of the DSC (r=0.63), as seen in the figure (4.11. This might be a result of the
lack of directional information obtained from the DSC. The p-value was found for both
correlations to be below 0.001.
The analysis of the volume and ∆COM of the obtained ITVWEPL is presented in terms
Figure 4.11: Correlation between the HD95 and DSCwith the V95CTV in the figure a) and b), respectively,
for all the evaluated beam configurations. In grey the 95% confidence interval is drawn.
of median and quartiles values in table (4.3). A better interpretation of the results is
possible through the figure (4.12), where the ∆COM is depicted along the three axis
relative to BEV (depth, lateral and cranio-caudal). Additionally, figure (4.13 b) shows
the HD95 per beam direction and gives the Pearson correlation coefficient for the HD95
-V95CTV relationship, with the beam direction. From this image is shown that the Pear-
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son correlation coefficient has different values with beam direction, as result of the small
variation of V95CTV is this sample.
In brief, the ∆COM give us the information of how the ITVWEPL expands/contracts
Table 4.3: Evaluation of the calculated ITVWEPL by: volume comparison with the ITVG5 (mean, mini-
mum andmaximum are shown); directional expansion relative to the CTV (HD95); COM variation relative
to the CTV. The reported values as Q25% and Q75% correspond respectively to the first and third quartiles
of the data.
∆V CTV exp. ∆COM ∆COM ∆COM
ITVG5-ITVWEPL (mm) depth (mm) lateral (mm) cc (mm)
Beam
Param. Mean(%) [Min;Max](%) Q75% of HD95 [Q25%;Q75%] [Q25%;Q75%] [Q25%;Q75%]
A,F1 -28.0 [-35.3,-22.6] 4.5 [-1.2; -0.3] [-0.2;0.3] [-0.3;0.5]
B,E2 -27.9 [-36.5,-22.1] 4.5 [-0.8 -0.5] [0.0;0.2] [-0.3;0.5]
C -16.9 [-30.5,-8.4] 10 [-5.3;2.8] [-0.2;0.5] [-0.2;0.4]
D,E1 -26.9 [-37.2,-15.5] 6.8 [-3.1;0.4] [0.1;0.7] [-0.2;0.9]
F2 -28.7 [-35.9,-21.4] 5.0 [-0.7;0.7] [-0.1;0.5] [-0.3;0.4]
relative to the CTV, while the HD95 says how much. To explain this statement in detail
let’s get the example of the geometry C. From fig. (4.13 a) results that the margin to
apply to the CTV to cover all the cases was superior to 10 mm in one of the directions,
i.e just 75% of the evaluated ITVWEPL volumes were up to 10 mm. From figure (4.12)
it is clear that for the geometry C no strong COM variation was detected in the lateral
and cranio-caudal BEV direction, so this large margin will have to be added in depth
direction (∆COM > 5 mm), larger in the proximal edge of the beam for the majority of
patients. Therefore, this 10 mm margin (valid in 75% of the patients) will be asymmet-
rically distributed in depth, where from the Q25% and Q75% of the ∆COM (cf. table 4.3)
corresponds to a proximal expansion of 10 mm ( 10/2 + 5:3) and a distal increase of
7 mm ( 10/2 + 2:8).
Using the same thought, it results that for the geometry D the required ITVAsy margin,
to cover 75% of the dose distributions, corresponds to 6 mm and 3 mm in the proximal
and distal direction, respectively.
Based on these results, new plan optimisations were performed for these asymmetric
ITV (ITVAsy) that cover 75% of the sample. Regarding the lateral and cranio-caudal
direction an expansion of 2.5 mm in each direction was applied. The delivery of these
new plans to each weekly-CT, showed an improvement of the V95CTV superior to 2%
relative to the use of a geometric 5 mm expansion, depicted in the last row of the table
(4.2). This proved the validity of this concept, improving the target coverage even with
less robust beam geometries. However, the increase of the geometric margin will result
unwanted doses to the normal tissues.
For robust geometries the analysis showed that the use of a symmetric margin is suit-
able, where 5 mm was enough for 75% of the evaluated fractions. The results pointed
toward a minimal margin of 3.5 mm needed to overcome the uncertainties coming from
the inter-fractional changes.
4.3.4 WEPL-maps for detection of inter-fractional changes
For all the patients the accWEPL were calculated for the four different beam entrance
channels, i.e., anterior, lateral left, posterior and oblique posterior left to the patient
anatomy, designed as Ant, Lat, Pos, Obl along the results discussion. The ∆accWEPL
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Figure 4.12: Variation of the COM of the ITVWEPL relative to the CTV in the longitudinal (a), lateral (b)
and superior-inferior (c) direction with respect to the beam entrance channel.
Figure 4.13: Changes of the HD95 as function of the beam geometry, with each box showing 25-75% of
the data. b) Correlation, per beam direction, between the CTV V95 mean dose for the weekly CTs (plan
optimised to the ITVG0) and the HD95. In grey the 95% confidence interval is drawn.
was obtained from the comparison between each weekly-CT to the planning-CT. After-
wards, the ∆accWEPL was evaluated using different parameters and correlated with
dosimetric parameters, as V95CTV , HCTV and gammap:rate.
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4.3.4.1 ∆accWEPL evaluation
The complete evaluation of the ∆accWEPL for all patients and CTs is presented in the
appendix, table (A.2), while a summary of these results per beam angle is shown in
figure (4.14).
From the first overview of the ∆accWEPL distribution, it is again concluded about the
Figure 4.14: Resume of the evaluation performed to the ∆accWEPL maps along the specific beam
direction in BEV for all the patients by comparison of each week-CT with the planning CT. The plots
show the variations of the accWEPL maps per beam incidence in terms of percentage of voxels within
a [-3;3] mmwater variations (PVin), mean ∆accWEPL, variance of the ∆accWEPL and the LUTmin and
LUTmax.
robustness of some beam directions against inter-fractional changes. This is explained
by the average of the patients and CTs showing smaller ∆accWEPL for the posterior
and oblique posterior beam incidence, i.e. smaller box width of the ∆accWEPL mean
and variance and around zero (figure 4.14.
An illustrative example of the analysis performed, per patient and pair of CTs, is de-
picted in figure (4.15). Shown is the case of patient A1 where an anterior beam is
applied to the CT1 (CTPlan), CT3 and CT4. By comparison with the CTPlan an increase
of the air amount comparative to the planning CT is noticed. This results in a strong
reduction of the number of voxels below the defined PVin, i.e. inside the interval of
[-3;3] mmwater variations. This evaluation is possible either though the visual analysis
of the bi-dimensional ∆accWEPL map, where regions with high ∆accWEPL are shown
in lighter colours (fig. 4.15 b) or by the histogram of the accWEPL diferences, in which
the PVin is delimitated by two horizontal green lines (fig. (4.15 c). For the case of this
patient it is also concluded that the inter-fractional anatomy chances are stronger in the
CT4 than in the CT3 comparatively with the CTPlan. This postulate is confirmed when
looking for the dose distributions forward calculated for these CTs, where the obtained
∆V95CTV G0 is of 5.5% and 31.0%, respectively.
To demonstrate this relationship between dose and accWEPL, in figure (4.16) the
∆accWEPL (through the parameter PVin) and the parameters from the dose distribu-
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Figure 4.15: Example of the performed evaluation in the MeVisLab module for the patient A1, for which
the accWEPL in the CT3 and CT4, were compared to the CTPlan in anterior BEV (a). The results are
then presented through ∆accWEPL 2D maps (b) and respective histograms (c). For the histogram of
∆accWEPL differences a PVin for a selected acceptance range was defined. In this study the range of
[-3;3] mmwater was selected, and is shown in check-board in this figure.
tion (V95CTV G0 and gammap:rate) for patients A1 and A8 using an anterior beam, are
drawn simultaneously. From here is observed that variations in the V95CTV were de-
tected by the concept of PVin. The PVin value is, however, not representative of the
same V95CTV or Gammap:rate value. Another example is outlined in figure (4.17) for
patient A3 and A4, where the PVin along the treatment weeks showed strong variation
with the use of a posterior beam, when no significant variation in the V95CTV was mea-
sured.
The situation of patient A3 is justified due to the non-sensitivity of the V95CTV to changes
in the dose distribution outside the target volume, fact that was detected when us-
ing the gamma index for comparison of the dose distributions, being visible that the
changes due to the accWEPL variations occur for the OARs, as in this case the bowel,
see figure (4.18). On the other hand, for patient A4 the same wasn’t observed, where
the gammap:rate presents constant along the week-CTs. Another important conclusion
about patient A4 is the constantly low PVin, not showing an anatomy change over one
week, but a systematic variation. The inspection of the CT-value of the planning CT in
one of the week-CTs (e.g. CT3) gives the hint about a systematic positioning error, at
least when the positioning is bone-based as performed in this analysis, see figure (4.19)
for the illustration of this case. From the x-profile, a difference in the beam entrance is
visible. It is this variation that results in the low PVin, however it does not correspond
to a strong decrease in the V95CTV ( 98.41.0 % for the set of four week-CTs). One
possibility, to justify this can be the fact that the accWEPL doesn’t consider the beam
characteristics. Then the same ∆accWEPL in two different CT can lead to a different
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impact in the dose distribution depending of the used beam intensity and energy.
The complete evaluation for each patient, beam incidence and CT is available in the
appendix from (A.6) to (A.9). Additionally figure (A.3) shows more examples of the ac-
cWEPL maps and its histogram of differences.
Figure 4.16: Comparison for patient A1 and A8 using an anterior beam of the variation along the week-
CTs of the ∆accWEPL (through the concept of PVin), V95CTV and Gammap:rate.
Figure 4.17: Comparison the patient A3 and A4 using a posterior beam of the variation along the week-
CTs of the PVin, V95CTV and Gammap:rate.
4.3.4.2 Definition of the correlation accWEPL to dose
Aiming to establish a correlation between the variations on the accWEPL and the dose
distribution, linear regressions were tested between different parameters and the sta-
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Figure 4.18: Comparison of the Fail-Map for the Gamma Index for patient A3 using a posterior beam
for the CT3 and CT5.
Figure 4.19: Comparison of the CTplan (a1) and CT4 (a2) for the patient A4, using the unidimensional
CT value variation along the axis x (i.e., the posterior beam incidence) and y.
tistical relevance from them was assessed.
In order to check whether each parameter is normally distributed, statistical require-
ment for the definition of confidence levels, the Shapiro-Wilk test (Pruim 2011) was
performed. The distribution of these parameters is depicted in figure (4.20), and the
Shapiro-Wilk test showed that PVin and V95CTV have both normal behaviour.
Considering this, the correlation between the PVin, V95CTV and gammap:rate was eval-
uated, as shown in the figure (4.21). The PVin parameter set forth to have the better
balance between the V95CTV and gammap:rate correlation, i.e. target information and
dose distribution in the normal tissues. The linear regression for these two parameters
is presented in the table (4.4) with the respective R2, which showed up to be small as
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Figure 4.20: Density distribution per beam direction of the V95CTV , PVin, standard deviation of the
∆accWEPL and its variance.
a consequence from the spread of the data around the linear fit. To assess the differ-
ences from each point to the regression line, the residual values were determined. The
median residual is close from zero with a significantly low quartiles which supports the
use of this linear fit.
Moreover, the correlation between the PVin and the V95CTV was also verified per beam
angles, showing to be always positive, however stronger for the anterior and lateral
beam as result of the reduced variance of the sample for the other beam’s direction
(small statistic relevance).
Figure 4.21: Graphic of the dispersion of the dosimetric quantities (i.e. V95CTV and Gamma passing
rate) versus theWEPL evaluation parameters (PVin, standard deviation and variance of the ∆accWEPL).
The Pearson correlation (r) is shown for each relationship. The red dashed line corresponds to the
defined acceptance threshold of the dose distribution. In grey the 95% confidence interval is drawn.
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Table 4.4: Statistical evaluation of the correlation between the PVin, V95CTV and gamma passing rate.
PVin vs
Parameter V95CTV gammap:rate
Linear fit (y=A+B.X) A=87.15; B= 0.10 A=77.10; B=0.18
Conf.Interval [2.5%; 97.5%] A 85.4; 88.9 72.53;81.68
B 0.07;0.13 0.11; 0.24
R2 0.2729 0.1523
Residual [Q1;Median;Q3] -2.63;0.29;2.89 0.64;3.17;5.23
p-value <0.001 <0.001
r-pearson 0.52 0.39
With the model settled, the prediction condition can now be drawn. Thus, consid-
ering the linear regression between the V95CTV and the PVin, if a preservation of the
V95CTV above 95% the PVin is a intend, it will need to be superior to 66.1% with a
confidence interval of 49.1 - 83.1% for a confidence level of 50% (see the Linear fit of
table 4.4) . In the same way, if the aim is to have a gamma passing rate above 90%
come out that PVin, in a confidance level of 50%, will have to be superior to 63.1%, with
a confidence interval of 44.8 - 81.5%.
In conclusion, for the defined V95CTV and gammap:rate acceptance levels, based on
the usually adopted clinical criteria, a PVin below approximately 65% might mean a
clinically significant change in the dose distribution, which should be verified through
the dose forward calculation. Moreover, values below 45% (i.e. lower limit of the con-
fidence interval) indicate inevitably a degradation of the original dose distribution, at
least in terms of the normal tissues, and an adapted plan is strongly suggested.
4.4 Clinical evaluation
The presented concepts and conclusions were evaluted by a master student super-
vised by the author (Asim 2016), for the set of patients under treatment at HIT and the
clinically delivered plans.
The summary of the application to the these patients is outlined here.
4.4.1 Material and methods
From the twenty pancreatic patients treated at HIT from 2014 to April 2016 using pro-
tons or carbon ions, a subset of fifteen patients were included in this dissertation, see
table (4.5). However, in the context of this inter-fractional evaluation, just eleven of
them include weekly CT imaging and are discussed in this chapter. This dataset will be
redeemed is the next chapter for intra-fractional inspection.
All the patients were prone positioned and had a free-breathing CT for planning pur-
poses. The treatment planning was done using the TPS Syngo® RT Planning, IMPT
or SFO technique (cf. table 4.5), with an IES spacing of 3 mm and a minimum pencil
beam FWHM of 10 mm for carbon ions and 8 mm for protons. Plans were optimised
to cover the CTV with an homogeneous effective dose while keeping the dose to the
OARs to the clinical dose constraints. In order to reduce sources of inter-fractional vari-
ations, the adopted beam geometry matches the conclusions from the previous study
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Table 4.5: Dataset H: Description of the set of patients (Pt.) treated at HIT containing the description
of the dose prescription (total and by fraction), particle used (protons or carbon ions) and number of
control CTs. The adopted beam configuration (B.config) follows the naming of the figure 4.1.The patients
highlighted in grey were excluded from this analysis.
Pt. T. dose Gy (RBE) F. dose Gy (RBE) Particle B.config. Optim. week-CTs
H1 45+9 1.8 p F IMPT 5
H2 45+9 1.8 p F SBO 3
H3 45+9 1.8 p F+B IMPT 3
H4 45+9 1.8 p F IMPT 3
H5 45+9 1.8 p F IMPT -
H6 45+9 1.8 p F IMPT 3
H7 54 2 p F IMPT 3
H8 45+9 1.8 p F IMPT 3
H9 45+9 1.8 p F IMPT 4
H10 48 4 12C F IMPT 1
H11 45+9 1.8 p F IMPT 5
H12 45+9 1.8 p E IMPT 6
H13 48 4 12C F IMPT -
H14 48 4 12C F IMPT -
H15 45+9 1.8 p F IMPT -
(i.e. posterior beam directions) and is set in table (4.5).
Regarding the weekly-imaging, the number of sessions that each patient underwent
along the whole treatment course is detailed in table (4.5). These CTs were performed
using the PET/CT scanner at HIT (Siemens Biograph mCT, Siemens Molecular Imag-
ing) under the same CT protocol, patient positioning, free-breathing and without con-
trast.
Weekly-CTs were rigidly registered with their respective planning-CT using the 3D slicer
software. The matching criteria included bones i.e. vertebral column and ball-bearing
fiducial, which were placed on patient skin for alignment at the time of scanning. The
registration considered 6 DOF.
Forward calculations of the treatment plan
Forward calculation of the dose distributions for the rigidly registered CTs and the plan-
ning CT were performed using TRiP98.
The plan quality assessment was based on ICRU (1999) criteria:
• Target Volume - V95CTV , V95PTV , PTVmaximumdose (DmaxPTV ), PTVminimum
dose (DminPTV ) and PTV mean dose (DmeanPTV );
• OARs - spinal cord (DmaxCord), both kidneys (V40kidney) and bowel (V20bowel,
V80bowel), i.e. maximum, and volume receiving 40%, 20% or 80% of the precribed
dose, respectively;
• Comparison between dose distributions - gamma index (∆d 3%/ DTA 3mm)
accWEPL assessment
The analysis was performed on theMeVisLab framework, using themoduleMVLCT V eri,
in a similar workflow to the one described in section (4.2.5).
In the registration stage all the CTs were rigidly co-registered, in the same manner as it
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was done for dose forward calculation, i.e. using the same image registration parame-
ters acquired from 3D Slicer into the MVLCT V eri module.
Since the WEPL calculation is performed for one treatment field at a single time and
these patients possessmultiple beams, one beamwas evaluated at a time. The VOIWEPL
used for the calculations was defined by the initial CTV as a reference volume, addi-
tionally a margin of 1 mm in x, y directions (anterior-posterior and left-right) and 3mm in
(superior-inferior) z direction was added. The accWEPL was originated from the WEPL
sum along the beam path, starting from the patient surface to: (i) the distal edge of the
VOIWEPL; and (ii) to the proximal edge of the VOIWEPL. The sketch of these two meth-
ods is shown in figure (4.22).
The evaluation was done using the accWEPL difference map and histogram of tissue
Figure 4.22: Diagram of the accWEPL calculation through the distal and proximal edge of the VOIWEPL.
Image coutesy of Z.Asim
variation among planning-CT and weekly-CT by the PVin parameter.
To evaluate the total plan a weighted average of the PVin for each beamwas considered
by taking into account the respective field weight, here considered as approximation the
number of particles, designated as PVnorm. This strategy doesn’t consider the dose de-
livered by the beam but approximate beam weight by the number of particles. This is
especially meaningful for some patients, as the patient H3, in which case one of the
beams delivers significantly less dose (30%). In general, this weighting is nearly con-
stant (5010 % per beam).
To evaluate the correlation among WEPL and dosimetric parameter, PVnorm was cor-
related with the ∆V95CTV , ∆V95PTV , gammap:rate and V20bowel, where ∆ corresponds
to the difference with the planned dose distribution. The correlations were measured
using the Pearson correlation coefficient (r) and the linear regressions were calculated.
Considering the results of the previous study (in section 4.3.4.2) and the clinical rea-
sonable variations of the forward calculated dose distributions, action and tolerance
level were narrowed. For the variation in V95%, either for CTV or PTV, 2% and 3%
variation was set as tolerance and action level respectively. Similarly, for gammap:rate
97.5% and 96.5% were considered as tolerance and action level respectively.
4.4.2 Results
A short summary of the main results and conclusions are here presented as validation
of the previously suggested, in terms of beam geometries, margins and assessment of
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inter-fractional changes through WEPL-maps.
Forward Calculations of the treatment plan
The results for the ∆V95CTV are shown in figure (4.23).It is concluded that the majority
of the treatment fractions were kept below 5% variation (mean of 2.02.9 %), with pa-
tient H12 as an exception with three out of six fractions above this threshold.
It comes out from the forward calculations in the follow-up CTs, a relatively small varia-
tion of the PTV coverage (2.21.8)% with 23% of the fractions with a ∆V95PTV superior
to 3%. Regarding the variation of the DmaxPTV , it fluctuates among 0.02 Gy (RBE) /fx
and 0.5 Gy (RBE)/fx. Nevertheless, the DmeanPTV was fairly consistent along the treat-
ment course.
To quantify the impact in the overall dose distribution, the gamma index was computed
Figure 4.23: Variation of the V95PTV along the weekly-CTs for all the patients comparatively to the
CTplan dose. The dashed lines indicate the 2%,3% and 5% of ∆V95CTV , respectively.
for each dose distribution calculated in the weekly-CT versus the one in the CTplan. This
analysis reveals that the gamma passing rate was in general high (97.41.7)% varying
between 91.3% and 99.7%.
Relatively to the OARs doses, the strongest impact was found to be for the bowel,
with variations of the V80%Dbowel that can reach 8.0% and with the V20%Dbowel rang-
ing within [-11.1;9.6]%. As far as kidneys and spinal cord are concerned no significant
differences were found.
It was concluded that the dose distributions with lower gammap:rate correspond to the
higher dose delivered to the normal tissues compared with the planned distribution
(Asim 2016).
accWEPL assessment
The obtained PVnorm, considering first the distal analysis, for this set of patients varied
between 23.0% and 98.7% with an average of (67.5 16.9)%. Comparisons with the
proximal analysis showed no significant differences between the two methods, with two
thirds of the fractions below to 3%. This finding supports the fact that in the majority of
the evaluated cases the density variations occur in the beam path before reaching the
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target volume, while the target density changes are almost negligible.
Figure (4.24) shows an example of the evaluation performed for patient H11, in which
CT1 is compared to the CTplan. The presented example corresponds to the geometry
F and depicts a case where low density of the bowel results in a high accWEPL differ-
ence. The gammap:rate showed to be reasonable for this case (97.7%), the V95PTV and
the OARs doses had a variation below 2%. Just a closer look at the dose distribution
showed the reason for this low PVnorm which is related with the high doses in the soft
tissues, see figure (4.25).
Figure 4.24: Evaluation of the accWEPL for the patient H11 for the CT1 (a2) comparatively with the
CTplan (a1) for the oblique posterior right field. (a3) shows the difference in the CT value for a profile
drawn along the beam path. This difference will be translated in accWEPL changes as the pointed to
in image a4). The yellow axis in image a4) can be moved along the ∆accWEPL in order to measure
its current value. Moreover, this axis is synchronously moved in the CT of the patient (a1 and a2) and
the unidimensional profile (a3) to help in the interpretation of the results. As example of this evaluation
method the axis was in this figure placed after a region of large density variations, i.e. air in the bowel
compared to the planning CT.
In order to evaluate the correlation between dose and accWEPL in figure (4.26
) the relationship between the plan quality parameters (i.e. ∆V95CTV , ∆V95PTV and
gammap:rate) with the PVnorm is shown. It raises that ∆V95CTV and PVnorm were weakly
correlated (r = -0.05), however when looking for the p-value the high value (0.78) leads
to the conclusion about the low statistic relevance of this sample in this correlation. The
same can also be concluded when considering the small V95CTV variations for most of
the fractions. The correlation improves when the proximal VOIWEPL is considered (r =
-0.21).
In pursuit of taking a more significant volume to quantify the dose distribution, the rela-
tion between the PVnorm and both ∆V95PTV and gammap:rate was evaluated. Although
the PTV is not the clinically relevant volume to be irradiated, in this approach it is ex-
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Figure 4.25: Transversal and sagittal view of the dose distribution of patient H11 from the forward cal-
culation in the CTplan and CT1. The CTV, ITV and PTV are drawn in blue, white and red, respectively.
pected that it allows to account with variations in the dose distribution immediately sur-
rounding the CTV. Additionally, it will allow to spread the data sample, since the de-
tected mean ∆V95CTV was only of 2%. Both the V95PTV and gammap:rate showed a
strong correlation with the PVnorm in the distal analysis, with a person correlation of -0.6
and 0.7, respectively, and p-value below 0.001.
The fact that the gamma criterion considers the entire variations in the dose dis-
tribution clearly is closest to the information given by the PVnorm. This was detected
for several patients, where the inter-fractional anatomy changes strongly affected the
bowel doses without compromising the CTV dose. The same conclusion is also ob-
tained when looking for the number of false positives (high PV norm but low gamma)
and false negatives (low PV norm but high gamma), which has reduced in comparison
to V95PTV correlation, because the gamma index gives a complete information of dose
distribution (target, OARs and normal tissues).
Therefore, based on the linear regression between V95PTV and the gammap:rate with
the PVnorm the calculated action and tolerance levels are defined in the table (4.6). The
tolerance level corresponds to the linear fit value, while the action level to inferior inter-
val of the confidence level (for a 50%). Additionally, the results obtained in the previous
analysis (section 4.3.4.2) are also shown.
In short, the obtained results for this set of patients under real clinical situation, i.e.
beam configuration and plan optimisation strategy, culminate in similar action and tol-
erance levels than in the previous evaluation, in which only single beams were con-
sidered. This validates the method and settled reference levels for further patients.
However, a decision is always dependent of the understanding of which were reasons
that affected the WEPL and of the clinical report of each patient.
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Figure 4.26: Correlation of ∆V95CTV , ∆V95PTV and gamma passing rate with the PVnorm. The person
correlation coefficients (r) are written in the correspondent graph. The blue line corresponds to the
linear regression and the respective 95% confidence band in grey. The dashed lines correspond to the
acceptance levels defined, with yellow, orange and red, corresponding to the acceptance thresholds of
2%,3% and 5% for doses and 97.5%,96.5% and 95% for the gamma passing rate.
Table 4.6: Action and tolerance levels obtained from the linear regression V95PTV and the gammap:rate
with the PVnorm. The results are presented for different threshold criteria. The last row corresponds to
the value obtained in the previous analysis for a different dataset, considering single fields and using the
CTV as VOI.
Volume Beam Threshold PVin
∆ dose gammap:rate Tolerance L. (%) Action L. (%)
PTV Multiple 2.0 97.5 68.3 59.5
PTV Multiple 3.0 96.5 61.9 53.1
PTV Multiple 5.0 95.0 51.0 41.8
CTV Single 5.0 95.0 64.8 45.1
4.5 Summary and discussion
In conclusion, the combination of two oblique posterior beams with a geometric mar-
gin can be robust to the majority of the inter-fractional changes affecting pancreatic
patients, and yields to acceptable dose coverage for most patients and fractions. How-
ever, daily anatomy variations may be large and routine soft-tissue imaging and adapta-
tion strategies will likely improve the treatment. Moreover, the evaluation of the WEPL
from the pre-treatment CT will help to detect extreme anatomy variations and prevent
the treatment with a plan that might substantially decrease the dose in the target and/or
over-dosage the healthy tissues. This method can still be improved, and the correla-
tion between the variation of the accWEPL and dose distribution strengthened, by (i)
the use of gated-CT images, to avoid influence of motion artifacts and differences in
the pancreas positioning due to the averaging breathing; (ii) consideration of the posi-
tioning shifts applied to the patient at the specific treatment day; and (iii) removing the
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surgical clips from the WEPL evaluation, to avoid too strong changes in the accWEPL
that might mask anatomical changes.
Relative to the population-based asymmetric ITV margins may be a feasible clinical
strategy to account for density changes and to reduce the irradiated volume. However,
a patient-specific concept, either based on a series of pre-treatment images (e.g. MRI)
or adapted along the treatment course (e.g. control CTs and MRIs), will be worthwhile
to the improve the plan quality.
Chapter 5
Intra-fractional motion
5.1 Aim of this chapter
The intra-fractional motion as result of the patient’s breathing is also a concern for pan-
creatic patients. Moreover, the dose delivery using a scanning system results in inter-
play effects and consequently in dose degradation.
The goal of this chapter is to quantify the impact of the patient’s motion on the dose
distribution and to assess the need of mitigation techniques.
Before the implementation of the pancreatic irradiation at HIT the plan robustness to the
intra-fractional motion for different beam geometries was evaluated, such study is pre-
sented in section (5.2.1), with the respective results in section (5.3.1). Subsequently,
for patients under treatment at HIT the dose distribution under motion was simulated
pre-treatment (section 5.2.2), and furthermore the delivered dose was reconstructed for
some of the treated fractions (section 5.2.3). The results of this evaluation are shown
in section (5.3.2).
In this chapter the results from the time resolved dose calculations will be designed as
4D Dose Simulation (4DDSim), when the accelerator beam delivery sequence (BDS)
is unknown and consequently simulated, and as 4D Dose Reconstruction (4DDRec)
when the BDS and the breathing signal correspond to the measured data during the
patient treatment.
5.2 Material and methods
5.2.1 4D dose simulations - dataset B
When a pre-treatment 4DCT is available a prediction of a set of possible dose distribu-
tions, as resulting from different interplay patterns, can be simulated. This simulation
relies on a sample of the patient’s breathing, the treatment plan information (beam
spots, positions, energies) and on a set of simulated accelerator irradiation patterns.
The first step of this study, prior to the beginning of treatments for pancreatic patients
at HIT, was to use an available dataset of patients, previously treated at the University
Clinic of Heidelberg, to assess the impact of HIT’s delivery method in the plan quality.
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5.2.1.1 Patients and imaging description
Seven patients with a planning CT and a 4DCT, acquired in the same imaging ses-
sion, constitute the set of patients included in this section (referred as dataset B). The
planning CTs of the patients included the outline of kidneys, liver, bowel, stomach and
spinal cord.
The planning CTs and 4DCTs were acquired under free-breathing in the Somaton Sen-
sation Open (Siemens, Erlangen, Germany), which performs a relative phase-based
reconstruction considering the surrogate signal of the motion-monitoring system AZ-
733V Respiratory Gating System, Anzai Medical Co, Tokyo, Japan, (cf. 2.3.4.1, and
called as Anzai).
The 4DCT was sorted in eight predefined states: 0%Ex, 40%Ex, 70%Ex, 100%Ex,
75%In, 50%In, 25%In and 20%In, where In correspond to the inspiration and Ex to the
expiration state. The state 0%Ex is the end-exhale and 100%Ex is the end-inhale state
(as seen in fig.2.10).
Due to the contrast agent in the planning CT, CTBPL, this CT was ignored. Hence, the
end-exhalation CT, named as CT0Ex, was used for planning purposes.
All the CTs were pre-processed in order to remove couch and indexing devices.
5.2.1.2 Treatment plan optimisation
The dose distribution was biologically optimised using the TPS TRiP98 for a geometric
ITV, which was in first approximation originated from a generic 5 mm expansion of the
CTV0Ex, based on the mean motion of the CTV for this patient-population.
The plans were optimised for a prescription dose of 3 Gy (RBE) in 15 fractions with
carbon ion-beams.
The CTV0Ex was obtained through contour propagation of the physician’s delineated
contours on the CTBPL using the vector field from the deformable registration between
the CTBPL and the CT0Ex. This process follows the one outlined in section (3.1.2).
Algorithms and planning parameters follow the definition in the previous chapter (4.2.2).
The selected beam geometries, for which the plan robustness was evaluated, were
based on the previous results of the inter-fractional study, where two so-called robust
geometries (single posterior beam and two oblique posterior beams) and one non-
robust geometry (single anterior beam) were used for comparison, that in figure (4.1)
correspond to the geometry B, F and C, respectively.
5.2.1.3 Image registration
The deformable image registration (DIR) was performed using Plastimatch (see chapter
(3.2) for details), using two stages of a B-Spline algorithm (Shackleford, Kandasamy,
and Sharp 2010).
The registration was performed between the CTBPL and the reference 4DCT state,
CT0Ex, with the aim of contour transformation. Moreover, each of the 4DCT states was
registered against the CT0Ex with the objective to be used as motion information during
the calculation of the time resolved dose distribution.
The quality of the deformable image registration was assessed using the Registration
Quality Module of the software SlicerRT (see chapter 3.3.1) through visual inspection
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and numerical quantification, such as the determinant of the Jacobian matrix (JD) of
the vector field, inverse consistency error (ICE) and mean absolute difference. Due
to the aim of this section to be the evaluation of different beam geometries, the DIR
analysis was performed for the complete CT volume, since different beam directions
were considered.
5.2.1.4 Breathing signal and irradiation patterns
Since this set of patients was treated with photon therapy without 4D image guidance,
no breathing signal during the treatment was recorded. Therefore, to simulate the
breathing signal for these patients a regular trajectory with a regular period of 3 sec-
onds (Lujan motion, Lujan et al. 1999) and an irregular breathing curve corresponding
to other patients were used. The example of these two signals is shown in the figure
(5.1). The dose distributions resulting from these two signals were compared to esti-
mate the effect of different surrogate signals.
The beam delivery structure was simulated using the tool makeLmdout-MH (see sec-
Figure 5.1: Sample of the breathing signals employed for the simulations of the patient B3: regular
signal (Lujan shape) and irregular.
tion 3.4), whose inputs were the previously optimised treatment plan, the breathing
signal (both cases) and the accelerator spill information. The spill was characterised
by the maximum beam hold time of 20.0 s, the maximal extraction time of 5.0 s, pause
length and pause length at the end-of-plane of 4.2 s. These parameters were based
on the accelerator characterisation performed by M.Härtig (University Clinic of Heidel-
berg). As output of the makeLmdout-MH the BDS in TRiP format is directly generated.
In order to describe the spectrum of possible irradiation scenarios, which result in dif-
ferent interplay patterns, a temporal shift to the starting phase of the surrogate signal
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was applied, i.e. a temporal delay of the starting of the breathing signal. This will corre-
spond to the irradiation of a different raster point at a defined breathing phase. Studies
from Hild, Durante, and Bert (2013) and Richter (2012) showed that the manipulation of
the starting breathing phase is sufficient to cover the variability of the interplay patterns.
In brief, in order to cover the influence of the asynchronous between the beam delivery
and the breathing signal, temporal shifts in the breathing starting phase were induced.
These shifts were spaced 350 ms in a total of ten different irradiation starting points for
each of the two breathing signal types (Lujan and irregular).
5.2.1.5 Time resolved forward calculation of the dose distribution
The TPS TRiP4D was used for the forward calculation of the dose distributions con-
sidering the breathing influence. Each calculation was based on the treatment plan
information (raster points, energies and beam focus), breathing signal and in the simu-
lated accelerator temporal pattern.
The breathing data was set for eight motion states in one direction (x in this case due
to the 4DCT acquired with the Anzai breathing belt), considering a relative amplitude-
based sampling and normalised to 0-200%, i.e. inspiration corresponds to 0-100% and
expiration up to 200% of the signal amplitude. More details about the used mode can
be found in the section (3.1.2).
The spill information was described by the simulated lmdout signal, which is temporally
correlated with the breathing signal.
Additionally, the vector fields obtained of the DIR between each of the 4DCT states and
the reference state (selected as CT0Ex) were also given as input.
For comparison with these calculations, where the interplay effect is considered, the cal-
culations were also performed in the individual 4DCT-states in which range variations
and displacements affect the plan quality, discarding the dynamic irradiation. These
simulations were called quasi-4D.
Calculation and biological algorithms correspond to the ones used in the plan optimi-
sation.
5.2.1.6 Evaluation methods
The internal motion of each patient was quantified using the vector field information,
particularly through the measurement of the median vector field length (VFL) inside the
CTV0Ex, which was obtained from the DIR between the CT0Ex and each of 4DCT states.
The maximum of these values will be used as quantification of the intra-fractional tu-
mour motion, usually corresponding to the CT100Ex.
The dose distributions, namely the static, the quasi-4D and the 4DDSim, were evalu-
ated taking as metric the V95CTV and HCTV (cf. section 2.4.0.2).
Note that the 4DDSim correspond to a set of dose distributions, as representative of
different interplay patterns, giving rise to the need of displaying the results as mean and
standard deviations and the DVHs as band-DVHs.
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5.2.2 4D dose simulation of the treated patients at HIT - dataset H
In this and in the following section (5.2.3), the same set of patients was adopted. This
set of patients, dataset H, corresponds to the patients treated at the Heidelberg Ion-
Beam Therapy Center since the beginning of the clinical application of ion-beams to
pancreatic patients.
5.2.2.1 Patients and imaging dataset description
From the total number of pancreatic patients treated at HIT since 2014, shortly pre-
sented in chapter (4.4), a subset of fourteen underwent monitoring of their breathing
signal and beam delivery sequence during the irradiation. The description of the dataset
H is presented in table (5.1), expressed by the treatment planning parameters (prescrip-
tion dose, particle type, beam configuration and optimisation technique), the existence
of pre-treatment breathing signal acquisition and the number of fractions with online
monitoring of the breathing and irradiation sequence.
The planning CTs and 4DCTs were acquired under the same condition of the dataset B,
i.e., in the Somaton Sensation Open scanner using the motion-monitoring system Anzai
for the phase-based sorting for the eight predefined phases (0%Ex, 40%Ex, 70%Ex,
100%Ex, 75%In, 50%In, 25%In and 20%In).
Concerning the patient positioning, they were immobilised using a vacuum mattress
and in prone position, as shown in figure (5.2). This positioning is a consequence from
the need of irradiation using posterior beams, in order to reduce the inter-fractional
anatomy variations in the delivered dose, and the limitation of the Syngo® RT TPS to
incorporate the density of couch and indexing support in the planning process. As con-
sequence of this prone immobilisation no abdominal compression was used and the
patients were irradiated under free-breathing.
Table 5.1: Dataset H: Description of the set of patients treated at HIT, containing the information of the
total dose prescription (T.dose), and per fraction (F. dose), particle used (protons or carbon ions), plan
optimisation technique, existence of pre-treatment breathing signal (y- yes, n- no), number of treatment
fractions with recorded monitoring (Fx.monit). The adopted beam configuration (B.Config) follows the
naming of the figure 5.3. Since no breathing information was recorded in the treatment, the patient H10,
marked in grey, was excluded from the intra-fraction study.
Patient T. dose Gy (RBE) F. dose Gy (RBE) Particle B.Config. Optim. Pre-TT Breath. Fx.monit
H1 45+9 1.8 p F IMPT y 2
H2 45+9 1.8 p F SBO y 1
H3 45+9 1.8 p G IMPT y 1
H4 45+9 1.8 p F IMPT y 3
H5 45+9 1.8 p F IMPT y 4
H6 45+9 1.8 p F IMPT n 3
H7 54 2 p F IMPT n 1
H8 45+9 1.8 p F IMPT y 1
H9 45+9 1.8 p F IMPT y 1
H10 48 4 12C F IMPT n -
H11 45+9 1.8 p F IMPT y 3
H12 45+9 1.8 p E IMPT y 6
H13 48 4 12C F IMPT y 2
H14 48 4 12C F IMPT y 1
H15 45+9 1.8 p F IMPT y 1
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Figure 5.2: Patient positioned in prone in a vacuum mattress during the 4DCT acquisition, which uses
the Anzai sensor as trigger signal.
5.2.2.2 Treatment plan
The treatment planning was performed using the TPS Syngo® RT Planning, previously
described in section (3.1.3), which uses the LEM model for the effective dose calcula-
tion of the carbon ions and a fixed RBE of 1.1 factor for protons.
In general, the plans were optimised using IMPT for an initial dose of 45 Gy (RBE) - 54
Gy (RBE) with an additional boost of 9 Gy (RBE) for some cases, as referred in table
(5.1).
For the proton-beam’s plans a scanning raster spacing of 3x3 mm in lateral direction
and an iso-energy slice spacing of 3 mm water-equivalent, for a pencil beam focus
of 8 mm FWHM, was used. While for carbon ion-beams a pencil beam of 10 mm
FWHM was choosen. The selection of these parameters is a result of the previous
study from Richter et al. (2014b), in which the interplay effects are minimised for an
enlarged FWHM of the pencil beam.
The selected beam configuration for each patient was consequence of: (i) superior
inter-fractional robustness of ion-beams posterior to the patient (according to the re-
sults from the previous chapter); and (ii) spares the OARs (spinal cord and kidneys)
of unwanted doses. From these facts, followed that thirteen out of the total number of
patients were planned with two posterior oblique fields. The remaining two cases were
planned with a different geometry as consequence of OARs constraints, however also
considered robust from the inter-fractional point. The used beams arrangements are
illustrated in figure (5.3).
For all the cases, the plans were optimised to the PTV in order to deliver the pre-
scribed dose (Dpresc) to the CTV while keeping the OARs doses below the dosimetric
constraints. These are in general given by: kidney V40%Dpresc < 80%, spinal cord Dmax
< 45 Gy (RBE) and bowel Dmax < 90% Dpresc. Due to the short distance between the
tumour bed and the intestine, the prescribed dose wasn’t achieved for all the patients
over the complete CTV.
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Figure 5.3: Beam configurations adopted for the dataset H, in which the patients were prone positioned.
The PTV was assigned as an ITV expansion, by 7 mm in beam direction and 5 mm
laterally, while the ITV was inferred from the 4DCT motion information.
5.2.2.3 Image registration
The 4DCTs were rigidly registered using the bony anatomy to the CTBPL for patients in
which differences above 2 mm between the two acquisitions were found.
Regarding the quality of the 4DCT deformable image co-registration, it followed the
procedure described in the previous section (5.2.1).
5.2.2.4 Breathing signal and irradiation sequence
A pre-treatment acquisition of the breathing signal was performed for twelve of the pa-
tients during the CTBPL acquisition session, as indicated in the table (5.1) by the column
Pre-TT Breathing. For the other two patients the Lujan motion with a regular period of
3 sec was considered.
The asynchronism patterns between beam delivery and breathing were considered by
the same procedure as for the dataset B (5.2.1.4), i.e. using a pre-treatment breathing
signal plus a set of five sequentially shifted breathing signals by 500ms.
5.2.2.5 Time resolved forward calculation of the dose distribution
The calculation of 4DDSim was performed using TRiP4D according with the process
explained in section (5.2.1.5). For both particles types, the dose forward calculation
followed the same parameters as in the Syngo® RT TPS, differing just for the proton
plans, where just the physical dose was computed in TRiP. One of the parameters
tuned in order to approximate the results between Syngo® RT and TRiP, was the dose
extension factor, which is the maximum distance to which the neighbouring voxels are
considered to contribute with dose to a specific voxel. For carbon ion-beams the found
value correspond to 1.4 and for protons to 2.2 times the focus value for each IES.
However, to keep the effect of other disregarded factors minimum, e.g. the models
to consider multi-scattering, fragmentation and other unknown factors of a commercial
TPS, the dose distribution was also calculated in the static case, i.e. for the CTBPL,
and this dose distribution was considered as reference for the comparison.
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5.2.2.6 Evaluation methods
The evaluation of the dose distributions followed the same process as described in
section (5.2.1), with the assessment of the internal motion for each patient through the
mean VFL and the dose distributions evaluated in terms of V95CTV and HCTV , in com-
parison to the static case.
For simplification, only the initial plan was considered in the evaluation and the dose
distribution for the boost plan was ignored.
5.2.3 4D dose reconstruction of the treated patients at HIT
The set of patients and the available imaging correspond to the one described in the
section (5.2.2).
In order to accomplish the planned beam directions, all the patients were treated in
the gantry room each treatment fraction. The patient positioning was verified in-room
by a 2D-3D bony anatomy image registration between the orthogonal X-ray taken at
the isocentre and the DRRs calculated from the planning CT. This match allows to de-
termine the translational and rotational shifts to apply to the treatment couch for the
accurate patient positioning at the isocentre.
Once a week a pre-treatment CT was performed for soft tissues control, which were
evaluated in chapter (4.4) in the context of the inter-fractional motion analysis.
5.2.3.1 Breathing signal and irradiation sequence
After the treatment of the patient the calculation of 4DDRec was performed based on
the measured data (breathing and irradiation sequence) during the irradiation of the
individual treatment fractions. The number of available fractions with monitoring data
is listed on the table (5.1).
The Anzai system was used for the motion monitoring during the irradiation. In general
the signal acquisition was performed at a rate of 25 msec/sample (40Hz).
During the patient irradiation, the Anzai output was connected to a data acquisition sys-
tem, EtherCat system, that correlated the breathing signal and the beam delivery tem-
poral sequence of the accelerator in time. The sampling time was defined as 0.15msec
and 0.25msec for protons and carbon ions, respectively. The output of the EtherCat
system in .csv format was then converted in the TRiP4D formats using scripts devel-
oped at HIT (CVS2LMDOUT and CVS2MPOS) as explained in section (3.4.2).
5.2.3.2 Time resolved forward calculation of the dose distribution
Taking into account the monitoring data recorded of the patient, i.e. breathing signal
and the time correlated BDS, the calculation of 4DDRec was performed with the same
procedure of the 4DDSim, see section (5.2.2). The difference resides only in the BDS
(.lmdout) and motion (.mpos) data, which correspond to a real patient treatment frac-
tion, instead of a simulated situation.
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5.2.3.3 Evaluation methods
The obtained 4DDReco distributions were compared with the static distribution and with
the respective set of pre-treatment 4DDSim, in terms of target dose differences (V95CTV
and HCTV ) and DVHs.
To evaluate the impact of the dose modulation on the plan robustness to intra-fractional
changes and interplay events, the normalised standard deviation of the number of par-
ticles per slice was evaluated (IES). This parameter is given by the equation (5.1).
There, meanies is the mean number of particles in a specific IES and IES is the re-
spective standard deviation in a total of n iso-energy slices.
IES =
PIES=n
IES=1
ies
meanies
n
(5.1)
Furthermore, in order to account for variations between adjacent raster points, the con-
cept of the Modulation Index (MI) was applied. The MI was adapted to ion-beams from
the concept developed by Webb (2003) for IMRT with the aim to measure the complex-
ity of the beam structure. It is calculated from the treatment plan information (given by
the raster field from each field) using the equation (5.2) and (5.3). First, the magnitude
of the difference between the intensity from neighbouring raster points (rp) is calculated
though ∆ = jIrp Irp 1j. Secondly, the number of raster points (np) that in each IES are
above a threshold of the standard deviation of the IES (defined as  = 1:2) is counted.
This parameter is called N and is the base of the function F, see equation 5.3.
The function F quantifies the modulation of a plan by the measure of changes in adja-
cent raster points that exceed a certain fraction of the standard deviation in the specific
IES. Hence, the area of this spectrum of deviations, i.e. area below the F function,
gives the degree of modulation, MI.
The value of  was selected in a manual iterative process in a way to be sensible to
strong variations in the standard deviation of the np. Therefore, the value of  was var-
ied, and the resulting function F compared with the dose distribution per beam in order
to get for clinically homogeneous plans, a function F with a small value and gradually
larger for regions with larger dose gradients.
MI =
Z IES=n
IES=1
F (np) (5.2)
with,
F (np) = N∆>/(np  1)IES (5.3)
Since both parameters are applied per field a weighted mean per plan for the different
fields was used. The weighting was approximated by the number of particles per beam.
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5.3 Results
5.3.1 Dataset B : 4D simulations
5.3.1.1 Image registration quality
The DIR was evaluated through the comparison of the two most opposing states, i.e.
0%Ex and 100%Ex, by visual inspection and by calculation of the parameters JD, ICE
and absolute differences. These results are shown in table 5.2.
The results showed a good JD (close to 1) and ICE (close to 0), which point out for
the accuracy of the obtained vector field to be used in the 4DDSim. A low ICE is also
particularly important for the accuracy of the transformation of the contours.
Relative to the absolute difference between the original image and the transformed
one, in average differences of 14 HU were found. However, the visual inspection of the
images, by overlay, showed a good agreement in the pancreas region, with the major
differences in the liver-lung interface.
Table 5.2: Evaluation of the Deformable image registration evaluation for the fixed 0%Ex state and
the moving 100%Ex. The values correspond to the mean value over all the patients. The quantitative
parameters were the determinant of the Jacobian matrix (JD), inverse consistency error (ICE), absolute
difference between the reference image (0%Ex) and the transformed image, measured for the complete
CT VOI.
Parameter Mean  Std.Dev Range (min,max)
JDmean 1.00.1 1.0 ,1.0
JD[min;max] [-0.20.3; 5.12.5] [-0.7, 0.2 ; 2.7, 8.9]
ICE (mm) 0.6 1.1 (0.4,1.0)(0.6, 2.0)
Abs.Diff (HU) 14.133.4 (12.2,18.8)  (27.5, 40.0)
5.3.1.2 Motion analysis
For this set of patients the mean length of the motion vector in the CTV region was
(4.72.7) mm, with the major contribution in the cranio-caudal direction (4.12.7mm).
The respective values per patient are presented in the table (5.3).
The average ITV had the volume of 399140 cm3 for the respective CTV of 26197
cm3 .
5.3.1.3 Influence of breathing pattern
The comparison of the 4DDSim distributions obtained from the use of two different
breathing patterns, regular and irregular, showed differences in the V95CTV not larger
than 3%. The summary of the results is shown in figure (5.4) and in table (5.4).
From the figure 5.4 is shown that for both breathing patterns the mean values (horizon-
tal solid line in the boxplot) are similar for each of the beam geometries. The variation
of the boxplot width is associated with the different simulated interplay patterns. This
leads to the conclusion that the variation of the breathing starting phase results in a
stronger variability in the dose distribution than an irregular breathing. This result may,
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Table 5.3: Dataset B: Description of set of patients used in the intra-fractional motion evaluation pre-
implementation at HIT. It includes the information of the CTV size in the planning CT. It is also shown
the median vector field length (VFL) that corresponds to the mean length of the vector field between the
reference breathing phase (0%Ex) and the most extreme phase, usually 100%Ex, inside the CTV.
Patient CTV Volume (cm3) median VFL (mm)
B1 346.2 3.2
B2 233.3 6.5
B3 116.8 3.1
B4 284.2 3.8
B5 274.5 5.5
B6 174.0 1.2
B7 398.1 9.6
Mean  St.dev. 261.0  96.5 4.7 2.7
Figure 5.4: Distribution of the V95CTV (a) and HCTV (b) for the dataset B by beam geometries andmotion
type. Each boxplot is defined by the median value (solid black line), the 25% and 75% percentiles and
outliers (full black circles). The blue boxplot represents the results using a regular breathing, while the
red plots the irregular breathing curve.
however, arise because the 4DDSim were performed phase-based in a relative scale
(i.e. 0-200%) and hence, amplitude variations do not affect the results. The reason for
the selection of this mode for 4DDSim is related with the Anzai working principle and
4DCT acquisition method.
5.3.1.4 Dose degradation and homogeneity in the target
From the single phase forward calculations (named as quasi-4D), the quantification of
the V95CTV differences relative to the static case showed reduced influence of the range
changes as a consequence of the intra-fractional anatomy variations. The worst case
was for the anterior beam direction, a non-robust geometry from the inter-fractional
point of view, with a mean decrease of the V95CTV below 1%, with a maximum of 2.2%.
Table 5.4 summarises the results.
However, when the interplay effect is taken into account, using the 4DDSim and con-
sidering both breathing patterns, the use of a single anterior beam leads to a mean
reduction of the V95CTV of (94.94.2) % and an increase in the HCTV from (2.60.6) %
to (10.23.6) %. On the other hand, when using a single posterior beam, the V95CTV
decreases only to (97.71.7) % and the HCTV changes to (7.01.5)%.
The interference between the patient breathing and the temporal delivery structure, i.e.
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Table 5.4: Comparison of the 4D dose distribution for three different beam configurations (B= posterior
beam; C= anterior beam; F= two oblique posterior beams) through the mean and standard deviation
of the V95CTV and HCTV for all the patients, breathing and interplay patterns in case of quasi-4D and
4DDSim. For comparison the results for the static case are also shown.
Beam Configuration: B C F
FW Breathing V95CTV (%) HCTV (%) V95CTV (%) HCTV (%) V95CTV (%) HCTV (%)
static no 100.00.1 2.8  1.2 99.7  0.4 2.8  0.5 100.0  0.1 2.72.7
quasi-4D no 99.7  0.4 3.0  1.0 99.5  0.6 2.7  0.6 99.9  0.3 2.9  2.6
4DDSim Lujan 97.91.9 7.01.6 94.8 4.2 10.54.0 99.8  0.3 6.41.7Irregular 97.6 1.7 7.01.5 95.3  3.5 10.02.9 99.80.3 6.51.6
the interplay effect, is attenuated for all the patients when two oblique posterior beams
are used. For these cases there is no significant influence in the V95CTV values. How-
ever, the interplay effect still results in an increase in the HCTV , approximately to the
double of the static case.
Figure 5.5 shows a representative patient case, patient B3, of one of the simulated dose
distributions, for different beam configurations.
For patients with larger target internal motion ( > 5 mm), the use of a single posterior
Figure 5.5: Example of a dose distribution of the Patient B3, with a regular breathing pattern for the set
of tested geometries. Treatment plans were optimised for the ITV of 5 mm (blue line) and evaluated for
the CTV0Ex (green line), the respective V95CTV are shown.
beam might not guarantee a V95CTV above 95% for all the simulated scenarios (8% of
the dose distributions).
In conclusion, the use of two oblique posterior beams was the only tested geometry that
showed no significant influence of the variation of the breathing trajectory or breathing
starting phase. This supports the need of multiple beams in order to average out the
interplay effect and improve the quality of the delivered dose. Moreover, for all the eval-
uated cases the target coverage was found below 3% difference relative to the static
delivery.
5.3.2 Dataset H : 4D simulations and reconstructions
This section covers the evaluation of the dataset H from the intra-fractional motion point
of view. It includes for the patients treated at HIT, the pre-treatment 4D simulation and
the reconstruction of the delivered dose in some of the treatment fractions.
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5.3.2.1 Motion and DIR evaluation
The results of the DIR quality assessment are shown in table (5.5), for the CT VOI and
the beam path VOI. This beam path VOI is shown in figure (5.6) together with the visual
inspection of the DIR.
It was concluded from this analysis that the vector field is invertible (small ICE) and
the patient suffers no changes in volume (JD equal to 1). Relative to the absolue dif-
ferences, it correspond to small differences along the CT image are in average not
significant.
For this set of patients the mean volume of the CTV of the main plan was 256125
Figure 5.6: Evaluation of the deformable image registration between the end- and full-exhale state for
the patient H1. The software used was the Slicer 3D through the evaluation of the absolute difference,
determinant of the Jacobian matrix, Inverse Consistency Error and vector field (shown from left to right).
Table 5.5: Evaluation of the deformable image registration between the end- and full-exhale state for
the patient H1, shown by the mean and standard deviation inside the full CT or in the beam path VOI of
the absolute difference, determinant of the Jacobian matrix and Inverse Consistency Error.
Parameter VOI Mean Std.dev.
JD Body 1.00.1
Beam Path 1.00.1
ICE (mm) Body 0.60.9
Beam Path 0.70.8
Abs.Diff (HU) Body 15.327.8
Beam Path 33.034.4
cm3 for an ITV 442253 cm3.
The mean vector field length inside the ITV is shown in the table (5.6). The median of
the vector field for this set of patients was 5.5 3.8 mm, ranging from 2.2 to 12.7 mm,
comparable with the one from the dataset B. The main component of the motion was
detected in cranio-caudal (z) direction, followed by the anterior-posterior (y) direction.
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Table 5.6: Median length of the vector field, obtained by DIR between the reference state (0%Ex) and
each of the breathing states, inside the ITV for the largest difference relative to the 0%-Ex state. The
directions x, y and z correspond to the left-right, anterior-posterior and cranio-caudal directions, relative
to the patient, respectively.
Maximum of the median VFL (mm)
Patient ~x; ~y; ~z ~r
H1 0.2; 2.2; 8.2 8.7
H2 0.2; 0.9; 6.8 6.9
H3 0.6; 1.2; 4.1 4.6
H4 0.9; 1.1; 2.7 3.1
H5 0.2; 0.5; 3.2 3.3
H6 0.0; 0.8; 4.2 4.5
H7 0.8; 0.3; 4.6 4.6
H8 0.2; 1.0; 2.6 4.1
H9 0.8; 1.8; 4.2 4.7
H11 1.0; 1.5; 4.6 5.0
H12 0.3; 0.0; 12.6 12.7
H13 0.9; 0.1; 4.6 5.0
H14 0.1; 0.0; 3.0 3.1
H15 0.1; 1.1; 1.9 2.2
Mean  Std.dev. 0.50.3; 0.90.6; 4.82.7 5.22.7
5.3.2.2 4D simulations Vs static situation
Due to differences in dose calculation between TRiP and Syngo® RT the evaluation of
the 4D dose distributions was performed by comparison to the static dose distribution
also calculated with TRiP.
Figure (5.7) gathers the 4DDSim V95CTV difference relative to the static case, for all the
patients and simulated starting phases. Note, that the results for the 4DDSim corre-
spond to the propagated CTV (CTV0Ex) from the CTBPL to the reference state CT0Ex.
The first impression from these results may be that the delivered plans were not as
much robust against intra-fractional motion as expected from the previous simulations
with dataset B, section (5.2.1). The variation of the V95CTV reached values up to -28.0%
with a mean of (-7.67.6)%. Regarding the H95CTV , it was also strongly affected by the
interplay, and displacements, going from (15.97.5)% in the static case to (27.88.5)%
under motion (see appendix A.2 for the full results).
To guide in the interpretation of the results figure (5.8) shows the DVH for the CTV of
the reference dose distribution (i.e. static) and of the set of 4D simulations, for two
extreme cases. Patient H12 corresponds to the patient with largest internal motion (>
10 mm), which is the reason for the broad DVH and a mean reduction of the V95CTV of
(-15.88.1)%. In contrast, patient H15 with a mean tumour motion below 3 mm shows
a reduction in the V95CTV of just (-6.71.6)%.
This analysis assumed that the dose degradation was strongly affected by the internal
motion amplitude. Therefore, the variation of the V95CTV was represented against the
internal motion amplitude in figure (5.9).
This comparison suggests that some patients, like H1, H2, H12 and H13, fall in red
group (> 5mm motion and >5% of CTV dose reduction), however, other patients, as
H7, are not conforming to this hypothesis. In resume, from figure (5.9) its is observed,
that five patients for which the motion amplitude was below 5 mm the target suffered
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Figure 5.7: Differences of the V95CTV for all the patients relative to the static dose distribution value.
Each boxplot corresponds to the five simulated interplay patterns from the 4DDSim, while the green
crosses are the results from the 4DDReco. The red dashed lines define the 5% of variation in comparison
with the static dose distribution, and is here used to help in the detection of the patients with major
deviations.
Figure 5.8: DVH of the patient H12 (a) and H15 (b) for the CTV0Ex in the static case (red line) and for
the set of 4DDSim as the blue band.
a significant dose degradation (yellow region of fig.5.9). Another conclusion, was that
any patient with a median motion superior to 5 mm was detected with a reduced target
degradation (grey region in graph 5.9), although no linear correlation was found be-
tween the two parameters. This justifies the need to monitor the motion amplitude for
pancreatic patients, along the treatment, and apply some strategy to reduce its impact
(e.g. gating, robust optimisation, rescanning, etc).
Considering this remaining issue, in the next sections the 4DDReco and the treatment
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Figure 5.9: Mean difference of the V95CTV between the static and the 4DDSim versus the median
vector field length inside the ITV. Red region corresponds to large motion and consequently high dose
degradation, while green are patients with a robust dose distribution against intra-fractional motion. The
yellow region corresponds to patients where the motion amplitude is small (<5 mm) but a reduction in the
V95CTV is demonstrate. A region without cases was found, grey area, which correspond to a no patients
with large motion and small V95CTV variations.
plan were evaluated.
5.3.2.3 Reconstructed Vs simulated dose distributions
The evaluation of the 4DDReco is shown also in the figure (5.7), by the green crosses,
overlaid with the static and 4DDSim results. From this graph, it is observed that the
4DDSim resulted in a good approximation of the robustness of the plan for some pa-
tients, while for other can be used as an indicator of the probability to get a dose reduc-
tion on the CTV, either by the mean or width of the boxplot.
Figure (5.10) shows the dose distribution for the patient H3 in the static, 4DDSim and
4DDReco situation, in which is observed similar conclusion obtained from the 4DDSim
and 4DDReco. Nevertheless, other patients (as H7 and H12) exhibit a 4DDReco sig-
nificantly outside the predicted set of 4DDSim.
In general, patients with minor internal motion tend to have more similar 4DDSim so-
lutions, i.e. a small interplay effect and therefore a small box width in figure (5.7).
However, the number of calculated simulations showed limited capability to describe
all the possible interplay patterns, as the ones detected during the 4DDReco. Despite,
the failure of the 4DDSim in the quantification of how much the dose is degraded, it is
able to detect if a plan is or is not robust, at least the order of the differences can be
understood as a probability indicator.
From the visual inspection of the dose distributions, as the example shown in figure
(5.10), it was observed that the static plans were highly modulated for many patients.
This was related with dose constraints to the OARs (mainly bowel), which result in
sharp dose gradient between the GTV and the bowel contour. Hence, other studied
conjecture was the influence of the plan modulation on the robustness to the breathing
motion. Therefore, the next section addresses this question.
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The dose distributions and DVHs for others patients are available in the appendix (A.2).
For the patients showing higher tumour motion amplitude, i.e. H1, H12 and H13, the
beam delivery using beam gating was additionally simulated using a standard gating
window of 50%Ex-50%In. These simulations showed a reduction of the interplay ef-
fect, as shown in table (5.7), with reduction of the standard deviation of the V95CTV
and HCTV for the set of simulations, however the residual motion still compromises the
dose distribution. Another factor to consider in this approach, is that beam gating will
introduce a correlation between the beam application and the breathing motion, thus
any residual motion will affect the dose distribution always in a similar way. Therefore,
dose fractionation will not attenuate the interplay effect, since the effect will be fairly the
same.
Figure 5.10: Dose distribution in the transversal CT view for the patient H3 in the static (a), one of the
simulated cases (b) and in the reconstructed fraction (c). In yellow, blue and white, the GTV, CTV and
ITV are displayed, respectively. The dose distribution was tailored in order to keep the bowel (in purple)
below the dosimetric constraints. In a) is shown the planning CT, while in b) and c) is the CT0Ex.
Table 5.7: Comparison of the plan quality parameters of the CTV ( homogeneity HCTV , V95CTV and
V107CTV ) relative to the static case, for the beam delivery under free-breathing and beam gating, for the
simulated 4D dose distributions (4DDSim). The mean and standard deviation values correspond to the
set of 5 simulations performed in each case.
Patient 4DDSim ∆HCTV (%) ∆V95CTV (%) ∆V107CTV (%)
H1 Free-Breathing 11.42.8 -5.7 3.6 21.34.1
Gating50%Ex 50%In 10.91.1 -2.60.7 21.52.5
H12 Free-Breathing 28.95.8 -11.7 7.3 11.18.8
Gating50%Ex 50%In 27.05.6 -12.04.8 9.53.5
H13 Free-Breathing 2.91.0 -14.7 2.1 0.6 0.7
Gating50%Ex 50%In 2.51.3 -13.2 1.6 0.90.4
5.3.2.4 Impact of dose modulation
The modulation index for all the patients of the dataset H was determined. In order to
understand the differences between the plans, the MI for the dataset B using the two
oblique beams were also calculated. Figure (5.11) compiles the result for all the plans.
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Figure 5.11: Beam-weighted Modulation Index per patient. The patients B1 to B7 correspond to the
patients from the section (5.2.1), whose plans where optimised using the TPS TRiP98. The set of patients
H1 to H15 had the treatment plan optimised using the TPS Syngo® RT and correspond to the clinically
applicable plans. To help in the visualisation, the red squares correspond to the plans whose MI were
superior to 10, and green squares to the ones below or equal to 10. This threshold was selected in order
to be superior to the maximum value of the dataset B.
As example of this MI variation patient H9 and H11 were selected because although
both patients exhibit the same amount of tumour motion (median VFL inside the ITV),
their 4D dose distribution varies significantly. In figure (5.12) the function of the modula-
tion F, in which the MI corresponds to the area below the curve, is represented for these
cases. In general, as in the example of the patient H11, it was observed, that the plans
optimised in Syngo® RT tend to have a stronger modulation at the tumour borders.
This effect is related with the proximity of OARs, otherwise the shape of the function
is similar to the one for the patient H9. Hence, the MI is commonly larger for Syngo®
RT, as compared to TRiP, as a result of the number of OARs used during the optimisa-
tion process, significantly smaller in TRiP. In general, Syngo® RT prioritises the OARs
constraints against the tumour irradiation, which result in the increase of the MI when
more constraints are defined. Moreover, and maybe the main source of differences, is
the optimisation method used by the two TPS. Syngo® RT uses a Broyden–Fletcher–
Goldfarb–Shanno (BFGS) algorithm to solve the optimization problem, which solution
does not have a regularization the number of particles between neighbour raster points.
Otherwise, TRiP uses a conjugate gradient method to obtain a smoother distribution of
particles in the target volume.
Figure (5.12) shows also the mean and standard deviation of the number of particles
per IES for the patients H9 and H11. From these two concepts no clear conclusion
is directly possible. To help in its interpretation, the overall results are summarised in
table (5.8), while the MI graphs for all the patients are shown in the appendix (A.6).
From these results it can be concluded that the value of IES is not as so represen-
tative of the plan heterogeneities as the MI. From the theoretical point, IES should be
higher for plans with major intensities differences between raster points. However, be-
cause this concept ignores the location of the raster points, it may not be representative
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Figure 5.12: Distribution along the IES of the modulation function, mean and standard deviation of the
number of particles (NP) for the beam 1 of patient H9 (a) and H11 (b).
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Table 5.8: Mean and standard deviation of the variation of the V95CTV and HCTV for the 4DDSim and
4DDReco and for the respective plans the calculated IES and MIweighted.
Patient ∆V954DDSIM+4DDReco (%) ∆H4DDSIM+4DDReco (%) IES MIweighted
H1 -8.13.0 11.7 3.7 2.7 7.6
H2 -2.32.2 12.72.6 3.6 9.9
H3 1.91.4 7.83.3 6.4 20.5
H4 -7.41.9 12.70.6 5.2 9.9
H5 -5.80.6 12.12.9 4.2 11.5
H6 -10.81.5 13.22.0 4.2 12.3
H7 -20.93.9 20.72.4 5.3 17.8
H8 2.91.8 16.31.8 3.9 4.1
H9 -3.12.2 8.13.1 4.3 8.8
H11 1.21.0 0.6 1.0 3.1 22.5
H12 -11.68.6 30.05.9 5.1 16.7
H13 -15.91.9 3.20.7 3.5 8.0
H14 -3.60.7 1.30.6 3.3 3.0
H15 -6.01.5 4.21.3 4.8 4.0
of the plan modulation.
An alternative method to verify this relationship between dose degradation under mo-
tion and plan modulation is through the visual inspection of the dose distribution per
radiation field. Another two cases are shown in figure (5.13), in which patient H12 with
high MI is compared with patient H13 with MI below 10. Although patients H12 and H13
were both planned with IMPT, the dose distribution is quite homogenous per field in
the case of H13, as depicted by the distal profile for each of the beams (5.13-a1,2). In
contrast, the plan of the patient H12 (5.13-b1,2) shows a higher dose for the beam 01,
with the beam 02 just adding dose to the regions not completely covered by beam 01.
The profile in beam direction for this beam 02 (5.13-b2) shows the high gradients inside
the target, which complements the dose to the lateral profile of the beam 01 (5.13-b1).
As consequence, the tumour motion will result easily in raster points mispositioned.
Although, for many patients the combination of the motion amplitude and the MI can
justify the dose degradation, there are some cases still to be explained. Considereing
patient H15 as an example (see fig.5.9 and 5.11), in which the reduction of the V95CTV
of more than 5% wasn’t expected, i.e. small motion and small MI should produce a
small ∆V95CTV . This can be a consequence of the sensitivity of the V95 parameter
that just measures a point on the DVH and not the overall change in the DVH shape.
If instead of looking for the V95CTV , the DmedianCTV is analysed, then patient H15 is
not significantly affected by the interplay effect since its DmedianCTV under motion is
(181.50.8) cGy (RBE). For other patients in which MI is high, as the case of H11 the
DmedianCTV was reduced to (177.50.8) cGy (RBE).
5.4 Summary and discussion
The results allow to conclude that the use of two oblique posterior beams can mitigate
the influence of intra-fractional motion and the interplay effect. Nevertheless, patients
with internal motion amplitude superior to 5 mm require precaution, and strategies to
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Figure 5.13: Transversal slice of the dose distribution and dose profiles for each beam of patient H12
and H13. a1-2) Example of patient H13 where a homogeneous dose distribution is delivered for both
beams as also visible by the dose profile in beam direction along the white solid line shown in the dose
distribution. b1-2) The case of patient H12 that has a total homogeneous dose distribution but which
resulted of the overlap of two heterogeneous dose distribution for each individual beam. The example of
the same dose profile for each of the beams shows that the beam 02 complements the dose distribution of
the beam 01.The mismatch of this overlay, as result of the breathing motion, lead to target under-dosage.
reduce impact in the irradiation should be considered.
Another aspect to be considered is the plan optimisation, where plans with stronger
modulation, as resulting from high dose gradients and inhomogeneous number of par-
ticles in neighbour raster positions, result in a plan with less robustness against range
and positioning uncertainties. Therefore, the inclusion of robustness into the optimi-
sation process is demanding and will allow to use the full potential of beam scanning
techniques without compromise the plan quality.
The introduced modulation index showed promising results to support the treatment
plan evaluation. Further implementation of it application to the clinical routine still need
to be performed, as well as, optimisation of thresholds and more accurate methods to
account for multiple beams.
Regarding the potential of 4D dose simulation in the prediction of the movement influ-
ence in the delivered plan, its main weakness is the surrogate signal used. In this study
was assumed a perfect correlation between breathing and organ motion, however, it
was shown by different authors (Brevet 2011; Torres 2011) a weak correlation in some
patients. Alternative methods to monitor the patient internal motion should be explored,
or strategies to assess the daily correlation with the existing external surrogate signal
should be investigated.
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Chapter 6
Outlook: Magnetic resonance imaging
for motion detection
6.1 Motivation
Pancreatic cancer patients are very susceptible to anatomical changes along the treat-
ment delivery, mainly as a result from the respiratory motion, which affects the dosimet-
ric plan quality. 4D dose reconstructions based on a 4DCT dataset allow to estimate the
impact of the organ motion and the originated interplay from a scanned beam delivery in
ion-beam radiotherapy. However, 4DCT is limited in the identification of baseline-shifts
and irregular patterns, as a consequence of its acquisition and reconstruction process,
as described in section (2.4.0.1).
One solution that has been rising in radiation therapy (RT) is the application of MR-
sequences with the capability to sort the images according to a trigger signal, namely
4DMRI. Additionally, pancreatic cancer treatment is strongly affected by the poor soft-
tissue contrast in CT-imaging; hence MRI would add excellent soft tissue contrast to
the target definition.
The application of MRI-data for ion-beam has the potential to be used in the motion de-
tection, including the feature of inter-variability of the intra-fractional motion, and there-
fore, in the motion sampling of the specific patient and in the definition of an individu-
alised robust plan against motion. Moreover, it might be used for real-time monitoring
of the internal patient motion - if an integrated solution is available - and for online adap-
tation strategies , such as beam gating or tracking.
The aim of this section is to assess the existing issues to the application of MRI imaging
for motion assessment and to quantify the impact of intra-fractional motion detected by
4DMRI.
In summary, this chapter intends to answer the following questions:
• Is it clinically feasible?
• What needs to be adapted in the clinical workflow?
• Will the workload increase?
• Which additional information can be obtained?
• Which is the clinical role of this new imaging modality in radiotherapy?
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6.1.1 Principles of magnetic resonance imaging
Unlike CT and PET, MRI does not use ionising radiation to obtain a body image. MRI
takes advantage of the high percentage of hydrogen atoms in the human body and
uses the magnetic properties of the protons.
While the patient is placed into a magnetic field its protons of the hydrogen atoms are
aligned to the magnetic field. When a radio frequency (RF) pulse is emitted from the
scanner the protons follow a precession to out of the alignment. Succeeding to the end
of the pulse, the protons will re-align with the magnetic field and the MRI signal dissi-
pates. The description of how the signal changes in time is named as relaxation.
The different MRI signals are resulting of the different densities and relaxation proper-
ties of the tissues. Two types of relaxation happen: spin-spin and spin-lattice, which
are respectively described by the relaxation times T1 and T2. In the process of T1
relaxation the protons longitudinal magnetisation recovers after the RF pulse. The T2
signal originates when the protons dephase, which results in decay of the transverse
magnetisation.
In brief, the spatial encoding of theMRI signal is accomplished through the use of super-
imposed magnetic fields, gradients, which perturb the main magnetic field, and cause
hydrogen protons in different locations to precess at slightly different rates.
6.1.2 MRI in radiotherapy treatment planning
MRI has been arising as a modality with a high potential for use in radiation therapy,
due to its high spatial resolution, ability to image with superior soft tissues contrast,
compared to CT, and the absence of additional radiation dose to the tissues.
However, the direct implementation of MRI in the RT workflow is subject to several dif-
ficulties. When MRI is used to help in the tumour delineation, rigid registration between
multi-modal image data is required and additional uncertainties need to be taken into
account. Further, if the treatment planning is only MRI-based no electron density is
available and therefore no dose calculation can be directly performed.
6.1.2.1 Artifacts and geometric distortions
In addition to the previously mentioned points, MRI images are highly susceptible to ar-
tifacts and geometric distortions. Image artifacts are caused by a variety of factors that
may be patient related such as physiologic motion, metallic implants or foreign bodies,
or due to the acquisition process, as finite sampling, FOV size, k-space encoding, RF
overflow and among others. These artifacts will then result in an MRI not representative
of the true patient anatomy.
Geometric distortions are caused by magnetic field inhomogeneities in the main field
and non-linearity of the gradients (Torfeh et al. 2016).
Some artifacts don’t affect the diagnostic quality of the MRI, however that doesn’t mean
that they won’t influence the RT planning process, since all the anatomy in the beam
path needs to be considered during the dose calculation process. Depending of the
application, i.e. target delineation or dose calculation, RT images are required to have
resolution in the order of 1-3 mm, constance of the pixel value and high contrast.
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6.1.2.2 MR in motion management
Besides the already pointed advantages of the use of MRI in RT, another encouraging
feature is the possibility to performmotion monitoring in larger acquisition intervals, with
more periodicity and without additional radiation to the patient.
Motion is usually included in RT through the use of 4DCT, however the many asso-
ciated limitations are well known. First, daily imaging is restricted as consequence of
the increase of the dose to the patient that results in an under-sampling of the possible
intra-fractional motion variations. Then, the measured anatomical motion is confined to
a 10 min acquisition in addition to the fact that the represented breathing cycle by the
4DCT corresponds to an average along the acquisition time.
For these reasons, 4D-MRI has been sought as an alternative or additional method for
the direct characterisation of the internal motion of the patient (Boye, Lomax, and Knopf
2013; Moteabbed, Schuemann, and Paganetti 2014).
The application of this technique is limited to some scanners, which may be the reason
for the lacking of a standard 4D-MRI technique for RT. One of the approaches is to
use fast MR sequences to continuously acquire images from all respiratory phases and
then retrospectively sort these images by respiratory phase. Consequently, the data
sorting requires some kind of surrogate signal, either external (e.g. MRI pressure belt)
or internal (e.g. using a navigator slice at a fixed position (Siebenthal et al. 2005).
This first attempt to perform 4DMRI for pancreatic patients, followed the approach de-
veloped by Rank et al. (2016) and is described in the following section.
4DMR acquisition sequence
The method proposed by Rank et al. (2016) is based on a 3D-encoded gradient echo
sequence with a radial stack-of-stars sampling, named Radial Vibe in the Siemens
scanners. In this approach the k-space center of the radial acquisition is used as nav-
igator in the estimation of the motion amplitude. During the reconstruction process
the radially acquired spokes (i.e. radial projections of the k-space) are transformed
onto a rectilinear grid. These sequences are strongly affected by streak artefacts that
arise from the under-sampling in each motion phase. Therefore, the reconstruction
method applied here performs a motion-compensation (MoCo), pre-processing of the
data based on the motion estimation, between each of the motion phases. This infor-
mation is obtained from the VFs calculated between phases. Additionally, a motion
estimation using a high-dimensional total variation algorithm (HDTV) is performed in
order to minimise the image artifacts.
In summary, the method MoCo-HDTV shows potential for the generation of a 4D time
resolved MRI with low streak artifacts and high image sharpness and will be subse-
quently applied in this testing phase.
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6.2 Material and methods
6.2.0.1 Patients and imaging
The patients H13, H14 and H15, discussed in the previous chapter (5.1), which had
a planning CT, 4DCT and respective structure set were additionally imaged with MRI.
The MRI acquisition was performed in the National Center for Tumor Diseases (NCT),
Heidelberg, which is adjacent to HIT, using the scanner Magneton Aera 1.5T, Siemens,
Erlangen, Germany. The patients were positioned, as in the planning CT and treatment,
in prone immobilisation with the hands raised above their head in a vacuum mattress.
No contrast agent was used and the patients where imaged under free-breathing.
In order to fix the vacuum mattress to the MRI couch a wood flat base with adjustable
plastic pins was developed at DKFZ (see figure 6.1). The RT isocentre, marked in the
mattress, was used to align the patient into the MRI scanner and to place the body coil
in the VOI.
The MRI’s sessions were scheduled along the treatment course. The total number of
Figure 6.1: Setup of the MRI acquisition for the pancreatic patients treated at HIT and imaged in the
National Center for Tumour Diseases (NCT). The apparatus consists of the patient specific vacuum
mattress indexed to a wood flat base that is attached to the MRI’s couch. The body coil is then placed
in the patient’s RT isocentre.
acquisitions per patient is shown in the table (6.1). Each session included a T2-gated or
breath-hold acquisition, a diffusion-weighted echo-planar, 2D cine in coronal and sagit-
tal planes to the tumour location and a T1-Radial Vibe sequence. This last method,
previously described in the section (6.1.2.2), was the only considered in the following
analysis.
The T1-Radial Vibe sequence was performed with a repetition time of 3.3 s, an echo
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time of 1.6 s, 2504 radial spokes, a FOV of 400x400 mm2, pixel spacing of 1.56 mm,
slice thickness of 4 mm and fat suppression active. The acquisition time was approxi-
mately 8 min for all the sessions.
Table 6.1: Description of the subset of patients used for the assessment of the 4DMRI functionality.
It includes the maximum median vector field length (median VFL) measured for these patients using
the 4DCT, the number of MRI sessions and which MRI reconstruction strategy was performed. The full
reconstruction uses the entire raw data, while the partial reconstruction is split in time the raw data and
reconstruct three sequential 4DMRI.
Reco.Strategy
Patient CT max. VFLCT (mm) MRI session Full Partial
H13 3 5.5 2x 3 3
H14 3 1.2 1x 3 3
H15 3 9.6 2x 3 3
6.2.0.2 Image reconstruction and processing
The available T1-Radial Vibe sequence in the Magneton Aera scanner doesn’t include
the sorting and reconstruction of the phase-based sequence, therefore for the recorded
raw data a post-reconstruction was performed.
The 4DMRI was reconstructed based on themethodMoCo-HDTV (see section 6.1.2.2),
developed by (Rank et al. 2016). The application of this algorithm in the context of this
work was performed by the working group E0401 and E0404 of the Department of Med-
ical Physics in Radiation Oncology (DKFZ).
This reconstruction algorithm has available different modes, which allow the definition
of the number of bins, overlapping width between bins, how the raw data is divided
in amplitude, definition of image filters, definition of the starting breathing phase and
others.
Considering the approach here investigated, the first phase was defined as end-exhale
(i.e. bin 0) and for the sharpest width of signal distribution as possible, for a overlap-
ping phase width between bins of 10% of the entire respiratory cycle and the sorting
considering the global maximum.
The self-gating signal is used for the 4DMRI reconstruction in two schemes:
• Full - the complete raw data (2504 spokes) is included in this reconstruction. The
sorting is performed through the self-gating signal of the entire acquisition in 20
overlapping motion phase bins. This scheme represents the averaged breathing
cycle in the acquisition time.
• Partial - the raw data is split in three approximately equal sets (800, 800 and 900
spokes), sequentially distributed along the acquisition time course. The data of
each of these sets is then phase-sorted and used for the reconstruction of 10
bins per breathing cycle. Therefore, for this method a total of 3 x 10 bins were
reconstructed.
The self-gating signal used for the data sorting in these two methods is exemplified for
patient H13 in the figure (6.2).
After the image reconstruction, the MRI data was processed in order to match with
the planning CT properties, such as the image data type, orientation and pixel spacing.
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Figure 6.2: Self-gating signal magnitude for each radial spoke of the first session of patient H13. The
dashed vertical lines correspond to the splitting of the signal into three dataset for partial reconstruction.
This step has to be done for the DIR process implemented in Plastimatch. The data
processing steps are described in the flowchart of figure (6.3).
Additionally, a first approach to correct the geometric distortion correction was per-
formed for the patients H13 and H14. This process is based on the DIR between the
original Siemens corrected image (not sorted in bins) and an average of all the recon-
structed bins. From this DIR is then obtained a corrected vector field that is applied to
each individual bin. This correction was performed using the software Plastimatch with
a set of B-Spline functions and as cost function the gradient magnitude (see section 3.2
for details). The images with correction of the geometric distortion (GD) will be called
”GD-corrected” and the other ”sorted raw”.
6.2.0.3 Deformable image registration
The previously described pre-processing of the MRI and CT data (cf. figure 6.3) was
performed for all the patients and imaging sessions.
The method tested in this work to generate a 4DCT based on the 4DMRI was based
in DIR between images. The goal is to evaluate the feasibility of this approach and
associated issues.
The DIR was executed between each of the MRI-bins and the reference bin, i.e., bin 0,
and between each of the MRI-bins and the planning CT. Both DIRs were performed us-
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Figure 6.3: Flowchart of the processing steps performed to the MRI data. The planning-CT, 4DCT and
4D-MRI were convert to match in their pixel spacing and orientation. In order to simplify the deformable
registration process, the images were firstly registered using rigid registration based on bone anatomy
and cropped to removed background artefacts of the MRI.
ing the software Plastimatch (presented in the chapter 3.2). Different procedures were
adopted for each case and, therefore, are individually described below.
The DIR quality was evaluated using the SlicerRT module (cf. section 3.3.1) through
the parameters: determinant of the Jacobian matrix (JD), inverse consistency error
(ICE) and absolute difference between the reference and transformed image. These
parameters were calculated for the full image, for a VOI including the beam path and
for a VOI restricted to the ITV volume. These VOIs are exemplified in the figure (6.4).
Figure 6.4: VOIs used for the evaluation of the DIR quality. The yellow box corresponds to the VOI
restricted to the ITV volume, the red box includes the ITV and the beam path, i.e. posterior oblique right
and left field. The evaluation for the full image was also performed, named as ”Body”.
a) Image registration: MRIbin ref -MRIbin i
The aim of this registration is to provide the vector fields that describe the anatomy
motion along the different bins relative to the reference one. These transformations will
be one of the essential pieces of the 4DDSim. Further, this data will be also used to
characterise the tumour motion as will be explained in the section (6.2.0.4.)
By virtue of being images from the same modality of imaging, the DIR was performed
using a sequence of two registration stages, both for a B-Spline function with a regu-
larisation (or smoothness) factor of 0.005 and using as cost function metric the mean
squared error (MSE).
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The bin 0 was defined as reference bin and set as fixed image, the others bins were
defined as moving images. Due to the configuration defined during the image recon-
structions, the bin 0 corresponds to the end-exhalation breathing phase.
b) Image registration: MRIbin i - CT
Because the DIR is a much more complex procedure, which is as consequence of
the multi-modality images, an iterative process was performed to determine a better
strategy to register CT to MRI. As first approach, the multi-modality registration was
performed with the aim to obtain a CTMRI , i.e, the planning-CT deformed to match with
the MRI’s anatomy in each of the bins, and to propagate the contours from the planning-
CT to the MRI dataset. Alternative methods, as DIR CT to MRIbin 0 and subsequent
registration between MRI-bins will be scope of a further investigation.
Several problems were faced during the DIR, such as the influence of the MRI’s ar-
tifacts in the registration process and the different origins of the CT and MRI-cubes.
The latter, due to the requirement of the initial stage of the DIR of a minimum overlap
between the two images. This alignment was performed through the rigid registration
of the bony anatomy and the resulting images were used as input to the DIR.
With respect to the image artifacts, background noise and B1 field inhomogeneity, the
MRIs were cropped to the 4DCT size in order to exclude them from the DIR. Addition-
ally, this process will permit the propagation of the structures set between the images,
which requires the same image size.
Different deformable registration attempts, using different parameters, algorithms and
metrics were performed. The better DIR result was obtained using mutual information
as similarity metric, a sequence of two stages of a B-Spline function, a histogram equal-
isation in 400 levels and a very small regularisation factor 0.5E 5.
The DIR was performed for each of the bins as fixed-image and the planning CT as
moving image. Thus, the obtained warped (i.e. transformed) image corresponds to the
CTMRI for each of the bins.
Some of the bins from the obtained 4DCTMRI were co-registered to crosscheck if the
motion information from the 4DMRI was kept. The reference bin was considered the
bin 0, CTMRI 0. This registration was performed using the procedure described in the
previous section.
Additionally, the inverse registration, planning-CT as fixed-image andMRIbin0 asmoving-
image, was calculated to allow the propagation of the contours from the planning-CT
to the referenceMRI bin (see section 3.1.2 for details about the transformation process).
6.2.0.4 Motion characterisation
The extracted vector fields from the registration MRIbin ref -MRIbin i were used to quan-
tify the median motion inside the ITV for each of the sessions (full and partial recon-
structed). The used ITV corresponds to the propagated VOI from the planning-CT to
the MRIbin ref .
The obtained results were compared with the 4DCT vector field length.
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6.2.0.5 Generation of 4DCTMRI
As previously described, the fact that no information regarding the electron density in
the MRI is available, this is solved through the use of multimodal DIR between each
of the MRI bins and the planning CT. However, this 4DCTMRI was obtained from the
phase sorting of the k-space centre that doesn’t correspond directly to the breathing
motion. As compared to the 4DCT acquisition protocol, in which an external surrogate
(e.g. pressure belt) is used, in this 4DMRI acquisition any breathing signal is measured.
The phase information is required when giving the 4DCTMRI as input to TRiP4D, in or-
der to organise the CTsMRI bins within the breathing cycle (0%Ex to 0%In).
The strategy adopted to overcome this issue was to use the cranio-caudal motion of
the liver as surrogate signal. Hence, the vector fields obtained from the DIR MRIbin ref -
MRIbin i were evaluated inside the liver for the z-component. The bin 0 was defined
as 0%Ex and the corresponding bin to the maximum median length of the vector was
defined as 100%Ex. All the others bins, were linearly normalised to this range consid-
ering their median vector length in z.
6.2.0.6 Plan optimisation
In order to discard inaccuracies arising from the CTMRI creation and propagation of
structures, new treatment plans using the TPS TRiP98 were optimised for the CTMRI 0,
i.e. 0%Ex state and respective transformed contours. The optimisation was performed
using the same particle, prescription dose and beam geometry of the original Syngo
plans. The settled goal was to cover the PTV with the prescription dose while keeping
the OARs constraints.
In order to obtain comparable results, using the same OARs constraints a new plan
was also optimised in TRiP98 for the 4DCT0%Ex.
These new optimisations were only performed for the sorted raw images, while for the
GD-corrected images the original Syngo optimised plan was used.
6.2.0.7 Time resolved dose calculation
4D dose calculations were performed using the TPS TRiP4D for the respective pa-
tient’s surrogate-breathing signal acquired with Anzai during the immobilisation day, in
an analogue process to the 4DDSim described in the section (5.2.2).
The irradiation temporal patterns were generated using the same procedure of the
chapter (5.2.2) but for this plan CTMRI 0-optimised and also considering five differ-
ent interplays as result from a successive temporal shift of the starting phase of 500ms.
The reference image was defined as the CTMRI 0 and considered a relative amplitude
sorting of the bins (see chapter 3.1.2 for details).
For all the patients, using the CTMRI raw images, the 4DDSims based of the 4DCT and
4DCTMRI were performed using the TRiP-optimised plan and compared with the static
case. Additionally for patient H13 and H15, 4DDSims using the original Syngo® RT
treatment plan and the CTMRI GD-corrected were performed.
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6.3 Results
6.3.1 Deformable image registration: MRIbin ref - MRIbin i
The summary of the evaluation of the DIR MRIbin ref -MRIbin i is shown in the table
(6.2).
The obtained transformed image and vector fields showed satisfactory results, i.e. JD
close of 1, small ICE and absolute differences. Therefore the corresponding vector
fields were used for the 4DDSim calculations.
Table 6.2: Deformable image registration evaluation for the fixed bin 0 and the moving bin 10. The quan-
titative parameters were the determinant of the Jacobian matrix (JD), inverse consistency error (ICE),
absolute difference between the reference image (bin 0) and the transformed image. The presented
values correspond to the mean and standard deviation.
MRI0-MRI10 H13 H14 H15
Parameter VOI Session 1 Session 2 Session 1 Session 1 Session 2
JD Body 1.00.1 1.00.1 1.00.0 1.00.1 1.00.1
Beam Path 1.00.1 1.00.1 1.00.0 1.01.0 1.00.1
ITV 1.00.1 1.00.0 1.00.0 1.00.0 1.00.0
ICE (mm) Body 0.30.6 0.40.7 0.20.3 0.40.6 0.71.1
Beam Path 0.20.2 0.20.2 0.10.1 0.10.1 1.00.2
ITV 0.10.1 0.10.1 0.10.1 0.10.1 0.10.1
Abs.Diff (voxel value) Body 6.014.6 6.515.6 1.85.2 2.97.5 4.510.1
Beam Path 18.618.1 17.517.4 4.05.1 10.29.7 12.111.7
ITV 11.712.0 12.611.8 2.42.4 7.66.9 9.610.1
6.3.1.1 Motion evaluation
For the set of vector fields, the median vector length inside the propagated-ITV to the
reference bin, ITVbin0, was evaluated. Figures 6.5, (6.6) and (6.7) show the results of
the three patients in each of the imaging sessions and reconstruction method (full and
partial) comparatively to the 4DCT analysis. In all the cases the phase sorting was
based on the z-component of the median vector field length inside the liver.
Relatively to each of the vector components, the cranio-caudal direction showed to
correspond to the main motion direction, with the anterior-posterior direction showing
amplitude below 1 mm and the lateral direction neglected. The details for each imaging
session are available in the appendix, figures (A.14) to (A.16) .
The case of patient H13 is an interesting example that justifies the need to include
the irregular behaviour of the breathing amplitude when performing 4DDSim. In this
case, the average breathing along the 8 min of the 4DMRI for both sessions fairly
matches with the information of the 4DCT, however, the partial MRI data shows a varia-
tion of its breathing amplitude along the acquisition. This result is also confirmed when
looking for its radial spokes magnitude of one of the sessions, shown in the figure (6.2).
Nevertheless, the fact that the partial data shows smaller amplitude compared with the
full reconstruction is not yet clear. This might be related with the reconstruction method
or with lost of motion information when less spokes per bin are used. This issue will be
investigated in a future study, through the adjustment of the reconstruction parameters
and improvement of the DIR quality.
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Figure 6.5: Median vector field length inside the ITV per breathing phase for patient H13 for the 4DCT,
4DMRI sessions 1 and 2 using the full or partial raw data for the image reconstruction.
Figure 6.6: Median vector field length inside the ITV per breathing phase for the patient H14 for the
4DCT, 4DMRI session 1 using the full or partial raw data for the image reconstruction.
Another meaningful example is the patient H15, figure (6.7), in which the detected mo-
tion amplitude of the 4DMRI in the session 1 was twice larger than the 4DCT. Also the
patient H14 showed an irregular behaviour, with a mean difference of 1.5 mm between
4DCT and 4DMRI sessions. For this patient, it was also detected that for the third part
of the acquisition time (fig.6.6), although the liver showed a z-component of motion, the
pancreas itself showed reduced motion. This aspect justifies the need of an internal
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Figure 6.7: Median vector field length inside the ITV per breathing phase for patient H15 for the 4DCT,
4DMRI sessions 1 and 2 using the full or partial raw data for the image reconstruction.
motion detection for pancreatic patients.
In conclusion from the analysis of these three patients, it is suggested that the breath-
ing induced tumour motion is susceptible to daily variability. However, this investigation
should be enlarged to include more patients and more imaging sessions per patient.
6.3.2 Deformable image registration: MRIbin i- CT
As result of the deformable image registration the transformed CT, the so-called CTMRI ,
was evaluated by visual inspection, as shown in the example of the figure (6.8). The
consistency of the vector field was also quantified by the JD and ICE and is shown in
the table (6.3).
Table 6.3: Evaluation of the multi-modality DIR quality in terms of the determinant of the Jacobian matrix
(JD) and the Inverse consistency error (ICE) for the bin 10 in the full reconstruction.
CTMRI 10-MRI10 H13 H14 H15
Parameter VOI Session 1 Session 2 Session 1 Session 1 Session 2
JD Body 1.10.2 1.00.1 1.00.2 1.10.2 1.10.2
Beam Path 0.90.1 0.80.1 0.50.1 0.80.1 0.80.1
ITV 1.00.2 0.80.2 0.60.2 0.90.2 0.80.1
ICE (mm) Body 11.87.2 21.610.7 32.222.8 14.39.6 11.77.9
Beam Path 10.33.6 12.33.8 27.99.8 15.75.7 14.33.8
ITV 10.44.1 14.04.1 38.714.1 12.57.0 12.45.3
From these results, the judgement about the quality of the registration is straight-
forward, since JD and ICE showed higher values. The ICE value that for this case is
in average 18.3 mm, for the body VOI, compared to the CT-CT DIR of 0.4mm, which
deserves special attention. This high value implies that the correspondence mapping
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Figure 6.8: Visual inspection of the DIR MRI-CT for the example of the patient H13, 1st session for
the bin 10. Upper images show the false colour comparison between the original MRI-bin10 and the
transformed planning-CT, i.e. CTMRI 10. From this overlay some mismatch between the two images
(i.e. blue or pink colour) is detected, which is however small in the central body region. Structures of
the original planning-CT and CTMRI 10 are also superimposed. Kidneys and liver are represented by
the light colours for the original VOI and by the dark colours for the propagated to the bin 10. ITVbin10 is
represented in white and CTVbin10 in dark blue.
between the pair of images is not consistently pointwise, hence the inverse vector field
won’t result in the same initial image. This effect can be a consequence from the reg-
istration algorithm used which wasn’t able to match the patient’s surface between the
two images and a small regularisation parameter was used.
Another method to evaluate the registration quality is through the overlay of the trans-
formed structures into the transformed image. This because the structures are trans-
formed through the inverse field while the CTsMRI are generated by the forward vector
field. From this analysis the same conclusions were obtained, i.e. a good agreement
in the pancreas volume and larger differences were noticed in the periphery of the pa-
tient’s body.
6.3.2.1 Propagation of contours
Another method to access the quality of the registration is through the evaluation of the
location of the propagated contours.
For all the MRI-sessions the contours of the planning-CT were transformed by the re-
spective vector field to the MRIbin 0. One example is shown in the figure (6.8) in which
the original contours of the OARs (light colours) are superimposed to the transformed
OARs.
For some sessions the agreement with the OARs contours with the OARs visible in
the CTMRI was acceptable, as the shown example, while for others the reduced con-
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sistency of the inverse field in the periphery of the patient’s body result in a lack of a
disagreement between the contour and the anatomy.
6.3.2.2 Generation of 4DCTMRI
By visual inspection of figure (6.8) the agreement between the MRI and the CTMRI is
acceptable in the VOI region. However, when comparing the CTMRI with the original
planning CT, as shown in the figure (6.9), a deformation in the patient surface is ob-
served.
This effect is a result of the geometric difference observed in the MRI, particularly larger
for the most distant voxels from the centre of the image, and anatomical differences be-
tween the MR and CT sessions. The obtained CTMRI transported these effects, how-
ever, this effect shouldn’t affect the results since the plan was optimised to the CTMRI
image and respective structure set. Namely, since all the images are deformed in the
samemanner, the geometrical relationship is kept and the optimised dose to the CTMRI
can be used for 4DDSim.
The extractedmotion vector between each CTMRI i, for the bin i, and the CTMRI 0 com-
pared to the vector MRIbin0-MRIbin i showed to conserve the major component of the
motion. From the evaluation of a subset of 4 bins (3,7,12,17) the average differences
between the median vector fields length were of (-1.71.1) mm, with the magnitude of
the vector field MRIbin0-MRIbin i always smaller and showing larger deviations for the
registrations with higher ICE value.
Figure 6.9: Overlay of the planning CT with the CTMRI 10 for patient H13 in which the differences in
the patient’s external surface are visible, for the case of the raw images. Using the geometric distortion
correction the differences are minor.
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6.3.3 Dose calculation
The results of the 4DDSim for each imaging session is shown in the figure 6.11. All the
plans that gave origin to these results were optimised using the same constraints and
using TRiP and showed an MI of 1.71.3, with the highest value for the patient H14
(MI of 3.2) and with minor differences among the different plans of the same patient.
Unexpectedly the patient H14, which shows a small motion amplitude, demonstrated
Figure 6.10: CTV Dose Volume Histogram of the patient H14 in the static case (red line) and in the set
of 4D dose simulations (blue band).
∆V95% superior to 5%, however when evaluating the HCTV , as in the figure 6.11-b, or
the median dose (3.90.05 Gy (RBE)/fx) no significant differences were found. An in-
terpretation of these results is suggested when the DVHCTV for the static and 4DDSim
dose distributions are compared (figure 6.10). In order to spare the OARs, the CTV is
not completely covered by the prescription dose and the DVHCTV got a broad shoulder
in the V95 region, resulting in a strong difference, that is not significant in terms of plan
quality.
Relative to the patient H13, which shows the same breathing amplitude for the 3 ses-
sions (CT, MRI-1,MRI-2), no strong differences were detected. Patient H15 showed
consistent 4DDSim results using the 4DCT data with this new optimisation and the op-
timised by Syngo-RT. Relative to the 4DDSim using the 4DCTMRI minor deviations in
the V95CTV were found as consequence of the small target motion (below 5 mm).
Regarding the dose calculation using the original Syngo® RT plan, the results are sum-
marised in figures (6.12) and (6.13). For both patients, H13 and H15, differences in the
target coverage between imaging sessions are shown, pointing again for the need of
more imaging data to accurately assess the impact of intra-fractional motion in pancre-
atic patients.
Figure (6.14) shows the dose distribution for the patient H13 using the GD-corrected
CTMRI in the static and 4DDSim situation. Differences between the static dose dis-
tribution in the CT and CTMRI result from changes in the patient ’s anatomy between
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Figure 6.11: Changes of V95CTV and homogeneity of the CTV relative to the static case for the patients
imaged with 4D-MRI and 4DCT as result of a set of five 4D dose simulations with different breathing
starting phases.
sessions and therefore related with inter-fractional changes.
The differences between these 4DDSim and the previous cases (CTMRI optimised) are
the result from the different delivered plans and from the anatomy changes in the beam
entrance as result of the geometric correction. However, the same order of differences
were detected for the some cases (e.g. patient H13 session 1 and patient H15 session
2). Further investigations still need to be conducted, with the aim to understand the
main reason for the differences, how the 4DDSim changes with the MRI reconstruction
parameters, and which is the impact of the surrogate signal in the calculation.
Figure 6.12: Variation of the plan evaluation parameters between the static and the 4DDSim situation
for patient H13 using the GD-corrected MRI data of the sessions 1 (blue boxes) and 2 (red boxes).
CTV maximum, minimum and median dose are in Gy (RBE) and the homogeneity, V95 and V107 in
percentage of differences.
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Figure 6.13: Variation of the plan evaluation parameters between the static and the 4DDSim situation
for patient H15 using the GD-corrected MRI data of the sessions 1 (blue boxes) and 2 (red boxes).
CTV maximum, minimum and median dose are in Gy (RBE) and the homogeneity, V95 and V107 in
percentage of differences.
Figure 6.14: Transversal view of the dose distribution for patient H13 in the CT and CTMRI 0 static case
and in one of the 4DDSim scenarios. GTV, CTV,ITV and PTV are represented in yellow, dark blue, white
and red, respectively.
6.4 Summary and discussion
Many approximations were performed in this first approach to the use of MRI for the pur-
pose of 4D dose calculations. However, it becomes clearer which are the main issues
to be aware of and which alternative approaches might be worthwhile investigating.
Starting from the reconstruction of the 4D-MRI, the used method MoCo-HDTV showed
significant improvement of the image quality in terms of reduction of artifacts. An im-
portant advantage of this reconstruction method is the definition of a large bin number,
without significant reduction of the image quality and the option to split the raw data
in intervals. This last point is of major importance to monitor baseline shifts and intra-
fractional variations. It also offers more options of sorting modes that would improve
quality of motion data and might open a new era to explore detailed motion sampling.
However, this algorithm is still slow and the results are not available directly after the
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imaging session, at the current stage.
Concerning the generation of the 4DCTMRI , another method to evaluate is to reduce
the number of multi-modality registrations, by just transforming the planning-CT to the
MRI-bin 0 and then creating a set of 4DCTMRI transforming this CTMRI 0 to each of
the bins using the MRI-MRI registration vector fields. This method might reduce the
uncertainties from consecutive multi-modality registrations, as the detected geometric
differences of the MRI compared to the CT.
The use of an external surrogate signal, as a pressure sensor, is an alternative to test
and evaluate differences in the dose distribution when using different breathing signals.
Also the influence of the artifacts in the MRI needs to be well defined, mainly the ge-
ometric distortion and susceptibility effects, that might cause position errors of several
millimeters. The reduction of these effects, will later allow the direct forward calculation
of the dose in the 4DCTMRI , that is the main scope of this technique. Therefore, the
variability of the intra-fractional motion, that can be obtained from the partial data re-
constructions, can be included in the 4DDSim calculations. This will result in a 4DDSim
based on multiple breathing cycles instead of an average cycle (current procedure).
In conclusion, the clinical implementation of 4D-MRI as a tool to determine uncertainties
in the dose delivered to the tumour is a feasible approach. To include it in the clinical
workflow, minor changes need to be done, since the same patient’s positioning is pos-
sible, the scanner location is close to the therapy rooms and the acquisition of a time
resolved MRI is achievable in a session of 30 min (including positioning). The image
processing and reconstruction need to be automatised and the major challenge still re-
sides in a deformable image registration for inter-modality matches, with less artifacts
and higher accuracy.
This technique will furthermore allow to include the follow-up MRI of the patient and
an adaption of the target contour along the treatment, without additional image dose to
the patient. The data can be also used to improve the treatment robustness through
the sampling of the probable range uncertainties and further inclusion in the treatment
planning process.
Additionally, this can be used as a method to categorise the patient in terms of breath-
ing pattern robustness. The evaluation of the consistency of the correlation between
breathing signal and the pancreas internal motion, the variability of the breathing ampli-
tude and frequency will help in the definition of the patients requiring more monitoring
and mitigation strategies during the irradiation.
Chapter 7
Discussion and conclusion
The Heidelberg Ion-Beam Therapy Center (HIT) started in 2011 to treat moving targets,
in particular hepatocellular carcinomas. Nevertheless, the clinical implementation to
treat pancreatic patients isn’t a straightforward procedure, since the different tumour
location and the distinct anatomical variations along the treatment course will compro-
mise the planned treatment differently. Therefore, a pre-implementation phase was
conducted between 2013 and 2014, in which both inter- and intra-fractional aspects
that might affect the plan quality were evaluated.
Since 2014 twenty pancreatic patients using the scanned beam system at HIT were
irradiated. In the course of this thesis, the delivered dose for those that have follow-up
data was assessed. These results were analysed in a way to get conclusions that might
lead to an improvement of the treatment for future patients.
Inter-fractional variability
The challenging anatomical location of the pancreas, surrounded by hollow organs
(bowel and stomach) makes its irradiation highly sensitive to inter-fractional variation.
By using daily cone-beam imaging and fiducial markers Horst et al. (2013) detected
mean variations of the pancreas center-of-mass (COM) along the treatment of (9.44.8)
mm. Additionally, the authors stated that based on the intra-fiducial markers distance a
small deformation of the organ was observed. This disagrees with the measured COM
variation quantified in this thesis using contours delineated by physicians (1.81.3) mm.
This contrasting finding is related with the used method to quantify the inter-fractional
tumour motion. The lack of contrast in the weekly CT imaging reduces the physicians
ability to detect the tumour margins accurately, a fact that is not present when fiducial
markers are used for motion assessment. Jayachandran et al. (2010) looked for this
issue and quantified that the mean shift to apply to the patient based just on bony land-
marks or on additional fiducial markers differs in a mean vector length of 5.5 mm.
While in photon therapy these changes of the tumour and surrounding organs in the
beam path can be overcome with the use of margins, with minor changes in the target
coverage, Liu et al. (2012a) obtained a V100%CTV of (97.8 3.7)% along the treatment
using a simple 3 mm expansion of the CTV. In contrast to that, the irradiation with
charged particles is vastly affected by changes in tissues densities in the beam path
(Lomax 2008b). Even with a 5 mm geometric margin applied to the CTV, its cover-
age (V95%CTV ) might decrease by up to 30% depending of the used beam’s configura-
tion. The analysis for the different beam’s incidences and margins showed improve-
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ment in the target coverage for the combination of a geometric ITV margin of 3 mm
and two oblique beams coming from the patient’s posterior direction, i.e. V95%CTV of
(99.51.2)%. The statement regarding the required CTV-margin was confirmed by the
calculation of theWEPL variations per beam direction for this set of patients. The calcu-
lation of the ITVWEPL, including the full weekly-CT data, revealed that a symmetrically
CTV-expansion of approximately 2.5 mm is sufficient to conserve the V95%CTV for 75%
of the fractions when two posterior oblique beams are used. In case that a different
beam angle is selected, the ITVWEPL calculation suggested the need of an asymmetric
expansion in depth, in average larger in the proximal direction. For all the beam angles
symmetric margins in lateral and cranio-caudal direction can be kept.
In relation to the obtained results, Park et al. (2012) already discussed the design of
beam-specific PTV in terms of distal and proximal margins, considering the radiological
path length variations. The author stated that for a homogeneous medium the beam-
specific PTV will be close to the conventional PTV, which was confirmed using the
method presented on this thesis that considered the specific WEPL variation along the
treatment course of each patient per beam direction. This approach was performed per
beam and the optimisation method (SFO or IMPT) wasn’t considered. This is especially
meaningful when IMPT is performed and the dose delivered by each beam might be
inhomogeneous. However, considering the ITVWEPL per beam and the results from
chapter (4.1) that multi-beams tend to be more robust against inter-fractional changes,
the resulting ITVWEPL will be smaller. Moreover, this is a population-based approach
in contrast to an individualised patient assessment, which would be only possible from
multiple imaging sessions.
An alternative to this population-based method is to perform a weekly adaption of the
ITV along the treatment though inclusion of the updated imaging information (either CT
or MRI).
Hence, the patients started being treated at HIT using usually two oblique posterior
beams, an ITV margin to include intra-fractional motion, and a margin to account with
set-up errors and range uncertainties of 5-7 mm. The evaluation of eleven patients
showed similar results, with a mean V95%CTV of (2.02.9)% with 77% of the fractions
showing a V95%PTV reduction below 3%. As expected, the bowel, located distally to the
beam entrance, was the main normal organ at a risk of injury from the result of the pencil
beams over-shooting due to the density changes in the beam path. Already Kumagai
et al. (2009) has already pointed towards the vulnerability of the gastrointestinal tract
to density changes and a consequent decrease of the target coverage and increase of
the intestine doses.
Of particular interest for the analysis of this dataset was the detection of seven fractions
showing a V95%CTV superior to 3%. This justifies the need of routine monitoring of the
patient anatomy, even when a statistically robust beam configuration is applied, but no
robust optimisation is performed. Therefore, a method to define an adaptation point
was delineated based on the measurement of the water-equivalent path length varia-
tion (∆WEPL) between successive CTs. Also Matney et al. (2016) evaluated a similar
method but in the context of the respiratory motion in proton therapy for lung patients, in
which the ∆WEPL was used to guide the selection of the beam angles in the reduction
of intra-fractional changes.
In the concept defined here the accumulated WEPL variations (∆accWEPL) in BEV
were quantified through the percentage of voxels with absolute differences superior to
3 mm(PVin). This simplified approach showed to be sensitive to anatomical variations,
which are then translated into changes in the dose distribution. These changes might
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result in the tumour over- or under-shooting as well unwanted dose to the OARs. The
correlation between the ∆accWEPL, the V95% and the gamma criterion (as metric of the
three-dimensional dose distribution variations) was shown to be affected by the num-
ber of beams and optimization technique. The clinical evaluation of this procedure to
the patients treated at HIT, showed similar results to the previous analysis performed
for an independent dataset and using single beam’s incidence. In conclusion, a list of
tolerance and action levels was suggested when evaluating the accWEPL differences,
in terms of PVin values, to support in the decision of the re-planning or continue the
treatment with the original plan.
Right now this method just intends to decide when a plan should be re-optimized. How-
ever, it has potential to be extended to a plan of the day strategy, since it can guide
the selection of the most suitable daily beam geometry from a pre-calculated library of
plans.
Not many methods are found in the literature to perform plan adaption in ion therapy,
which is a consequence of the complexity of the process. As possible techniques, Chen
et al. (2015) suggested the creation of an offline library based on different planning-CTs,
Kurz et al. (2016) investigated the use of in-room CBCT to perform a new plan optimiza-
tion, whileWang et al. (2016) looked for the application of proton radiography to quantify
anatomical changes.
Intra-fractional motion impact
Additional to the variability of the patient anatomy between treatment sessions, during
the treatment itself the tumour is subject to motion induced by the breathing and peri-
staltic movements of the stomach and bowel. The breathing motion is considered the
main source of movement and consequently the surrogate signal at HIT uses this for
monitoring.
In terms of motion quantification, for the two sets of patients no significant differences
were found, despite the different positioning, with the patients in supine showing CTV
changes along the 4DCT of (4.12.7) mm in superior-inferior (SI) direction and the set
of prone patients with (4.82.7) mm. Solla et al. (2013) used also the 4DCT but with
fiducial markers for the motion assessment, which resulted in a larger motion ampli-
tude of 8.5 4.2 in SI. This result is again justified by the poor soft tissue contrast of the
4DCT. Tai et al. (2013) measured the pancreas motion by just relaying on the 4DCT
data and obtained (5.9  2.8) mm in SI, i.e. closest from the one measured for this
thesis dataset.
The quality of the dose distribution using scanned delivery is pointed out as an advan-
tage in the sparing of OARs compared to the passive delivery (Shiomi et al. 2016).
However, the appearance of the interplay can decrease this beneficial impact (Bert,
Grözinger, and Rietzel 2008).
A first estimation of the interplay impact in pancreatic irradiation was performed, based
on a set of patients previously irradiated with photons (dataset B), no strong impact
was detected if the dose is delivered through the use of posterior beams to the patient.
Later, for the patients irradiated at HIT (dataset H) the 4D dose distributions were simu-
lated and reconstructed. From this second analysis six out of fourteen patients showed
at least one fraction with V95%CTV differences, relative to the static case, superior to
10%. On the other hand, the dose heterogeneity increased from an HCTV of 15.97.5
to 27.88.5. These contrasting results might be associated with different factors as: (1)
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larger number of patients included in the dataset H; (2) superior number of patients ex-
hibiting a CTV motion length larger than 5 mm; (3) dose distribution in the original plan
already compromises the target irradiation due to the OARs constraints and therefore
the V95% corresponds to a more steep DVH region; (3) optimisation strategy adopted
by the clinical TPS different of the one from the research-TPS, used in the dataset B.
With respect to the optimisation strategy, the plans were evaluated in terms of dose
modulation with the aim to correlate it with the dose degradation under motion. Lomax
(2008a) suggested that IMPT has a potential for delivery with larger range and patient
setup uncertainties compared to the SFUD, a consequence from the three-dimensional
variation of the beam fluence. Moreover, the TPSs can reach different solutions that
might lead to similar dose distributions and otherwise. Therefore, this impact would be
larger or smaller depending on the optimiser strategy and the defined constraints.
This justified the reduction of the plan robustness to the intra-fractional motion in the
dataset H comparative to the dataset B, which resulted from different TPS optimisations
and different number of constraints. In the optimisation of the plans of the dataset B,
just four constraints were used and defined in terms of maximum dose to the OARs,
while for the dataset H the plans included, in general, a complete IMPT optimisation
using a larger set of OARs constraints, either maximum and dose-volume constraints.
Additionally, Syngo® RT and TRiP98 use different optimisation algorithms and, there-
fore, the obtained dose distributions from the two optimisers are different in terms of
modulation.
Webb (2003) suggested, in the context of IMRT, that the modulation of a plan should
be quantified, in order to understand how the TPS reached the solution, i.e. how the
inverse optimisation is performed to get the final dose distribution.
In this thesis a Modulation Index (MI) adapted to particle therapy was used and showed
a significant difference between the set B and H, with the plans from the set B, TRiP98
optimised, being more uniform compared to the Syngo® RT optimised, set H. More-
over, patients exhibiting higher MI and larger motion showed to be more susceptible to
stronger interplay effects. Nevertheless, this parameter is not directly correlated with
the delivered dose distribution, since this is dependent of other factors as breathing
frequency and amplitude, intensity of the raster points miss-irradiated and change of
patient anatomy. This MI just offers an additional information in order to quantify the
probability of dose degradation as consequence of the interference between the beam
and the patient’s breathing and promises to help in the decision between similar dose
distributions.
Additionally in order to mitigate the impact of the intra-fractional motion, strategies to
improve the plan robustness must be added in the plan optimisation process. The main
approachs under study are the worst-case robust optimisation (Liu et al. 2012b) or the
probabilistic methods (Unkelbach et al. 2009).
Another aspect that is missing in this intra-fractional evaluation is the inclusion of vari-
ability in the patient internal motion, since no additional 4DCT is used.
Additionally, due to the used external surrogate signal no baseline drifting and ampli-
tude changes of the tumour were included. Sharp et al. (2007b) found that phase delays
between the internal and external motion and baseline drifting for liver patients with ex-
ternal surrogates would compromise the gated beam delivery. Hence, these aspects
need to be quantified and considered in a further analysis.
In conclusion, the intra-fractional motion has the potential to compromise the dose dis-
tribution for some patients. Special attention to patients with large tumourmotion should
be taken and strategies to reduce its impact must be considered. Beam gating (Mori et
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al. 2010) or rescanning (Bernatowicz, Lomax, and Knopf 2013) are the techniques with
more potential to be used in the clinical routine at HIT, with beam gating already imple-
mented for selected patients. However, both techniques have drawbacks that must be
considered during their application. Beam gating introduces a correlation between the
beam and the breathing, which will increase dose degradation if the residual motion is
still considerable. Beam rescanning requires a lateral scanning and energy changing
speed inferior to the motion periods to avoid coherence between the signal. Moreover,
any of these techniques compensate for range variations, which need to be additionally
incorporated in the treatment planning.
More demanding strategies, as online adjustment of the individual pencil beam ener-
gies (Cheung et al. 2012) or 4D-optimised beam tracking (Eley et al. 2014) are not
accomplished with the current beam delivery system and TPS at HIT. These sophis-
ticated 4D techniques need a dedicated quality assessment with a secure verification
method of delivery, therefore these methods are currently not yet at a realisation stage
for clinical facilities of ion-beam therapy.
Variability of the Intra-fractional motion
Zhang et al. (2014) investigated the motion of the pancreas during radiotherapy ses-
sions and noticed that although the major component of the motion is in general in SI
direction, i.e. breathing induced, random patterns were also detected in many cases.
This justifies the need to inspect other sources of motion, as intestines and stomach
peristalsis, and also the correlation between breathing and pancreas motion that might
be rather correlated.
With this aim, 4D-MRI was evaluated as an approach to obtain more intra-fractional in-
formation and without increase the imaging dose to the patient. This first approximation
used the multi-modality image registration MRI-CT to transfer the MRI-detected motion
to the CT image. A similar approach was used by Boye, Lomax, and Knopf (2013)
but based on volunteer data, and larger acquisition times in order to stablish a library
of MRI data. The use of volunteer data has the advantage to obtain a larger sample
but the physiological anatomy of the tumour and the surrounding tissues in pathologi-
cal subjects is discarded. However, in both analysis different pancreas motion length
among 4DCT and MRI sessions, as well amplitude variation along the acquisition of
the 4D-MRI were detected. Also the 4D dose calculation exhibits the influence of the
different breathing amplitudes and anatomy changes.
Bernatowicz et al. (2016) performed a comparison between the motion quantification
population-based and subject-specific and concluded about a better accuracy of the
subject-specific liver modelling, although population-based results can be used to im-
prove the clinical workflow.
Despite the encouraging results, some important issues remain to be solved in order
to improve the accuracy of the results. One of them is the multi-modality image regis-
tration MRI-CT that is still sub-optimal. To overcome it, Björkman (2016) suggested the
calculation of pseudo-CT based on the MRI data, i.e., no deformable registration CT-
MRI is performed and the MRI is directly transformed to electron density. This method
has the potential to include with more accuracy changes in the patient anatomy, as
tumour shrinkage/expansion, bowel and stomach density and shape changes, without
relying in a pre-information of a CT image.
Concerning the detected geometric distortions, which in this analysis hindered the di-
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rect forward calculation in the 4DCTMRI , some studies have shown promising improve-
ments (Huang et al. 2016) and phantom-based measurements have been done in the
German Cancer Research Center in order to reduce this influence and will be used to
improve the image correction.
Another issue, is the time required for the reconstruction of the 4D-MRI, which in a
clinical workflow is unsuited. An alternative is 2D cine MRI, which was evaluated by
Heerkens et al. (2014) for pancreatic patients and might provide support for online mon-
itoring of the tumour and decision regarding the application or not of beam gating to a
specific patient, however, without replacing the complete 4D-MRI information.
In conclusion, this thesis determined the main issues associated with the treatment
of pancreatic patients using charged particles and suggested methods and solutions
for their quantification and mitigation. All the defined strategies were designed, though,
to be clinically feasible in the routine workflow at HIT, from the hardware and software
perspective.
The combination of inter-fractional and intra-fractional sources of uncertainties demon-
strated the potential to mask the clinical benefit of charged particles to treat this radio-
resistant pathology with low survival rate. Despite of that, simple strategies as selection
of beam geometries, planning margins, motion monitoring and mitigation techniques
can dramatically improve the dose distribution and consequently the patient outcome.
The key for a precise delivery of the treatment is the monitoring of anatomical changes,
either in the scale of seconds or days, and prompt reaction in order to minimise or elim-
inate potential uncertainties. In future, it is expected that the methods suggested in this
thesis, the experience gained at HIT on treating moving organs and, the developments
in treatment planning and treatment delivery will allow us to move towards the robust
plan optimisation, prediction of changes in the dose distribution and, to enable treat-
ment without a constant and complex monitoring of the patient movement.
Abstract
Treatment Plan Robustness in Pancreatic Patients treated with
Scanned Ion-Beam Therapy: Inter- and Intra-fractional Aspects
Pancreatic cancer is still an unsolved oncological challenge, however radiotherapy
with charged particles has been considered a promising approach to improve the pa-
tients overall survival. These patients might benefit from dose escalation, although
uncertainties during the beam delivery (intra-fractional) or along the treatment course
(inter-fractional) can compromise the accuracy of the treatment.
In this thesis, inter- and intra-fractional anatomy changes are explored in order to de-
fine the potential source of uncertainties, quantify their effect, and to define strategies
towards their reduction.
Anatomical changes along the course of the treatment showed to lead target under-
dosages up to 20% and an increase in the dose to the normal tissues. However, this
can be lowered through the selection of beam arrangements from the patient’s posterior
side and beam-specific margins. From the results of this work, it was concluded that
a combination of an Internal Target Volume (ITV), obtained by a geometric expansion
of 3 mm from the Clinical Target Volume (CTV), and two oblique posterior beams can
reduce the mean V95%CTV variations to less than 1%. For other beam directions, the
calculation of ITVs including the water-equivalent path length (WEPL), suggested the
need of a CTV asymmetric expansion in depth, and minimal in lateral beam direction.
Additionally, weekly monitoring of the patient anatomy using computed tomography
(CT) might easily be included in the clinical workflow and will assist in the decision
of treatment re-planning, when substantial anatomical changes occur. The suggested
prediction model was based on the variations of the accumulated WEPL (∆accWEPL)
relative to the planning CT, and showed a strong correlation between the ∆accWEPL
and the gamma index of the dose distributions. The gamma criterion was selected as
dose distribution quality metric, since it includes dosimetric changes in the target and
normal tissues.
Regarding intra-fractional variations, the induced breathing motion together with a dy-
namic beam delivery, affect the dose distribution in terms of homogeneity and target
coverage. This effect is stronger (∆V95CTV > 10%) for patients with a tumour motion
amplitude superior to 5 mm and a highly modulated dose distribution intra- and inter-
fields. The concept of modulation index was employed, it showed that different opti-
misers produce plans with contrasting distribution of the number of particles, resulting
in unlike robustness against range and positioning uncertainties. It was concluded that
under internal motion, the use of homogeneous plans, multiple beams, and geometric
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ITVs, originated dose distributions exhibiting a slight mean decrease of the dose ho-
mogeneity (HCTV ) and V95CTV of 4% and 1%, respectively.
Finally, a first approach to the use of 4D-Magnetic Resonance Imaging (MRI) for motion
detection was performed. The results revealed cases of non-linear correlation between
the breathing signal (diaphragm position) and the pancreas motion, and variability of
the motion amplitude along the acquisition time and between sessions. This reinforces
the need of an alternative method, comparative to the use of external surrogates, for
simulation of a 4D dose distribution. Therefore, MRI will allow to include baseline drifts,
amplitude variations and anatomical alterations in the 4D dose distribution assessment.
In summary, the key for a precise delivery of the treatment is the monitoring of anatomi-
cal changes, and a prompt reaction in order to minimise or eliminate potential uncertain-
ties. In future, it is expected that the methods suggested in this thesis, the experience
gained at HIT on treating moving organs and, the developments in treatment planning
and treatment delivery will allow us to move towards the robust plan optimisation, pre-
diction of changes in the dose distribution, and enable treatment without a constant and
complex monitoring of the patient’s movement.
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Appendix A
Complementary results
A.1 Inter-fractional analysis
A.1.1 Beam geometry and planning margins
Figure A.1: Variation of the conformity number (CN) of the CTV for all the patients along the treatment
weeks by beam configuration and used planning target margin.
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Figure A.2: Variation of the maximum dose to the CTV for all the patients along the treatment weeks by
beam configuration and used planning target margin.
Figure A.3: Variation of the mean dose to the CTV for all the patients along the treatment weeks by
beam configuration and used planning target margin.
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Figure A.4: Forward calculated dose distribution in the CT3 for all the patients of the dataset A with the
lateral beam of the plan optimized to the geometric ITV5mm.
(a) Patient: A1, Geom: D
(b) Patient: A3, Geom: D
(c) Patient: A5, Geom: D
(d) Patient: A7, Geom: D
(e) Patient: A9, Geom: D
(f) Patient: A2, Geom: D
(g) Patient: A4, Geom: D
(h) Patient: A6, Geom: D
(i) Patient: A8, Geom: D
(j) Patient: A10, Geom: D
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Figure A.5: Forward calculated dose distribution in the CT3 for all the patients of the dataset A with a
lateral beam and posterior beam of the plan optimized to the geometric ITV5mm.
(a) Patient: A1, Geom: E
(b) Patient: A3, Geom: E
(c) Patient: A5, Geom: E
(d) Patient: A7, Geom: E
(e) Patient: A9, Geom: E
(f) Patient: A2, Geom: E
(g) Patient: A4, Geom: E
(h) Patient: A6, Geom: E
(i) Patient: A8, Geom: E
(j) Patient: A10, Geom: E
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Table A.1: Evaluation of theITVWEPL for each patient and beam’s indicence (anterior, lateral right,
posterior and oblique posterior right) in terms of 95% of the Hausdorf distance (HD95), dice similarity
coefficient (DSC), difference of Volumes (dV) and variation of the center of mass (COM) in depth, lateral
and cranio-caudal (cc) direction relative to the BEV.
dCOM (mm)
Patient Beam HD95 (mm) DSC dVolume (%) CTV-ITVWEPL
CTV-ITVWEPL ITVG5-ITVWEPL ITVG5-ITVWEPL depth lateral c-c
A1 Ant 14.6 0.78 -10.5 -7.6 1.0 -1.0
Lat 7.0 0.78 -30.0 -2.5 0.7 -0.3
Pos 2.8 0.82 -27.9 0.6 0.0 -0.4
Obl 3.1 0.82 -28.1 0.6 0.2 -0.4
A2 Ant 8.4 0.77 -8.4 4.9 0.2 0.5
Lat 4.5 0.76 -29.1 0.6 -0.5 0.5
Pos 3.3 0.79 -28.9 -0.9 -1.0 0.5
Obl 2.8 0.79 -28.7 -0.1 -0.8 0.5
A3 Ant 9.8 0.82 -8.6 3.9 1.3 -1.2
Lat 5.9 0.79 -25.1 -3.6 0.6 1.0
Pos 4.9 0.84 -22.1 -2.0 0.0 0.1
Obl 4.1 0.84 -22.6 -1.8 0.1 -0.1
A4 Ant 3.9 0.80 -28.5 0.6 -1.5 0.3
Lat 4.6 0.77 -31.3 -3.1 0.9 0.5
Pos 5.3 0.79 -26.3 -3.6 0.8 0.1
Obl 5.0 0.80 -27.6 -3.6 1.2 -0.1
A5 Ant 5.6 0.80 -30.5 -0.7 -0.8 0.7
Lat 6.0 0.76 -37.2 -3.2 0.1 0.3
Pos 4.4 0.77 -36.5 -0.7 1.2 0.4
Obl 5.4 0.77 -35.3 -0.6 1.1 0.5
A6 Ant 6.1 0.83 -18.9 -1.3 0.3 -0.3
Lat 5.6 0.80 -23.9 -2.1 -1.5 -0.2
Pos 4.5 0.82 -25.0 -0.5 0.0 -0.6
Obl 4.7 0.82 -25.4 -0.8 -0.7 -0.7
A7 Ant 6.0 0.82 -21.1 3.5 -0.4 0.2
Lat 5.4 0.79 -27.6 0.0 0.1 0.1
Pos 3.3 0.81 -27.9 0.8 0.3 -0.2
Obl 3.5 0.81 -28.3 0.6 0.3 0.0
A8 Ant 10.8 0.81 -10.9 -7.5 0.2 0.2
Lat 7.8 0.78 -22.5 -4.6 1.1 -0.4
Pos 2.7 0.83 -27.5 -0.6 -0.2 -0.3
Obl 2.9 0.83 -27.8 -0.9 -0.3 -0.3
A9 Ant 8.6 0.78 -18.1 -1.3 0.6 0.3
Lat 4.6 0.78 -26.8 4.2 0.5 1.25
Pos 2.8 0.79 -30.7 -0.5 0.0 0.6
Obl 2.8 0.79 -30.5 -0.8 0.2 0.6
A10 Ant 10.1 0.82 -13.9 -6.6 0.4 1.16
Lat 11.8 0.76 -15.5 3.2 0.42 1.0
Pos 3.3 0.84 -25.9 -0.7 0.1 0.5
Obl 3.3 0.84 -25.8 -1.3 0.0 0.4
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A.1.2 Water-equivalent path length calculations
Table A.2: Evaluation per patient and beam geometry of the differences between the accumulated
WEPL, calculated in BEV from the patient’s skin to the distal edge of the CTV, of each weeky CT and the
planning CT. The used parameters were percentage of voxels with less than 3mm of diefference, mean,
standard deviation and variance of the 2D difference map and range look-up values (LUT).
Patient B.Direc. PVin Mean  Std.Dev. Variance LUT [min;max]
(%) (mm) (mm) (mm)
A1 Ant 50.6 21.7 5.94  2.75 0.24 40.57 -5.21  2.64;21.14  7.45
Lat 82.75  10.83 1.77  3.12 26.89  33.17 -6.78  2.21;20.76  13.33
Pos 98.25 1.26 -0.08  0.29 1.69  0.68 -4.58  1.4; 4.61  1.44
Obl 99.25  0.54 0.02  0.12 1.03 0.24 -3.67  1.29 4.25  2.71
A2 Ant 28.59  18.62 -4.39  0.64 -4.39  0.64 -17.72  8.45; -17.72  8.45
Lat 48.91  9.22 -0.09  1.46 27.5  14.72 -14.16  4.24; 16.38  10.28
Pos 92.94  9.15 1.16  0.16 1.56  0.4 -3.62  1.31;5.79  1.44
Obl 93.25  7.66 0.56  0.13 1.85  0.35 -4.49  1.86; 5.87  1.86
A3 Ant 28.28  4.17 -5.94  0.44 59.94  6.98 -24.81  3.25;10.26  4.48
Lat 53.99  12.2 2.31  0.73 22.16  6.84 -11.26  2.54;21.05  4.21
Pos 82.91  13.35 2.05  0.39 2.08  1.05 -2.42  0.35;7.37  2.29
Obl 80.76  13.37 1.99  0.32 2.56  1.01 -2.87  0.69;6.67  1.07
A4 Ant 62.7  19 -1.74  1.19 12.91  7.49 -9.05  4.76; 5.2  1.58
Lat 52.04  26.48 1.65  0.51 7.61  3.02 -5.56  4.27;9.91  6.46
Pos 12.97  9.12 6.27  0.31 5.64  1.49 -0.22  0.43;12.72  1.33
Obl 22.44  6.07 4.96  0.31 4.94  1.39 -0.73  1.46;9.93  0.97
A5 Ant 53.39  24.84 3.45  0.68 23.24  6.61 -8.46  0.79;13.12  2.5
Lat 58.51  38.42 3.11  0.81 8.63  4.88 -8.33  1.7;16.52  10.2
Pos 82.91  8.8 0.69  0.28 5.12  1.24 -6.82  1.35;7.15  0.76
Obl 78.89  12.13 0.88  0.42 5.34  1.82 -8.73  0.79;8.38  0.92
A6 Ant 48.61  27.84 3.37  0.05 7.69  0.3 -3.41  0.86;10.09  1.59
Lat 53.71  20.66 3.36  0.81 18.97  6.81 -5.89  1.39;25.32  5.62
Pos 80.95  21.55 -1.97  0.05 2.09  0.14 -7.56  1.49;2.85  1.62
Obl 82.44  24.15 -1.44  0.56 3.28  2.05 -6.36  2.26; 5.18  0.02
A7 Ant 40.12  15.2 -3.9  1.21 13.35  8.68 -12.79  0.64;4.76  4.17
Lat 68.2  13.72 -0.75  1.73 34.4  19.38 -27.9  7.94;7.68  5.44
Pos 94.7  7.29 -1.09  0.31 1.52  0.73 -5.17  2.19;4.93  3.56
Obl 96.79  3.1 -0.94  0.28 1.45  0.6 -5.15  1.9;4.37  3.8
A8 Ant 23.9  23.49 8.92  0.9 14.21  6.27 -0.89  1.46;15.86  4.86
Lat 41.89  19.96 5.51  3.22 35.18  42.19 -7.31  6.57;19.06  9.43
Pos 94.87  3.03 0.76  0.22 2.37  0.68 -4.11  1.27;5.88  0.93
Obl 89.69  8.54 1.31  0.41 2.43  1.38 -4.14  1.52;5.13  1.35
A9 Ant 39.59  15.93 -0.38  1.61 71.43  28.3 -22.3  5.79;15.32  3.15
Lat 24.22  15.34 -5.32  0.25 6.34  1.28 -10.67  3.12; 4.39  1.7
Pos 80.17  10.59 1.19  0.3 5.21  1.41 -4.28  1.06;10.02  2.11
Obl 78.68  10.01 1.6  0.4 4.97  1.71 -4.68  2.36;10.16  1.3
A10 Ant 37.66  4.22 1.84  1.48 48.49  19.99 -17.58  4.72;21.11  4.36
Lat 23.39  7.94 9.78  2.35 151.48  54.68 -37.81  17.17;44.68  17.33
Pos 59.27  23.56 2.75  0.24 4.13  0.98 -4.24  2.26;10.42  3.69
Obl 45.25  23.11 3.63  0.2 5.08  0.88 -2.49  2.05;10.77  1.33
APPENDIX 137
Figure A.6: Analysis variation of the accumulated WEPL for an anterior beam: performed for all the
patients and weeky CTs in terms of percentage of voxels with differences inferior to 3 mm (PVin), Gamma
passing rate between the planning dose distribution and each weekly forward-calculated dose distribution
and the respective V95.
Figure A.7: Analysis variation of the accumulated WEPL for a lateral right beam: performed for all
the patients and weeky CTs in terms of percentage of voxels with differences inferior to 3 mm (PVin),
gamma passing rate between the planning dose distribution and each weekly forward-calculated dose
distribution and the respective V95.
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Figure A.8: Analysis variation of the accumulated WEPL for a posterior beam: performed for all the
patients and weeky CTs in terms of percentage of voxels with differences inferior to 3 mm (PVin), gamma
passing rate between the planning dose distribution and each weekly forward-calculated dose distribution
and the respective V95.
Figure A.9: Analysis variation of the accumulated WEPL for an oblique posterior right beam: per-
formed for all the patients and weeky CTs in terms of percantage of voxels with differences inferior to
3 mm (PVin), gamma passing rate between the planning dose distribution and each weekly forward-
calculated dose distribution and the respective V95.
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Table A.3: Example of the performed analysis for three patients (A1, A6, A8) for a lateral beam or oblique
posterior beam for one of the weekly-CT versus the planning CT. The accumulated WEPL differences
are shown through the color map and a histogram
Pt: A1, Geom: D, CT1 CT2 CT1-CT4 CT1-CT4
Pt: A8, Geom: D, CT1 CT2 CT1-CT2 CT1-CT2
Pt: A6, Geom: B, CT1 CT3 CT1-CT3 CT1-CT3
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A.2 Intra-fractional analysis
Dataset B - 4D dose simulations
Table A.4: Analysis of the 4D simulated dose distribution of the patients of the dataset B, considering
the regular and Lujan motion, in terms of impact in the CTV coverage (min, max, median, conformity
number (CN), homogeneity (HCTV ), V95CTV and V107CTV ).
Patient B.Direc. Min. Max. Median CN HCTV V95CTV V107CTV
(%) (%) Gy (RBE) CN (%) (%) (%)
B1 Ant 87.6 1.5 110.4  1.4 3.0  0.1 0.5  0.0 6.9  0.2 98.7  0.3 0.2  0.1
Post 89.1  1.6 109.7  1.8 3.0 0.0 0.53 ± 0.0 4.4  0.1 99.8 ± 0.1 0.1  0.0
Obl 89.5  0.9 118.1  2.8 3.1  0.0 0.3  0.0 10.1  0.4 99.4  02 11.7  0.7
B2 Ant 72.5  1.8 127.1  9.2 3.0  0.0 0.4  0.0 14.3  1.6 90.0  2.1 5.3  2.0
Post 85.1  2.1 111.3  1.1 3.0  0.1 0.4  0.0 8.6  0.2 96.9  0.8 0.8  0.2
Obl 92.3  1.1 113.5  1.5 3.1  0.0 0.4  0.0 6.9  0.3 99.9 0.1 4.9 2.5
B3 Ant 61.7  8.7 127.4  5.3 3.1  0.0 0.5 0.0 16.3  1.0 89.2  2.4 8.7 2.0
Post 87.2  1.5 109.0  1.1 3.0  0.0 0.5 0.1 7.5  0.3 98.5  0.5 0.4  0.3
Obl 93.0 1.3 111.1  1.1 3.1  0.0 0.36  0 6.0  0.2 100.0  0.1 2.3  1.6
B4 Ant 83.8  0.8 112.0  1.1 3.0  0.0 0.5 0.0 8.2  0.4 97.5  0.6 0.5  0.2
Post 85.9  1.5 113.3  1.9 3.0 0.0 0.5 0.0 7.8± 0.2 97.0 0.4 0.4 ± 0.1
Obl 95.4  0.8 112.7  1.2 3.1  0.1 0.5  0.0 5.3  0.2 100.0  0.0 3.2  0.5
B5 Ant 85.1  1.3 113.5 1.7 3.0 0.0 0.5 0.0 8.3  0.2 97.3  0.3 0.4  0.2
Post 81.8  6.6 108.8  1.7 3.0  0.0 0.5  0.0 7.1  0.9 97.3  1.8 0.1  0.0
Obl 90.8 ± 3.6 113.6  1.1 3.1  0.0 0.4 0.0 6.3 0.1 99.9  0.1 4.2 ± 0.4
B6 Ant 81.9  1.9 123.4  4.1 3.0  0.0 0.6  0.0 7.1  0.4 98.1  0.3 0.8  0.2
Post 92.0 0.6 109.0  1.0 3.0  0.0 0.5 0.0 5.4  0.1 99.8  0.0 0.1  0.1
Obl 96.5 0.7 111.3 0.5 3.1  0.0 0.5 0.0 4.8  0.1 100.0  0.0 1.9  0.5
B7 Ant 74.4  2.7 122.1  1.3 3.0  0.0 0.5  0.1 10.5  0.3 94.7  0.5 2.4  0.3
Post 73.6 ±4.7 111.3  1.0 3.0  0.1 0.5  0.01 8.3  0.4 95.2  1.0 0.3  0.1
Obl 86.4  1.9 109.0  1.3 3.0  0.1 0.505  0.0 6.2  0.3 99.5  0.3 0.1  0.1
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Dataset H - 4D dose simulations and reconstructions
Table A.5: Analysis of the 4D simulated and reconstructed dose distribution of the patients of the dataset
H, in terms of impact in the CTV coverage (min, max, median, conformity number (CN), homogeneity
(HCTV ), V95CTV and V107CTV ), in comparison with the static dose distribution (∆ = 4DDSim or 4DDReco
- static). For the patients with more than a single reconstruction the mean and standard deviation is
presented.
Patient Type ∆Min. ∆Max. ∆Median ∆CN ∆HCTV ∆V95CTV (%) ∆V107CTV
cGy (RBE) cGy (RBE) cGy (RBE) (%) (%) (%)
H1 4DDSim -31.0  6.9 66.3  9.4 0.7  1.2 -0.07  0.02 13.7  1 -7.2  3 21.3  4.1
4DDReco -34.5  3.5 22.5  7.8 -2.0  0.0 -0.05  0.01 5.9  0.5 -10.7  0.2 8.6  1.7
H2 4DDSim -54.7  7.6 58  13 1.8  0.4 -0.01  0.01 13.5  1.6 -1.7  1.8 20.7  2.8
4DDReco -0.7 0.2 0.0 0.01 8 -5.5 7.9
H3 4DDSim -28.7  11 55.5  4.3 0.3  0.8 -0.14  0.01 8.8  2 2.2  1.3 11.1  2.3
4DDReco -0.3 0.2 -1.0 0.0 1.5 0.3 8.5
H4 4DDSim -120.5  2.6 42  7.8 2.5  0.5 -0.04  0.01 12.4  0.5 -6.2  0.5 18.9  1.5
4DDReco -117.0  2 29.3  9.0 1.3  0.6 -0.01  0.01 13.3  0.3 -9.7  1.2 10.5  1.1
H5 4DDSim -17.7 pm 3.1 68 pm 9.5 3 pm 0.0 -0.12  0.01 13.6  0.6 -5.7  0.7 18.9  1.5
4DDReco -18.0  2.8 8.5  3.5 0.0  0.0 -0.05  0 7.5  0.3 -5.9  0.6 3.4  0.3
H6 4DDSim -93.3  7.5 54.8  9.3 1.8  0.4 -0.07  0.01 13.9  1.2 -10.6  1.3 16.3  1.9
4DDReco -87.8  54.6 26.0  12.8 0.0  1.8 -0.05  0.01 12.2  2.7 -11.1  1.9 6.7  1.4
H7 4DDSim -76.3  2.3 62.7  6.4 0  1.8 -0.11  0.02 21.3  1.9 -19.8  2.9 13.4  4.2
4DDReco -0.6 0.2 -5.0 -0.1 17 -27.4 1.0
H8 4DDSim -36.3  4.6 47.7  6.1 2.2  0.8 -0.03  0.01 16.5  1.9 2.7  1.9 20.5  2.2
4DDReco -0.4 0.3 1.0 0.02 15.7 4.5 19.1
H9 4DDSim -25.3  7.3 32.3  5.2 1.7  1 -0.07  0.02 9.1  1.2 -3.4  2.2 17.6  3
4DDReco -0.2 0.1 0.0 0.0 1.5 -0.9 6.6
H11 4DDSim -10.5  5.7 9.1  7.5 -1.6  0.5 0.03  0.01 0.9  0.9 1.4  0.9 1.1  0.9
4DDReco -12.5  6.4 8.5  0.7 -2.5  0.7 0.02  0.01 -0.6  0.3 0.2  1 -0.7  1.4
H12 4DDSim -76.8  4.1 74.8  19.3 -2.5  5.6 -0.02  0.05 32.5  6.9 -15.8  8.1 11.1  8.7
4DDReco -95.4  12.5 73.8  28.6 1.6  3.8 0.03  0.05 26.9  2.7 -6.6  6.8 15.1  5.8
H13 4DDSim -20  9.5 12.5  4 -15.8  2.4 -0.16  0.02 3  0.5 -16.4  2 0.6  0.7
4DDReco -25  1.4 19  1.4 -13.5  0.7 -0.14  0.01 3.9  0.7 -14.5  0.8 1  0.1
H14 4DDSim -16.2  2.5 29.2  5.3 -3.5  1.4 -0.01  0.01 1.3  0.7 -3.6  0.7 0.7  0.2
4DDReco -0.2 0.3 -4.0 -0.02 1.2 -4 0.7
H15 4DDSim -72.8  7.2 19.3  6.5 -1.2  0.8 -0.03  0.01 6.9  0.8 -6.7  1.6 7.4  2
4DDReco -0.7 0.1 -1.0 -0.03 4.2 -6 3.1
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Figure A.10: Axial view of the dose distributions in the static, one example of the possivle 4D simu-
lation and the 4D reconstruction of one of the treated fractions for the patients of the dataset H. The
dose-volume histogram of the CTV shows the compresses all the 4D simulations (blue band), the 4D
reconstructions (green lines) relative to the static plan (red line).
(a) H1 Static
(b) H2 Static
(c) H3 Static
(d) H4 Static
(e) 4DDSim
(f) 4DDSim
(g) 4DDSim
(h) 4DDSim
(i) 4DDReco Fx16
(j) 4DDReco Fx15
(k) 4DDReco Fx24
(l) 4DDReco Fx05
(m) CTV DVHs
(n) CTV DVHs
(o) CTV DVHs
(p) CTV DVHs
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Figure A.11: Continuation of figure A.10.
(a) H5 Static
(b) H6 Static
(c) H7 Static
(d) H8 Static
(e) 4DDSim
(f) 4DDSim
(g) 4DDSim
(h) 4DDSim
(i) 4DDReco Fx1
(j) 4DDReco Fx06
(k) 4DDReco Fx07
(l) 4DDReco Fx24
(m) CTV DVHs
(n) CTV DVHs
(o) CTV DVHs
(p) CTV DVHs
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Figure A.12: Continuation of figure A.10.
(a) H9 Static
(b) H11 Static
(c) H12 Static
(d) H15 Static
(e) 4DDSim
(f) 4DDSim
(g) 4DDSim
(h) 4DDSim
(i) 4DDReco Fx20
(j) 4DDReco Fx10
(k) 4DDReco Fx05
(l) 4DDReco Fx17
(m) CTV DVHs
(n) CTV DVHs
(o) CTV DVHs
(p) CTV DVHs
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Figure A.13: Continuation of figure A.10 - Patients with Carbon Ions.
(a) H13 Static
(b) H14 Static
(c) 4DDSim
(d) 4DDSim
(e) 4DDReco Fx2
(f) 4DDReco Fx3
(g) CTV DVHs
(h) CTV DVHs
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Table A.6: Mean number of raster points (NP) per slice, standard deviation of the NP and spectrum of
the modulation Index per patient and beam direction (in IEC coordinates).
Patient H1
Gantry 20° Couch 0° Gantry 340° Couch 0°
Patient H2
Gantry 30° Couch 0° Gantry 330° Couch 0°
Patient H3
Gantry 300° Couch 340° Gantry 20° Couch 35°
Gantry 60° Couch 20°
Patient H4
Gantry 340° Couch 0° Gantry 25° Couch 0°
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Table A.7: Continuation of table A.6.
Patient H5
Gantry 350° Couch 0° Gantry 15° Couch 0°
Patient H6
Gantry 345° Couch 0° Gantry 20° Couch 0°
Patient H7
Gantry 330° Couch 0° Gantry 20° Couch 0°
Patient H8
Gantry 340° Couch 0° Gantry 30° Couch 0°
Patient H9
Gantry 330° Couch 0° Gantry 15° Couch 0°
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Table A.8: Continuation of table A.6.
Patient H11
Gantry 330° Couch 330° Gantry 30° Couch 30°
Patient H12
Gantry 350° Couch 0° Gantry 90° Couch 0°
Patient H13
Gantry 20° Couch 20° Gantry 340° Couch 340°
Patient H14
Gantry 20° Couch 0° Gantry 340° Couch 0°
Patient H15
Gantry 20° Couch 0° Gantry 340° Couch 0°
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A.3 Magnetic resonance imaging - motion detection
Figure A.14: Median length of the vector field and its components inside the ITV of the patient H13 ob-
tained from deformable image registration between the each of the MRI-bins and the bin-0 in the session
1 and 2. Dark blue: vector, yellow: cranio-caudal (z) direction, red: anterior-posterior (x) direction, cyan:
right-left (y) direction, relative to the patient.
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Figure A.15: Median length of the vector field and its components inside the ITV of the patient H14
obtained from deformable image registration between the each of the MRI-bins and the bin-0 in the
session 1. Dark blue: vector, yellow: cranio-caudal (z) direction, red: anterior-posterior (x) direction,
cyan: right-left (y) direction, relative to the patient.
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Figure A.16: Median length of the vector field and its components inside the ITV of the patient H15 ob-
tained from deformable image registration between the each of the MRI-bins and the bin-0 in the session
1 and 2. Dark blue: vector, yellow: cranio-caudal (z) direction, red: anterior-posterior (x) direction, cyan:
right-left (y) direction, relative to the patient.
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